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Abstract
Skin is the primary interface to the external environment, protecting us from harmful
compounds and infection. Over many millennia, coevolution has culminated in a mutu-
alistic relationship between ourselves and a specialised, yet diverse resident community
of microorganisms. This microbiota is thought to exist in a delicate balance to maintain
homeostatic equilibrium, and plays a role in the shaping of our immune system. Skin dis-
eases are some of the most common human disorders and present a considerable economic
burden. There is now growing appreciation of the role the cutaneous microbiome plays in
disease, and how host-microbe interplay is associated with disorders of the immune system.
The cutaneous microbiota as well as the host transcriptome and the interactions between
them is the focus of this thesis.
Computational methods were used to examine the microbiota and transcriptomes of a large
cohort of matched samples from healthy volunteers and patients with Atopic Dermatitis
(AD) and Psoriasis (PSO). The community composition of inflamed and healthy skin was
assessed and the specific species which are over-represented on diseased skin were iden-
tified. In parallel, the host gene expression was profiled to identify common and disease
specific transcriptional signatures revealing clinically relevant pathways.
Next, using schemes of dimensionality reduction and computational methods, the associa-
tions between microbes, disease severity and host transcription was interrogated. Staphy-
lococcus aureus demonstrated an impressive relationship with AD associated gene signa-
tures, whereas host-microbe associations in PSO were inconclusive. Using Weighted Gene
Co-expression Networks Analysis (WGCNA), gene-gene interaction networks were recon-
structed and differentially connected modules between healthy and inflammatory states
were identified. Modules encoding processes for the epidermal barrier, extracellular ma-
trix, non-coding RNA metabolism and immune system processes were all associated with
iv
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the relative abundance of S. aureus.
Overall, whilst associations in psoriasis were inconclusive, a range of host-microbe inter-
actions were uncovered in AD. The results presented in this thesis contribute towards a
greater understanding of the differences in the cutaneous microbiome and the transcrip-
tional mechanisms which underlie allergic and autoimmune inflammation.
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Our interactions with the world are experienced through the vast 2m2 of cutaneous mem-
brane that encapsulates our body. Whilst this primary interface protects us from the
harmful agents present in the external environment, it is also the home of a specialised,
yet diverse resident community of microorganisms [1]. This microbiota has accompanied
us throughout our evolution culminating in a mutualic kinship where they are supported
by the nutrient rich supply of secreted sebum and shed squame and in return we obtain
protection from potentially offending microbiota. Sometimes described as the forgotten
organ [2], the totality of the cells that make up the microbiota equals that of the human
[3]; however, unlike many other organs, the microbiota is dynamic and demonstrates a
considerable amount of diversity between individuals [1]. Enteric dysbiosis, when the com-
munity composition deviates from a healthy ecological equilibrium, has now been linked to
inflammatory disease [4, 5, 6], although much less is known about the relationship between
between skin microbiota and inflammatory skin pathologies. The purpose of this thesis is
to explore this relationship between cutaneous dysbiosis and host-transcriptional disease
signatures.
1.1 Studies of the microbiome
In the fifteen years since the initial draft of the human genome [7], incredible advances have
been made in both sequencing technologies and the bioinformatics capabilities to analyse
high-throughput data. Research showed that a 1500bp sequence encoding for a subunit
of the prokaryotic ribosome, known as the 16S rRNA gene, has a slow rate of evolution
and acts as molecular chronometer [8]. It was found that mutations within this gene can
1
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be used as a diagnostic fingerprint to distinguish between taxonomy up to the species level.
The utilisation of sequencing technologies for the 16S rRNA gene has made it possible to
explore the human microbiota at resolutions previously infeasible by phenotypic methods
[8]. Ever since, 16S sequencing has been used to explore the microbiota and has revealed
many novel commmensal species occupying the human body which were previously un-
known and unculturable [9]. We are now in the midst of a metagenomic revolution and
beginning to establish the fundamental principles that govern the relationship between the
human organism and its microbial cohabitants.





















Figure 1.1: Pubmed hits for the query ‘microbiome’
Interest in the microbiome and its role in health is rapidly increasing. A search for the term
‘microbiome’ in Pubmed clearly indicates the excitement in this new area of research where
the numbers of associated publications have rapidly increased in recent years (Figure 1.1).
A popular database for storing metagenomic data, MG-RAST [10], currently stores over
250,000 metagenome samples. Studies which have profiled the 16S rRNA gene are ranging
and varied. There are now microbiome surveys for several human habitats including the
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eyes [11], the blood [12], and the lungs [13].
1.2 The gut microbiome
The overwhelming majority of research into the human microbiome has been performed in
the gut which is mostly dominated by the Firmicutes and Bacteroidetes phyla [14, 1, 15].
As demonstrated by a recent metagenomics analysis, the genetic capability of gut micro-
biome is vast and consists of at least 150-fold more microbial genes than the human genome
[15].
The community of microbiota is believed to be acquired at birth; however, distinct differ-
ences in composition can be observed between babies who were delivered by cesarean or
born vaginally [16]. Genetic studies have indicated that components of the microbiome are
heritable suggesting that host genetics help to shape the microbiome. It has been shown
that the biotic composition of twins is more similar than unrelated individuals, and the
composition between monozygotic twins is more similar than dizygotic twins [17]. Many
environmental factors affect the gut microbiome; one of which includes the host diet [18].
Longitudinal studies of the infantile microbiota have shown that changes to diet such as
the weaning from breast milk to solid foods can be detected by shifts in community com-
position [19]. Changes in the gut microbiome have also been observed with respect to body
mass index (BMI) as well as gender [20] and, as would be expected, antibiotic treatment
[19].
It is now becoming increasingly clear that the microbiome plays a critical role in the shaping
of our immune system [21, 22]. Studies in mice which have never encountered microbiota,
known as germ-free mice, are characterised by reduced numbers of immune cells which are
functionally compromised and the mice themselves are more susceptible to infections [23].
One theory suggests that under-stimulation of the immune system during developmental
periods results in susceptibility to immune dysbalance [24]. This view is known as the
‘hygiene hypothesis’ [25] and reflects the increased prevalence of inflammatory diseases
amongst industrialised countries. This is further supported in that babies delivered by
cesarean, as well as those treated with antibiotics experience an unrecoverable reduction
in microbiota diversity [26]. Improved standards of hygiene due to clean water, sanitation
as well as continuous hand sterilisation have seen rates of infection plummet; however, this
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rapid change in lifestyle may result in an ill-prepared and dysfunctional immune system [27].
The overwhelming consensus view is that the gut microbiome plays an essential role in
host health. The genetic capability provided by the microbiome aids in metabolism of
indigestible compounds, training of the host immune system, and providing resistance to
infection [22]. If the microbiome behaves as a functional organ, then it is also likely to be
susceptible to disease. The intimate relationship with our microbiota exists in a delicate
homeostatic equilibrium and when this is disturbed, a state of dysbiosis can occur. Shifts
in community composition have been linked to wide range of pathologies including Crohn’s
disease [4, 28, 6], obesity and inflammatory bowel disease [5, 29]. As dysbiosis is clearly a
factor, there is now increasing interest regarding the therapeutic potential for modulation
of the microbiome.
1.3 The skin
The skin accounts for approximately 16% of total body weight and is our first line of
defence against foreign bodies. The healthy cutaneous membrane plays critical roles in
the maintenance of temperature, lipid and vitamin D synthesis as well as regulation of
appropriate fluid loss and retention. The skin is mostly composed of two structures, the
epidermis, which is the main barrier, and the dermis which supports the epidermis by
providing structure and facilitating nutrient transport. [30]
1.3.1 Structure of healthy skin
The dermal compartment is beneath the epidermis and contains a vast extracellular matrix
(ECM) as well as the hair follicles and subaceous glands. Two main layers compose the
dermis; the papillary layer, and the reticular layer. The reticular layer consists of a vast
amount of irregularly connected collagen and is responsible for structural integrity. The
papillary layer is the upper most layer of the dermis. This layer contains sensory neurons,
capillaries, lymphatic vessels as well as epidermal ridges which protrude into the epidermis
and facilitate the transfer of products, between the epidermis and dermis as well as struc-
tural support. [30]
The epidermis consists of several keratinocyte layers. The layer superficial to the dermis
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is the stratum germinativium which consists of a high abundance of basal cells which dif-
ferentiate to replace dead cells which are shed from the outermost layers. When basal
cells divide, the daughter cell moves up a layer into the stratum spinosum which consists
of keratonocytes bound together by desmosomes, a structure which anchors cells together.
The stratum spinosum also contains a rich source of Langerhans cells, which are specialised
dendritic cells situated in the cutaneous membrane and mediate immune responses against
offending microbiota. As keratinocytes continue to divide from the basal layers, they reach
the stratum granulosum, where they begin to produce high quantities of keratin protein.
The final layer, known as the stratum corneum consists of many keratinocyte layers, which
have been hardened and become flatter due to the volume of keratin production. Keratin-
isation, also known as cornification, occurs in this layer and is the formation of a strong
protective barrier of dead keratinocytes bound together by special desmosomes known as
corneodesmosomes. Keratinocyte layers in the the stratum corneum remain in this layer
for approximately 1-2 weeks when they are shed. They are then continuously replenished
by younger cells pushed up from the subficial layers. [30]
1.3.2 The skin microbiome
The skin is home to a diverse myriad of resident microbiota including fungi, viruses, mites
and bacteria [31]. It is hypothesised that this resident microbiota may provide resistance
to infection by production of antimicrobial peptides in exchange for host supplied sebum
[32]. This diverse community is believed to be acquired at birth and closely resembles the
mother’s vaginal microbiota [16]. The landscape of microenvironments in the skin is diverse
and is defined by differences in pH, sebum, moisture levels and temperature, requiring the
microbiota to be resilient to environmental changes [33].
One of the major functions of the skin is to regulate temperature. Sweat glands are un-
evenly distributed across the body resulting in diverse skin microenvironments. Several
different types of sweat gland are present on the skin including eccrine, apocrine and apoec-
crine as well as sebaceous glands which secrete sebum; all of these contribute to mixtures
of varying compositions supplying nutrients for microbial metabolism [31]. Sweating is
controlled by the nervous system and responds to changes in temperature, physical ac-
tivity, emotions and stress [34]. Differences in moisture and nutrient composition due to
sweating as well as anatomic variation such as hair follicle density all contribute to skin
microenvironments which may be colonised by niche-specific microbiota [34, 31].
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Eccrine sweat is 99% water and includes amino acids as well as the antimicrobial peptide
dermacidin [35]. They are found across the entire body with high density on the palms
and soles with only few on the back [34]. Apocrine sweat glands are found in the perianal
regions, armpit and eyelids. The secretion from apocrine glands is an odourless substance
rich with lipids and proteins, however, this is metabolised by bacteria such as Corynebac-
teria into volatile odorous compounds and is associated with bromhidrosis [31, 34]. Little
is known about apoeccrine glands but their secretion is thought to be similar to eccrine
glands and they occur mostly in haired areas [34]. Sebaceous glands secrete an oily com-
pound called sebum consisting of fatty acids, wax esters and cholesterol. They are found in
high density on the face and are closely related to the skin condition acne. The sebaceous
gland is directly attached to the hair follicle in a structure known as the pilosebaceous
unit which are anoxic and are colonised by microbiota including Propionibacterium acnes
[36, 31].
The distribution of eccrine, apocrine and sebaceous glands is variable across the human
body and several studies have attempted to map the cutaneous microbiome by dividing
up skin locations into moist, dry and oily sites. Moist sites contain an abundance of ec-
crine and apocrine glands and consist of flexural areas such as behind the knee, elbows and
between the toes [37]. These regions have been found to be colonised mostly by Corynebac-
terium (Actinobacteria) and Staphylococcus (Firmicutes) [38]. Analyses of body sites have
shown that the diversity of the skin microbiota varies according to the body site sampled
[39]. The oily sites have been found to have the lowest diversity amongst skin sites in
terms of both metabolic and taxonomic diversity [33, 38, 40]; however, they are enriched
for specific metabolic pathways such as glycolysis [33] indicating that taxa adapt to their
skin-specific niche. The taxa most dominant within the oily regions include Propionibacte-
ria (Actinobacteria) which colonise sebaceous glands and Staphylococci (Firmicutes) [38].
The dry areas consist of fewer sebacous glands and are dominated by Betaproteobacteria
[38]. Taxa residing in dry sites also showed niche specific genetic capability through over-
representation of genes involved in citrate cycle [33]. Overall, these studies have shown
that community composition is variable between body sites and further indicates that spe-
cific species are adapted to their microenvironments via the over-representation of specific
metabolic pathways.
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Whilst body site is seen to be the major factor which shapes the microbiome, several
other factors are also associated with community composition, one of which is the human
environment. A study by Ying et al. [40] showed compositional differences between peo-
ple residing within urban and rural areas of the same city. Furthermore, the same study
showed a relationship with age in which adults have more diverse microbiomes than both
adolescents and elderly, and elderly people were found to have lower abundance of Propi-
onibacterium [40]. Little is known about the effect of clothing, soaps and other cosmetics
on the skin microbiota although it plausible that factors of this kind may influence com-
munity composition [31].
When comparing the skin microbiota to different human body sites, the skin is composi-
tionally dissimilar to that of the gut [39, 1] and has a higher viral and fungal component
than other body sites [33]. The human microbiome project found that the skin had compa-
rable within-site diversity (α-diversity, see Section 2.1.2.2) to other (non-skin) body sites,
however, analysis of between-site diversity (β-diversity) showed that some skin sites are
amongst the most diverse microbiomes in the human body [1]. This finding has also been
supported by others [39] and indicates that the skin microbiota may be less stable between
individuals.
Costello et al. [39] showed that microbiota composition was more stable within an in-
dividual over time than between individuals. Furthermore, a recent study of the hand
microbiota showed that only 13% of species are shared between any two individuals [41].
Given the high degree of inter-individual variability, the idea of a ‘personalised microbiome’
has been proposed. Subsequent works have built upon this idea and demonstrated that
residual skin microbiota left on objects such as keyboards can be used as a personal sig-
nature for forensic analysis [42].
There is now an increasing drive to determine the relationships between host and micro-
biome in the context of health and disease. It is well known that dysbiosis or loss in species
diversity is a common symptom of gut inflammatory diseases, and it has been postulated
that this may exacerbate inflammation [22]. The cutaneous membrane is a rich source of
immune cells including T cells, dendritic and mast cells and recent studies in mice have
shown that the skin microbiota is associated with IL-1 signalling demonstrating a host im-
mune system-microbiome interplay [43]. Only with further analysis into host-microbiome
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interactions will be able to determine the relationship between the skin microbiome and
inflammatory skin diseases such as Atopic Dermatitis and Psoriasis.
1.4 Atopic Dermatitis
Atopic dermatitis is a relapsing inflammatory skin condition associated with erythematous
and intensely puritic papules which become lichenified in the chronic phase [44]. The dis-
ease has a negative impact upon the quality of life and treatment for atopic dermatitis is
long term and can be a financial burden. Approximately 15-30% of children have atopic
dermatitis, 85% of which develop before the age of five, and 2-10% of adults [44]. The
disease presents on different body sites varying with age and often affects the facial areas
in infancy and mostly flexural areas in adults [45].
AD is a multifactorial disease and is believe to be associated with complex interactions
between the immune system, host genetics and dysfunction of the epidermal barrier, how-
ever, its etiology is currently unknown. Genetic factors clearly play a role in AD as the
concordance rate amongst monozygotic twins is greater than dizygotic twins [46]. Further-
more, the risk of developing the disease is twice as high if at least one parent has AD [44].
The condition is associated with increased immunoglobulin E (IgE) sensitisation to envi-
ronmental allergens such as dust mites and is considered to be the first component of the
‘atopic march’ or the ‘atopic triad’ in which half of sufferers develop asthma, and two thirds
will acquire rhinitis [47]. It is important to note that whilst the majority of patients have
elevated IgE serum levels, some patients do not and this has resulted in definition of two
AD subtypes. The major most prevalent subtype is known as extrinsic AD and accounts
for 70-80% of patients and is associated with IgE sensitisation. The second subtype have
normal serum IgE levels and is known as intrinsic AD or non-atopic which have reduced
IL-4 and IL-13 levels and accounts for 15-30% of patients [48].
The most significant findings from genetic studies have linked dysfunction of the epider-
mal barrier to the pathogenesis of AD. Studies have shown that many patients with AD
carry loss of function mutations within the filaggrin (FLG) gene which is a key component
of the statum corneum [49, 50]. FLG aggregates keratin filaments in the epidermis and
plays a role in modulation of epidermal pH as well as keeping the skin barrier hydrated
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through generation of natural moisturising factors [51, 50]. Thus, FLG loss of function
mutations are thought to be related to the dryness often characteristic of AD lesions [49].
With a defective barrier, it is thought that increased barrier permeability results in ele-
vated transepidermal allergen transfer which increases the contact between environmental
allergens and immune cells [52].
AD is considered to be a biphasic disease which is dominated by T helper (Th) 2 cells in the
acute phase, and Th1 cells in the chronic phase [44]. In the acute phase, environmental al-
lergens enter the epidermal barrier and are processed by skin-resident dendritic cells (DCs).
Upon an encounter, DCs mature and down regulate E-cadherin allowing detachment from
neighbouring keratinocytes in conjunction with up-regulation of major histocompatibility
complex (MHC) class I & II molecules [53]. Keratinocytes in AD lesions express high
levels of thymic stromal lymphopoietin (TSLP) which condition DCs to induce Th2 cell
differentiation [54, 53]. The detached and activated DCs migrate to the lymph node and
present the antigen on MHCII which is recognised by T cell receptors (TCR) on naive
CD4+ T cells promoting the polarisation of Th2 cells. [53]
Upon return to the skin, Th2 cells secrete IL-4, IL-5 and IL-13 [53, 55]. IL-5 promotes
proliferation and activation of eosinophils, whereas IL-4 and IL-13 induce class switch-
ing in B cells stimulating the production of antigen-specific IgE [56]. This primes mast
cells which, upon cross-linking with an allergen, degranulate releasing proinflammatory
molecules. Besides inducing B cell class-switching, Th2 cytokines inhibit the expression of
terminal differentiation genes in keratinocytes such as filaggrin and loricrin which further
impairs barrier integrity [56]. In the chronic phase, the inflammation shifts from a primar-
ily Th2 mediated to a mixed response in which Th2, Th1 and Th22 cells play a role in
inflammation as well as fibrotic remodelling culminating in lichenification [57].
Aside from the defects associated with genetic mutations within the FLG gene, other
barrier deficiencies are present in AD resulting in xerosis and an increase of transepidermal
water loss (TEWL). These include variants within the region of genes which encode the
epidermal differentiation complex (EDC), as well as reduced ceramide and lipid expression
[58, 51, 59, 44]. It is important to note that the uninvolved skin of patients with AD is not
clinically normal and is also dry [48]. Reports have shown decreased levels of ceramides
[60], as well as increased expression of Th2 products in non-lesional skin [61].
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1.4.1 The AD microbiome
Early culturing studies performed in the 1970s revealed an over-representation of Staphy-
lococcus aureus [62] on the lesional and non-lesional skin of AD patients. This finding has
been replicated by others who showed that S. aureus is encountered more often, and to
higher density on lesional skin than on non-lesional skin [63]. Based upon this evidence, AD
is often treated with antimicrobial agents to control the growth of S. aureus [44], however,
the contribution of the microbiome to disease is not yet fully understood. Studying the
role of S. aureus and the further resident community can enable a better understanding of
the pathogenic and protective host-microbe interactions which may trigger and exacerbate
inflammation.
The most in-depth analysis of the AD microbiome utilised 16S sequencing on a cohort of
12 children with AD and 11 healthy controls [64]. Kong et al. confirmed a strong presence
of S. aureus but also demonstrated several other disturbances to the atopic microbiome
which could not have been identified using culturing methods. The study showed that the
microbiota exists in a state of dysbiosis due to a loss in species diversity [64]. Furthermore,
it was shown that patients with severe disease experienced further loss in diversity, and
that patients undergoing treatment had significantly higher diversity than those without.
A follow up study in a single patient showed that the diversity during an inflammatory
flare up (flare) which was untreated was lower than that of a bleach bath treated flare.
This analysis indicated that anti-inflammatory or antimicrobial therapy restores a level
of diversity and may limit the effects of dysbiosis. Furthermore, S. aureus was found to
strongly correlated with species diversity thus indicating that this pathogen is a major
factor in dysbiosis [64].
The role that S. aureus plays in the pathogenesis of AD is an intense area of research. S.
aureus produces superantigens including staphylococcal enterotoxin A and B [65]. It has
been shown that the abundance of superantigen isolated from S. aureus strains on AD skin
is higher than superantigen isolated from S. aureus strains on healthy skin [66]. Moreover,
the same study also showed that superantigen was correlated with T cell activation as well
as disease severity and thus may be one of the mechanisms by which S. aureus exacerbates
or initiates inflammation.
Kong et al. [64] also reported that S. epidermidis was of increased abundance on atopic
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skin, albeit not to the extent of S. aureus, and that the relative abundances of Strepto-
coccus, Corynebacterium and Propionibacterium increased post-treatment restoring a level
of species diversity. The role of S. epidermidis is an intense area of debate and is often
considered to be a healthy skin commensal [31]. Studies have shown at least two possible
mechanisms by which S. epidermidis may protect the host against over-colonisation of
S. aureus. S. epidermidis is thought to selectively inhibit S. aureus growth by produc-
tion of phenol-soluble module (PSM) peptides which have similar characteristics to host
antimicrobial peptides [67]. Another study showed that S. epidermidis can induce host ker-
atinocytes to produce antimicrobial peptides via the toll-like receptor (TLR) 2 signalling
pathway, enabling the host to improve response against pathogens [68, 65]. Other species
such as P. acnes which often colonises healthy skin [31], may also play a beneficial role
by the metabolism of glycerol into short chain fatty acids (SCFA) including propionic acid
which suppress the growth of S. aureus [69].
Whilst it is clear that S. aureus plays a role in the pathogenesis of AD, the mechanisms
of action are not yet fully understood. One way to gain insight is to study host-microbe
interactions and evaluate the effect of colonisation on the expression of host genes. Such
analysis would allow for a greater understanding into how S. aureus virulence factors are
associated with the expression of structural epidermal barrier genes and host immune
processes [65].
1.5 Psoriasis
Psoriasis has a current prevalence of around 3% in the USA population and its incidence
rate has doubled over the last 30 years [70]. The condition impairs quality of life and treat-
ment can be a considerable economic burden. Approximately 30% of psoriasis patients also
have psoriatic arthritis (PsA); these patients endure joint pains and debilitating physical
impairment [71]. As well as PsA, psoriasis patients are characteristic of many comorbidities
including metabolic syndrome [72], type 2 diabetes and cardiovascular disease [73]. The
age of onset of psoriasis is bimodal, with the first occurring between the ages of 20-30 and
the second between 50-60.
Psoriasis is a chronic, currently incurable inflammatory skin disorder associated with sil-
very plaques due to hyperproliferation of keratinocytes and incomplete cornification in the
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statum corneum [73]. Keratinocytes in the basal layer divide at a faster rate resulting in a
thickened epidermis with a defective outer layer in which the turnover time of basal cells
is rapidly increased.
Involvement of the immune system in psoriasis is clear with increased infiltration of both
innate cells including neutrophils and macrophages, as well components of the adaptive
immune system including T cells which secrete proinflammatory cytokines resulting in
inflammation [73]. Psoriatic skin contains an abundance of T-helper 1 (Th1) cytokines
including IL-1, IFN-γ and TNF-α, therefore, early views considered psoriasis to be mostly
associated with Th1 cells [74]. This model was challenged when it was discovered that
cytokines produced by Th17 cells including IL-17A and IL-22 were prevalent in lesions as
well as increased infiltrates of Th17 cells themselves [75]. IL-17A has wide spread proin-
flammatory effects which induces cytokine production in many other immune cells.
Whilst the trigger of psoriasis is not fully understood, it is thought that genetic factors
in conjunction with environmental factors such as stress, microbiota or trauma result in
stressed keratinocytes which release nucleic acids, as well as pro-inflammatory cytokines
TNF, IL-6 and IL-1B [76]. The self DNA/RNA complexes with an antimicrobial peptide
called LL-37 which activates plasmacytoid dendritic cells (pDCs). The activated pDCs
secrete interferon-α, which along with keratinocyte derived cytokines leads to the activa-
tion of dermal dendritic cells. Once activated, dermal dendritic cells migrate to the lymph
nodes where cytokines including IL-23 and IL-12 induce a Th17 or Th1 phenotype in naive
CD4+ t cells by presentation of a currently unknown antigen [76, 73]. Activated Th17
and Th1 cells migrate back to the skin along a keratinocyte-derived chemokine gradient
where Th1 cells secrete interferon-γ and TNF-α, and Th17 cells secrete IL-17A, IL-17F
and IL-22 [76]. These cytokines drive the proliferation of keratinocytes and promote secre-
tion of antimicrobial peptides including DEFB4 and S100A7 which are expressed to great
magnitude in psoriatic lesions [77] and neutrophil chemoattractants [76, 73].
The mechanisms underlying psoriasis are not yet fully understood and the triggering event
is still unclear. Genetic factors clearly play a role as genome wide scans revealed that
psoriasis is associated with variants in the IL23A and IL23R genes [78]. IL-23 is secreted
by dendritic cells and is involved with the differentiation of Th17 cells where variants may
enhance induction of the Th17 phenotype [74]. Biologic treatments that target IL-23 have
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shown effectiveness in the treatment of psoriasis [79, 80]. Another possible factor relates to
impairment to the epidermal barrier. Genetic variants have been discovered in the LCE3B
and LCE3C genes which may impair skin barrier function enabling increased permeability
and entry of immunoreactive microbial products into the skin [81]. Several of the genetic
variants associated with psoriasis are also factors in Crohn’s disease [80]. Crohn’s disease
is thought to be associated with enteric dysbiosis indicating that microbial stimuli may
well be a factor in psoriasis [80]. The basis for genetic association is further compounded
by patients undergoing bone marrow transplantation (BMT) which showed resolution of
psoriatic inflammation [82]. Similarly, there are also reports of patients developing psoriasis
after BMT from a psoriasis affected donor indicating that psoriasis is caused by genetic
factors affecting bone marrow-derived immune cells [83].
1.5.1 The PSO microbiome
Genetic mutations within the innate and adaptive immune system, as well as to genes en-
coding for components of the epidermal barrier suggest a potential role of the microbiome
in psoriasis. Several analyses of the psoriatic microbiome have been performed, however,
the results are varied between studies.
Gao et al. [84] found that Propionibacterium acnes was reduced on lesional skin. Fur-
ther reduction within the relative abundances of Proteobacteria and Actinobacteria phyla
were observed as well as an increase in Firmicutes. These initial findings confirmed that
the composition of microbiota on lesional and non-lesional skin were perturbed in psoriasis.
A more recent study indicated that the combined relative abundances of Corynebacterium,
Propionibacterium, Staphylococcus and Streptococcus were increased on lesional skin [85].
Furthermore, in the same study, psoriasis was shown to have reduced species richness on
both lesional and non-lesional skin, as well as higher intra-group variability compared to
control samples. In response to a high impact paper describing enterotypes in the gut
microbiome [14], Alekseyneko et al. described a similar phenomenon in the skin, which
they called Cutaneotypes. Cutaneotypes were defined as two clusters distinct microbial
compositions: Cutaneotype 1 was associated with Actinobacteria and Firmicutes whereas
cutaneotype 2 was associated with Proteobacteria. The Firmicutes-Actinobacteria domi-
nant cutaneotype was significantly associated with lesional psoriasis.
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A study of the psoriatic microbiota isolated from skin biopsies reached different conclu-
sions. Fahlen et al. [86] described a trend for reduced Actinobacteria in psoriatic skin
as well as increases in Proteobacteria at the phylum level. At the genus level they found
reductions in Propionibacteria and Stapylococcus on lesional skin from the limb.
Overall these studies have shown that the psoriatic microbiota does vary with psoriasis
status. Studies on swabs showed general trends for increases in Firmicutes and reduc-
tions in Proteobacteria, however, there were some inconsistencies. For example, Gao et
al. [84] identified Actinobacteria as being significantly under-represented on psoriatic skin,
whereas Alekseyneko et al. [85], did not report any significant difference in Actinobacteria,
but described psoriasis samples as being associated with a ‘Firmicutes-Actinobacteria-high’
cutaneotype. Analysis of biopsy data were even more inconsistent and suggests that micro-
biota may be able to penetrate the skin and interact with the host indicating another role
for intracutaneous microbiota. Further analysis with larger sample sizes may be required
to define the core characteristics of the psoriatic microbiome.
1.6 Contributions
In comparison to the gut, little is known about the skin microbiome and its role in host
health and disease. Whilst there are studies evaluating the composition of the atopic
dermatitis and psoriasis associated microbiomes, these studies were performed on few sam-
ples, and the results are varied, particularly in the case of psoriasis. This thesis presents
an analysis of the largest inflammatory skin disease microbiome dataset to-date consisting
of more than 600 samples of healthy, non-lesional and lesional skin from healthy volunteers
and patients with either atopic dermatitis or psoriasis generated by the Microbes in Allergy
and Autoimmunity Related to the Skin (MAARS) consortium. As well as 16S sequencing
of the cutaneous microbiota, the host transcriptome was profiled from biopsies taken at
the same location providing a unique opportunity to investigate host-microbe interactions.
The results in this thesis contribute towards a greater understanding of bacterial dysbio-
sis and the relationship with host gene expression in the in context of inflammatory skin
pathologies.
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In Chapter 3, the microbiota is comprehensively evaluated using the largest skin inflam-
mation associated 16S dataset to date. Across all levels of the phylogenetic tree, includ-
ing both lesional and uninvolved cohorts, this analysis identifies the taxa which are either
over-represented or under-represented in both psoriasis and atopic dermatitis. Here, whilst
confirming the presence of known pathogens such as S. aureus in atopic dermatitis, several
novel species were identified as potential pathogens in psoriasis, both on lesional and non-
lesional skin. As well as differential abundance analysis, the association of species diversity
with disease severity was established. Finally, using a co-occurrence network analysis of
disease associated species, differences in the topology of microbe-microbe interactions were
identified between AD and PSO.
In Chapter 4, the transcriptome is interrogated to identify differentially expressed genes
which may play critical roles in the mechanisms which underlie atopic dermatitis and psori-
asis. The genes which are active in the non-lesional tissue of both diseases were contrasted
revealing similarities and differences in the transcriptional architecture of disease suscep-
tible skin. A similar comparative analysis of the lesional tissue was performed and the
pathways which are common to both diseases or preferentially expressed in either AD or
PSO were determined. These results identify the particular cytokines and components of
the immune system which were common or specific to both diseases.
In Chapter 5, the microbiome and host-transcriptome were integrated to identify host-
microbe associations. Using differentially expressed genes and suitable schemes of dimen-
sionality reduction, the microbe-associated host transcripts were identified. The pathways
identified are highly relevant to disease pathology and provide insight into how pathogenic
microbes interact with the host to drive inflammatory disease.
In Chapter 6, skin co-expression networks were constructed within the weighted gene co-
expression network analysis (WGCNA) framework in order to identify modules of highly
co-expressed genes. By performing comparative network analysis, modules which were
differentially co-expressed between healthy, lesional and non-lesional tissue were identified
by module preservation analysis. Two modules of genes were found to be disconnected in
a healthy skin which formed a tight interacting coexpression module in a diseased state.
Using the same networks, eigengenes were used to elucidate host-trait relationships. This
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analysis revealed clinically relevant modules of the inflammatory transcriptome which co-
varied with both disease severity and pathogen abundance providing further insight into
microbe associated gene signatures.
Chapter 2
Methods to study the microbiome
and transcriptome
This chapter introduces the technology and methodologies used to generate and analyse
transcriptome and microbiome datasets. Following this, the methods and sampling proto-
cols used to generate the MAARS cohort are described.
2.1 The microbiome
Early studies of microbiota were performed on a phenotypic basis [87, 9] and to identify
differences between samples, morphological comparisons were performed using culturing
methods. One of the major drawbacks of quantitative culturing is that many species are
not easily cultured, especially anaerobic microbes with one estimate suggesting that more
than 99% of species cannot be cultured by traditional means [88]. Culturing approaches
are also slow, labour intensive and thus cost ineffective. To increase resolution, molecu-
lar genotyping methods were developed which are now far quicker and more accurate at
identifying species than culturing approaches [89].
2.1.1 Methods to study the microbiome
2.1.1.1 16S sequencing
With advances in DNA sequencing technologies, modern approaches emerged for bacte-
rial classification based upon comparative genomics. The first molecular markers focused
around the ubiquitous 16S rRNA gene [8] which is a highly conserved critical component of
17
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the translational machinery. The 16S rRNA gene is a short 1500bp sequence and behaves
as a molecular chronometer [90]. As the molecular function of the 16S gene is necessary for
cellular operations, it is one of the most conserved genes with a very low rate of mutation
[89].
The 16S rRNA molecule has several characteristics which make for an ideal phylogenetic
marker. First, the sequence is present in all prokaryotic organisms and contains both
variable and highly conserved regions [90]. The conserved regions mutate slowly and are
targeted by universal PCR primers enabling global amplification of all 16S genes con-
tributed by the bacterial population. Nine ‘hyper-variable’ regions evolve faster, and it is
within these regions that sequence heterogeneity is observed between bacteria reflecting
evolutionary distance and allows comparison between taxa [91]. These distinct character-
istics of the the 16S rRNA gene make it an ideal target for amplicon sequencing and the
polymorphisms specific to a bacterial lineage can be used as a molecular ‘fingerprint’ to
profile the taxonomic composition of a microbial community.
Due to the small length of the 16S gene, sequencing efforts are inexpensive; this has resulted
in numerous 16S sequence deposits in public databases. One such database called Green-
genes [92], contains over one million 16S sequences; BLAST [93] queries can be performed
on these to annotate unknown 16S sequences. Despite the many positive characteristics
of the 16S rRNA gene, amplicon sequencing is unlikely to capture the entirety of bacterial
diversity as the primers designed are based upon previously isolated microbes which may
not be characteristic of all prokaryotes.
2.1.1.2 Taxonomical characterisation
Upon obtaining 16S reads, the sequences are assigned to a taxonomy class for further anal-
ysis of bacterial composition. Several tools exist for taxonomic characterisation, although
the most commonly used methods include Mothur [94] and Quantitative Insights Into Mi-
crobial Ecology (QIIME) [95].
The task of annotating sequences with taxonomic information is performed by clustering
sequences into Operational Taxonomical Units (OTUs). An OTU represents a group of
highly similar sequences with small phylogenetic distance intended to approximate bacte-
rial species. Sequences are binned at different thresholds of sequence similarity to achieve
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different levels of taxonomic resolution. Binning at 97% similarity is thought to approxi-
mate differences at the species level, however in practice, similarity thresholds are arbitrary
and are dependent on the research question and values of 95% to 99% are typically used [87].
Clustering of sequences and the picking of OTUs is an important step which impacts
upon on downstream analysis. In the QIIME pipeline, OTUs can be defined by three main
strategies: De novo, open reference, or closed reference [95]. ‘Closed reference’ OTU picking
aligns reads to a reference database resulting in a high quality phylogenetic tree, however,
reads that do not match to a known sequence are removed thereby discarding potentially
novel sequences. ‘De novo’ clusters reads based on sequence similarity independent of
a reference database so that all reads are retained, however, the taxonomy of de novo
OTUs are unknown. ‘Open reference’ is a hybrid approach which clusters sequences using
a reference database like that in closed reference, however, reads which do not match in
the database are clustered using the de novo approach. Open reference OTU picking is
often used as it retains the ability to assign informative taxonomic annotations as well as
detecting novel diversity. Once OTUs are picked, a phylogenetic tree is constructed by
a multiple sequence alignment of OTU sequences with a tree building algorithm such as
FastTree [96]. Upon completion of OTU picking, the resultant taxonomical classifications
are summarised in a count matrix C(ci,j) where ci,j is the number of reads for an OTU i
in a sample j which is used for further downstream analysis.
2.1.2 Analytical methods for Microbiome data
This section will consider the analytical methods applied to microbiome data including
the preparation of raw data, analysis of community composition via α and β-diversity
measures, ordination, differential abundance and co-occurrence analysis.
2.1.2.1 Data normalisation
Before comparisons between pre-defined groups, a normalisation step must be performed
to account for the technical effects of sequencing and to allow comparisons between sam-
ples. Samples are often sequenced to uneven depths which range in orders of magnitude
[97]. Differences in library sizes across groups can result in the clustering of samples by
sequencing depth [98] instead of true biological variation. Further, if left uncorrected, un-
equalised library sizes can inflate the rate of false positives and any observed differences in
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OTU abundance could be due to technical and not biological effects [98].
One of the most popular methods for normalising microbiota count data data is rarefy-
ing. This procedure equalises the library sizes across samples by randomly subsampling
sequences to a fixed depth. A minimum library size is chosen and all samples below this
threshold are removed from the dataset. This threshold is selected in order to remove
only a small percentage of under-sampled communities. The remaining samples are then
re-sampled to the common minimum library size. Rarefying has been utilised in many
publications and is part of the standard QIIME pipeline [95], however, it has been criti-
cised and described as ‘statistically inadmissible’ [97] as the procedure throws away part
of available data and inflates variance due to random subsampling.
Other normalisation methods derive a normalisation factor fj representing the true library
size of sample j. The normalisation factor is used to globally adjust the counts in a sample
allowing for comparison across libraries [99]. The most widely applied method is total
sum scaling (TSS) which uses the total library size of each sample as the scaling factor fj.
TSS does not introduce additional noise by randomly subsampling and transforms counts
into proportions on a scale of 0-1 which are often called ‘relative abundances’. Other ap-
proaches have been developed specifically for microbiome data. These include cumulative
sum scaling (CSS) [100] in which the normalisation factor is derived from the total sum of
reads up to a quantile which is estimated from the data. The underlying concept is that
a sequencer will preferentially sample abundant sequences, and calculating scaling factors
from the total library size will penalise sequences of lower abundance. CSS thus attempts
to find an appropriate quantile and normalisation factor such that less influence is afforded
to highly abundant species.
Given the similarities between 16S and RNAseq data, recent studies have explored the
utility of methods initially designed for RNAseq data [97, 98]. These include trimmed
mean of M-values (TMM) [101] which is a method included as part of the EdgeR package
[102]. TMM normalisation uses the total library size, however, a normalisation factor
is first calculated to correct the library size for each sample. TMM works under the
assumption that most features are not differentially abundant and the normalisation factors
are calculated after removal of differentially abundant taxa [99]. This means that the
scaling factors are derived on the ‘non-differentially abundant’ component of the microbiota
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and places less influence on highly abundant sequences. Normalisation of microbiome data
is an intense area of research and debate, however, there is no agreed consensus [97, 98, 103].
2.1.2.2 Alpha diversity
It is common to describe a microbial community by means of α-diversity which profiles the
species composition within a sample. Two main components of α-diversity are commonly
used in microbiota studies: richness and evenness.
Species richness refers to the absolute number of unique species present in an environment.
The simplest measure of species richness is to count the number of individual species in a
sample, however, this approach can be sensitive to technical issues such as undersampling
and minor differences in DNA concentration. The Chao1 richness estimator [104] assumes
that if a sample has many rare species, i.e., singletons, then it is likely that there are more
species which were not detected. Chao1 therefore estimates the true species richness whilst
taking into account under-sampling based upon the number of singletons and doubletons
in a sample. The second measure, evenness reflects the homogeneity of species abundances
in a community. For example, a sample consisting of approximately equal species propor-
tions reflects high evenness, whereas a sample with an extremely dominant species has low
evenness.
To quantify species diversity, hybrid measures are often used to summarise both species
richness and the evenness of the community into one measure. One such popular approach
is the Shannon index [105] which calculates the sum of species proportions in a community




pi ln pi (2.1)
where pi is the proportion of species i. pi is estimated as pi = ni/N where ni is the count
of species i, and N is the total counts for all microbes identified in a community. The
Shannon index therefore increases with greater richness and evenness.
As alpha diversity is calculated for single community (sample) it is often used to compare
diversity between predefined groups such as disease status or body sites. In clinical mi-
crobiota studies, it is generally considered that higher diversity is a beneficial trait and
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protects against offending microbes whilst states of lower diversity can indicate dysbiosis
and a loss of homeostatic equilibrium [106, 87].
2.1.2.3 Beta diversity
Alpha diversity describes the composition at a single site, however, a major objective of
many microbiome analyses is to describe differences in community composition between
sites [14]. β-diversity is used to compare the compostion between communities and is cal-
culated as a measure of distance or dissimilarity between two samples. In most cases, more
than two samples are to be compared, therefore, β-diversity is calculated between every
pair of samples to generate a square distance or dissimilarity matrix.
For studies of the microbiota, there are two main classes of β-diversity measure. The
first type consider only species abundance patterns, known as taxon based, whereas the
second also take into account the phylogenetic distance between species [107]. Common
measures of non-phylogenetic β-diversity consist of Bray Curtis (BC) [108] dissimilarity
and the Jaccard index. Bray Curtis measures pairwise dissimilarity between sites using
the shared abundances of species as well as the total abundance at each site. The cal-
culation is robust to zero counts and as microbiome data is characteristic of many zeros,
BC is one of the most popular metrics for analysis of β diversity in microbiome studies [103].
Measures such as the Jaccard and BC treat species as independent features, however, newly
developed measures also consider the phylogenetic relationship between species. For exam-
ple, two species of the Lactobacillus genus are more genetically similar than two species of
the Lactobacillus and Peptostreptococcus genus. Phylogenetic β-diversity measures work
under the assumption that closely related species share many of the same functions rep-
resenting redundancy, and should be down-weighted compared to shared counts between
divergent species. Distance measures of this class have been designed specifically for mi-
crobiome studies such as the UniFrac distance [107]. Weighted UniFrac distance takes
into account both abundance and phylogenetic distance whereas unweighted UniFrac only
considers branch length of the phylogenetic tree as well as presence-absence patterns.
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2.1.2.4 Ordination
Calculation of beta diversity results in a distance matrix describing the pairwise dissim-
ilarity between samples. The resultant distance distance matrix is high-dimensional and
thus cannot be visualised. Ordination of the distance matrix projects the high-dimensional
sample distances into a low-dimensional ‘ordination’ space such that the relatedness be-
tween samples can be observed on a small number of axes (typically two to three). The
objective of ordination algorithms is to represent sample distances in a low dimensional
space whilst preserving the true distances as closely as possible. Whilst there are many
available methods for ordination, two of the most popular are principal co-ordinates anal-
ysis (PCoA) and non-metric multidimensional scaling (NMDS). PCoA is performed by
singular value decomposition of the distance matrix and finds the directions of greatest
variability between sites and projects them into a low dimensional space. PCoA assumes a
linear relationship between sites, however, if non-linear trends are present PCoA may fail
to accurately represent the true distance resulting in an ‘arch effect’ [109]. NMDS, on the
other hand, attempts to find the best position of samples in a pre-specified number of di-
mensions using an iterative procedure whilst minimizing ‘stress’ [109]. Stress is a measure
of the distance between points in ordination space compared to the true distances, thus
a low stress ordination solution closely represents the true distances. NMDS uses rank
distances meaning that it is robust to non-linearity and can be used to ordinate a wide
range of dissimilarity metrics.
2.1.2.5 Differential abundance analysis
A major objective of microbiome analysis is to identify a change in abundance for a specific
microbe in response to disease and or treatments. Such analysis is important to identify
species which may be lost in disease and may have a protective effect, or those which
increase and could be pathogenic. The term ‘differential abundance analysis’ refers to the
statistical challenge of profiling systematic changes in OTU abundance across pre-defined
groups.
16S data is usually non-normally distributed, therefore, common approaches are to apply
non-parametric tests such as the Wilcoxon-rank sum in the case of two classes, or Kruskal-
Wallis for multiple groups after normalisation of the OTU table. These statistical tests
have been used to identify differentially abundant OTUs in many studies [85, 64, 110].
Other methods have been specifically designed for 16S data including LEfSe [111], which
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is a tool based upon Kruskal-wallis and Wilcoxon tests coupled with linear discriminate
analysis.
Non-parametric tests do not assume a distribution and are an appropriate test for differen-
tial abundance analysis, however, they have been shown to suffer from limited sensitivity
[98] and do not have the capability to control for environmental factors or covariates. As
a result, there has been an increasing preference for the application of parametric tests to
studies of the microbiota due to their increased power, particularly in the detection of low
abundance OTUs, and their ability to quantify effect size. One such example is Metastats
[112] which uses a two sample t-test with permutation testing to estimate significance with
respect to the non-normal distribution.
Recent research has focused on the application of parametric models intended for RNAseq
analysis to studies of the microbiota; these are based upon the negative binomial distribu-
tion (NB) [97, 98]. Historically, RNA seq counts were described with a Poisson distribution
[113], however, when taking into account biological replicates, the variance in read counts
is greater than the Poisson distribution can explain [97]. This phenomenon, known as
overdispersion, means that the Poisson distribution tends to underestimate the variance
resulting in an inflated rate of false positives [97]. The negative binomial distribution has
an extra parameter which can take into account overdispersion allowing for a better fit of
biological replicates. Examples of such methods incorporating the negative binomial dis-
tribution include DEseq2 [114] and EdgeR [102], both of which have been shown to have
higher sensitivity than non-parametric statistics in recent comparative analysis [97, 98].
These models use raw read counts to estimate their own normalisation factors - TMM in
edgeR [101], and RLE in DESeq2, which are used to adjust for uneven library sizes. Despite
promising results, methods based upon the NB distribution do not always perform well
with excessive zeros [98]. Other approaches include metagenomeSeq [115] which is based
upon zero-inflated Gaussian (ZIG) mixture models that assume excessive zero counts are
not a result of absence but are due to undersampling. As with normalisation strategies,
there is a considerable debate as to which is the best approach for differential abundance
analysis and no consensus has been reached [98].
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2.1.2.6 Linear models for microbiome analysis
The application of linear models for differential abundance, as well as for omics’ integration
has gained in popularity due to its ability to control for multiple potentially confounding
variables. Extraneous sources of variation including sex [40, 41], age [40], body site [33, 38],
diet [18, 116, 19], and ethnicity [117] have all been shown to impact upon OTU counts and
multiple regression allows for estimation of the linear relationship between the response
and predictor of interest independent of all other factors included in the model.
The most well known package implementation for microbiome data is MaAsLin [5, 118]
which incorporates linear models with an arcsine square-root variance stabilising transfor-
mation to account for the heteroscedasticity of OTU proportions. For each OTU, a linear
model is fit of the form:
arcsin(
√
Y ) = β0 + β1X1 + ...+ βpXp + ε (2.2)
where Y is the proportion of an OTU, β0 is the intercept term, Xp are the metadata to be
tested, and β1 is the coefficient representing the marginal change in arcsin(
√
Y ) for a one
unit change in β1 whilst all other βp are held constant.
The ability of linear models to quantify an association independent of other factors has
resulted in a wide range of applications, not only including differential abundance anal-
ysis for disease association [6, 5], but also for host-microbiota and metadata-microbiota
interactions [119, 120, 29, 121].
2.1.2.7 Co-occurrence analysis
Differential abundance analysis is a reductionist approach which considers taxa as indepen-
dent entities, however, in reality, taxa interact with each other in intricate and complex
ecological systems. Whilst many conditions, particularly those with a genetic basis are
associated with a single causal mutation, it also clear that many phenotypes are complex
and are linked to multiple factors. It is therefore just as likely that a host phenotype is not
just driven by a single microbe, but by a group or community of pathogenic microbiota.
The underlying principal of co-occurrence analysis is that when pairs of species tend to be
present in the same communities often, there is likely to be an association between them.
Co-occurrence analysis is thus the identification of these interactions and the patterns of
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species abundances across samples or conditions.
Methods based upon presence and absence patterns have been successfully used to identify
co-occurrence patterns in studies of the microbiota. These include studies which have used
the checkerboard score [19], as well as the dice index [122], however, co-occurrence patterns
can also be represented as a network in which OTUs are modelled as nodes and associations
between taxa as edges. The underlying concept is that a community of highly connected
OTUs may be functionally related providing insight into the underlying ecological system.
Whilst correlation based approaches using Pearson or Spearman metrics have been used
to reconstruct ecological interaction networks [14, 123], they have been shown to result in
spurious correlations as relative abundance data is compositional [124, 125]. This means
that if the relative abundance of one species goes up then another must come down. To
account for this, methods specifically developed for microbiome analysis can be applied
such as SparCC [124] which estimates the correlation using the variances of the log-ratios
between taxa.
2.2 The Transcriptome
According to the central dogma, genes encoded within the DNA are transcribed into mes-
senger RNA (mRNA) by a process called transcription. Within a specific environment,
the totality of these transcribed DNA sequences is called the transcriptome. Whilst the
genome is static, the transcriptome is dynamic representing the components of the genome
which are actively transcribed in a tissue at a given time point. Microarrays, which have
emerged from the human genome project, have transformed mRNA analysis by allowing
simultaneous profiling of thousands of genes. Microarrays allowed researchers who had
become accustomed to focusing on small subset of genes to consider global shifts in gene
expression enabling detection of new phenotype responsive genes. Whilst initially microar-
rays were used to screen for associations amongst many individual genes, now they can be
used to understand the role of genes at the systems level.
High throughput omics’ technologies are constantly evolving and few technologies have
contributed as much to our understanding of complex disease. Gene signatures have now
been unearthed for many pathologies including cancers as well as response to treatment
and offer promise for future development of therapeutics.
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2.2.1 Methods to analyse the transcriptome
2.2.1.1 Microarrays
Hybridisation-based methods offer an inexpensive way to obtain transcriptomic information
from biological samples. A DNA microarray is a surface on which a high density of probes
are fixed at defined locations, each of which represents a specific gene encoded on the
genome [126]. The probes are constructed from millions of short 25 bp single stranded
DNA molecules known as oligonucleotides which act as biosensors for complementary RNA
(cRNA) targets. The cRNA targets are extracted from a biological sample of interest and
then bind to the probes in a process called hybridisation. Quantification of the amount
of target RNA binding at a specific probe can be measured by labelling targets with a
fluorescent marker and scanning with a high resolution epifluorescent microscope [126].
The fluorescent intensity level of each probe is quantified to obtain genome wide relative
measures of gene expression. Despite suggestions that microarrays have reached their
technical limit, and are to be replaced by more modern technologies such as RNASeq
which are not limited by a defined probeset [127], microarrays remain a powerful tool for
obtaining insight into the transcriptional architecture of biological systems.
2.2.2 Analytical methods for transcriptomics data
This section will consider analytical methods applied to transcriptome data including the
preparation of raw data, identification of differentially expressed genes, methods for func-
tional analysis and dimensionality reduction techniques.
2.2.2.1 Data normalisation
Technical errors introduced by ‘cross-hybridisation’, a phenomenon when target RNA hy-
bridises non-specifically, as well as instrumental and biochemical factors all contribute to
the noise associated with microarray experiments. The changes in raw expression values
across arrays are thus composed of both technical and biological effects. As a consequence,
it is important to normalise intensity values to minimise technical variation, and to allow
for meaningful comparison between arrays.
Early methods of normalisation scaled the global intensity values in a sample by a constant
such as the mean or median intensity across arrays [128]. Others realised that the expres-
sion of ‘housekeeping genes’ were constitutively expressed and used the expression of these
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genes as reference for normalisation. These genes were considered to vary little between
conditions, however, this was suboptimal as the high expression of housekeeping genes is
not representative of most genes, and their expression was not as stable as initially thought
[129]. Modern approaches for normalisation of microarrays include the MicroArray Suite
5.0 (MAS5) [130] algorithm which corrects for background noise using mismatch probes
(mm) and then a normalisation step is performed independently for each array based upon
a robust average of background corrected intensities. As each array is normalised indepen-
dent of other arrays, MAS5 is not dependent on the sample size or quality of individual
arrays and is particularly useful in circumstances where additional samples may be added
at later dates [131].
An alternative approach is used in the robust multiarray averaging (RMA) method [132]
which does not use mismatch probe information. Instead, RMA estimates the true signal
using a convolution model under the assumption that probe intensities are composed of a
signal and a common background noise component. RMA then uses quantile normalisation
to force the background corrected intensity distribution of all arrays to be equivalent.
Modern Affymetrix chips such as the HuGene 2.1st do not include mismatch probes which
limits the application of MAS5 and in such circumstances normalisation with RMA is
preferred.
2.2.2.2 Differential analysis
Transcriptomics data enables the identification of molecular signatures associated to a
pathology or treatment. The statistical task of identifying group responsive genes comes
under the category of differential expression analysis (DA), where the objective is to identify
differentially expressed genes (DEGs). Identification of DEGs is important as signatures of
up-regulated and down-regulated transcripts can provide a basis for understanding patho-
logical mechanisms.
Historically, DEGs were identified by calculating the fold change in mean expression val-
ues between predefined groups. Whilst an intuitive approach, fold changes do not consider
sample variances and can fluctuate greatly if the denominator is small, as is often the case
with lowly expressed genes. Further analysis showed that calling differential expression
based solely on a fold change criterion resulted in unacceptable levels of false positives
[133, 134]. To overcome problems with the fold change criterion, statistical tests were used
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as they take into account sample variances and also allow the calculation of p values. Early
studies used t-tests, however, the t-test suffers from low power with small sample sizes.
Problems with t-tests were also compounded by high false positives rates amongst lowly
expressed genes [135]. These genes can have low variances resulting in a large t statistic
even when the difference in means is small.
To overcome the shortcomings of t tests, more complex methods were developed such as as
Significance Analysis of Microarrays (SAM) [136], however, the most popular method used
today is linear models for microarray data (limma) [137, 138]. The principle underlying
of limma is to ‘borrow information’ across all genes on the array and combine the gene
specific variances with a population estimate in an approach known as ‘shrinkage’. This
ensures that genes with low variances are not falsely differentially expressed in the absence
of an acceptable difference in means. Whilst both SAM and limma are used in modern
microarray analyses, a recent study concluded that SAM had weak performance and was
outperformed by limma [139]. Many modern transcriptome analyses today combine both
p values and fold change criteria to ensure that associations are significant, whilst focusing
on the most biologically relevant changes [58, 140].
2.2.2.3 Multiple testing
Gene expression data consists of many features which are often orders of magnitude greater
than the number of samples measured. For a study of 10,000 genes, differential analysis
at an α level of 0.05 would result in 500 DEGs just by chance alone. This, known as the
‘multiple testing problem’, an issue which plagues hypothesis testing in high throughput
analyses. One way to reduce false positives is to control for the family-wise error rate
(FWER) using Bonferroni correction. This method aims to reduce the experiment-wide
probability of making a false positive to α [133] meaning that for the same study, a p
value of 0.05 / 10,000 = 5e-06 would be required for a gene to be called differentially
expressed. This is considered to be too conservative for many biological analyses which
often have small sample sizes. Instead of controlling the experiment wide error, false
discovery rate (FDR) correction aims to control the proportion of false positives amongst
the genes considered to be differentially expressed. Methods which control the (FDR) such
as the as the Benjamini Hochberg method [141] offer greater sensitivity for discovery at
the cost of increased type-I error.
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2.2.2.4 Functional analysis
The functional properties of genes which have been characterised through experimentally
or computationally derived methods are stored in rich publicly accessible repositories such
as Gene Ontology (GO) [142]. As well as ontologies, several databases hold mechanistic
information about the physical interactions between biomolecules known as biochemical
pathways. Pathways are often curated using the available literature describing the mecha-
nisms underlying particular biological responses. Databases of this kind include Ingenuity
Pathway Analysis (IPA) [143], the Kyoto Encyclopedia of Genes and Genomes (KEGG)
[144], and REACTOME [145].
For a list of differentially expressed genes, it is often of interest to determine if its con-
stituents are statistically associated with a functional process or pathway. Enrichment
analysis, also known as over-representation analysis (ORA), integrates experimentally de-
rived gene lists with ontology and pathway databases. The overall objective is to determine
if an experimentally determined list has a higher gene-specific overlap with a pathway than
would be is expected by chance. Tests to perform ORA use contingency tables represent-
ing the number of genes within a pathway, and the number of genes which were found to
be significantly differentially expressed. A statistical test such as the hypergeometric or
Fisher’s exact test is then used to determine if genes within a pathway are over-represented
with respect to the total numbers of genes in the pathway, and the total number of genes
under investigation.
Over representation analysis considers genes as equally weighted features which are de-
pendent on a hard threshold. Whilst a cut off of p < 0.05 is an accepted criterion for
differential expression, this threshold includes genes p = 0.049, and discards genes p =
0.051 which could potentially hinder the detection of biologically relevant pathways [146].
Furthermore, no information regarding the magnitude of differential expression is consid-
ered and the reductionist approach of considering genes as individual entities is not an
accurate representation of living systems. Other strategies for pathway enrichment such as
Gene Set Enrichment Analysis (GSEA) [147] address some of these issues by considering
a ranked list of t statistics or fold changes instead of a subset of the most DE genes. The
question is then asked whether genes within a given pathway are found in a greater quan-
tity towards the top (indicating upregulation) or towards the bottom of the DEG list by
calculating a running-sum statistic. As an enrichment score is computed for each pathway
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dependent on the expression changes of the whole set of pathway members, subtle changes
to the gene set in concert contribute a greater enrichment than changes in a small number
of genes which may be more biologically relevant.
2.2.2.5 Dimensionality reduction
High throughput omics’ experiments suffer from the ‘small n large p’ problem in which
the number of variables measured greatly exceeds the number of observations. This is
problematic as the number of pairwise tests required to perform a comprehensive unbiased
analysis is large and exhaustive pairwise testing inflates Type I error unless stringent mul-
tiple testing correction is undertaken. The main problem with FWER or FDR correction
is the subsequent loss of power to detect true differences, however, one way to overcome
this is to reduce the number of hypothesis tests performed with a suitable scheme of di-
mensionality reduction.
The most popular method for dimensionality reduction of transcriptomics data is princi-
pal components analysis (PCA). PCA is a linear function which summarises the variables
contained in a high dimensional dataset into a set of orthogonal factors called principal
components. PCA is achieved by performing eigen-decomposition of the covariance (or cor-
relation) matrix where the eigenvectors correspond to the principal components, and the
eigenvalues correspond to the variance explained by the corresponding eigenvector. In the
context of transcriptomics data the principal components (PCs) are linear combinations
of genes representing the maximally variable directions in multidimensional space [148].
In multidimensional space, the first PC is the direction which explains the most amount
of variance, followed by the second component which is the next most variable direction
which is also orthogonal to the first PC. In an example proposed by Ringer et al. [148],
100% of the variance of 8,534 genes was explained by only 104 components. PCA is often
used for visualisation of samples projected onto a small number of components to observe
global trends and is also used for data integration [29].
Others have expanded the utility of PCA by incorporating prior knowledge of gene sets
from pathway databases. The underlying idea is to reduce the hypothesis testing space
from tens of thousands of genes to hundreds of pathways by computing a ‘pathway activity’
score which can then be used for differential analysis. One such example is PLAGE [149]
which performs singular value decomposition of the pathway specific expression matrix.
CHAPTER 2. METHODS FOR DATA ANALYSIS 32
The major limitation with biochemical pathways is that they are usually a static repre-
sentation of healthy states [146], which are not characteristic of the dynamic processes
which underlie disease. For this reason, dimensionality reduction techniques which infer
the ‘set’ of genes directly from the data may be preferred. One such method is Weighted
Gene Co-expression Network Analysis (WGCNA) [150, 151] which reconstructs gene-gene
co-expression networks and performs community detection in order to identify modules
of highly co-expressed genes. Methods such as this assume that individual genes act in
groups of highly connected genes forming modules. Module members have similar expres-
sion patterns are thus considered to be functionally related due to the principle of ‘guilt by
association’. Singular value decomposition of the module-specific expression matrix, which
is equivalent to the first principal component, is used to calculate the module eigengene
which represents a pattern of module-centric gene expression. The module eigengene can
then be used to detect differences between groups, or for relating module expression with
clinical traits reducing the hypothesis space from tens of thousands of genes to tens of
modules.
2.3 The MAARS cohort
The datasets analysed in this thesis were generated by the Microbes in Allergy and Au-
toimmunity Related to the Skin (MAARS) consortium. A description of the protocol used
has been prepared by MAARS consortium members and is quoted in Sections 2.3.1, 2.3.2
and 2.3.3.
2.3.1 MAARS Subject recruitment and sampling
“To evaluate differences in the cutaneous microbial colonization and transcriptional profile
in atopy- and autoimmune-type skin diseases, adult patients (18-70 years) with mild-to-
severe chronic AD (SCORAD score > 25, n=88) and plaque-type PSO (PASI score >7,
n=129) as well as healthy volunteers (n=117) were recruited from three Depts. of Derma-
tology, at University Hospitals located in Duesseldorf (HHU, Germany), London (KINGS,
Great Britain) and Helsinki (UH, Finland). Each subject underwent a physical examina-
tion by a dermatologist and the medical history was recorded. The diagnoses were made
by a dermatologist based on clinical presentation, personal history, laboratory findings
and the criteria of Hanifin and Rajka [152]. The exclusion criteria included concomitant
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autoimmune diseases (e.g. rheumatoid arthritis, diabetes, alopecia areata, etc.) the use of
systemic antibiotics within 2 weeks and systemic immunosuppressive therapy or photother-
apy or systemic biologic agents within the previous 12 weeks prior to screening. Before
skin sampling, the biopsy sites were left untreated for at least 2 weeks and cleansing with
only the non-antibacterial Dove soap was allowed and washing was avoided for 24 hours
prior to sampling. The patients or healthy volunteers who did not match these clinical
exclusion criteria were removed from the study. The following biological samples were
then obtained and submitted to analysis: 1) microbiome samples from upper/lower back,
posterior thigh or buttocks (PSO, AD, healthy volunteers) with no prior cleaning or prepa-
ration of the skin surface using sterile gloves to prevent cross-contamination, were obtained
placing a sterile ring (2.5 cm diameter) onto the appropriate skin area, 1.5 ml PBS was
supplemented into the ring and the area sampled scraping a glass rod in a circular motion
10 times to the left and to the right. Subsequently, the microbiome-enriched PBS was
harvested and stored. In addition, mock samples containing only PBS were collected at
each sampling time in order to assess contamination. 2) 6 mm punch biopsies from skin at
the microbiome sites were taken in local anaesthesia. Subsequently, samples were stored
in RNAlater (Sigma-Aldrich) and subjected to further analyses. The study was approved
by the appropriate local Institutional Review Boards (UH, Dnro 91/13/03/00/2011; HHU,
3647/2011; KINGS, 11/H0802/6) and all subjects provided written informed consent before
participation.” (MAARS consortium. Unpublished, June 2016)
2.3.2 MAARS Microbiome processing
“DNA extraction. DNA was extracted from the clinical swab and mock samples using
Qiagens Pathogen Lysis Tubes and the QIAamp UCP Pathogen Mini Kit (Cat.No: 19092)
according to manufacturers instructions. In brief, sample pellets were resuspended in 500 l
Buffer ATL and vortexed for 10 min at maximum speed using Pathogen Lysis Tubes con-
taining glass beads. The samples were transferred to fresh Beckman tubes and incubated
in 16.5 mg/ml lysozyme (Sigma) for 30 min at 37C. 50 l proteinase K were added and the
samples were then incubated for 10 min at 56C. Addition of 250 l of Buffer APL2 was
followed by incubation at 70C for 10 min. 10 l RNA-grade glycogen (20mg/ml, Thermo
Scientific) were added to maximize DNA recovery. Ethanol was added to a final concentra-
tion of 25%. DNA was extracted and washed using spin columns, and subsequently eluted
in 50 l of Buffer AVE. 16S rRNA gene amplification and preparation for sequenc-
ing. 2.5 l template were amplified in RT-PCR GradeWater (Life technologies), 3% DMSO,
CHAPTER 2. METHODS FOR DATA ANALYSIS 34
with 1x PCR HF buffer using Phusion Hot start II DNA polymerase, 200 M dNTPs (all
Thermo Scientific), and 500 nM custom primers (Eurofins MWG Operon). One universal
forward primer (341f 5-CCTACGGGNGGCWGCAG with adaptor B, Lib-L) was paired
with one of 104 barcoded reverse primers (805r 5-GACTACHVGGGTATCTAATCC with
adaptor A, Lib-L). Each barcode consisted of seven nucleotides, contained no homopoly-
mers, and a pair of barcodes differed in at least 2 positions. Each PCR was run in triplicates
and the PCR products from each sample were pooled. A negative control PCR reaction
lacking template was included for all primer pairs in each run. The PCR was run for
30 cycles. The PCR products were purified from the reaction using Dynabeads MyOne
Carboxylic Acid (life technologies, Cat.No: 35401) and TruSeq precipitation buffer (16%
PEG-6000, 1.5 M NaCl) on the Magnatrix 1200 (LBH Advanced Bioservices AB, Swe-
den). The purity of the amplicons was visualized on the Agilent 2100 BioAnalyzer using
High sensitivity DNA chips and reagents (Agilent Technologies, Cat.No: 5067-4626) ac-
cording to manufacturers instructions. DNA concentrations were measured by real-time
PCR (KAPA Library Quantification Kits For Roche 454 GS Titanium platform, Cat.No:
KK4821 and BioRad CFX96 Touch Real-Time PCR Detection System; C1000 Thermal
cycler) according to manufacturers instructions with samples diluted 1:500, 1:1000, and
1:2000 in 10 mM Tris-HCl, pH 8.0. Extension time was 90 sec. Finally, the samples
were adjusted to 1.0*108 DNA molecules for each sample before pooling 50-60 samples
per 454 sequencing run. 454 amplicon sequencing. EmulsionPCR was performed on
the amplicon library using a large volume emPCR (Lib-L, v2 reagent kit) according to
the manufacturers amplicon protocols and pyrosequenced (one way read direction) on a
Genome Sequencer FLX-Titanium instrument (Roche/454 Life Sciences) at Science For
Life Laboratory (SciLifeLab) Stockholm. Each library was sequenced in both regions of a
two region gasketed 7075 mm Titanium PicoTiterPlate, and base calling was performed
with the on-instrument amplicon filter settings. Samples containing only water were se-
quenced in order to assess contamination during the sequencing process. Demultiplexing
and preprocessing of 454 reads. All sequence reads were assigned to their samples us-
ing the unique sample barcodes. Raw sequence reads were analyzed with AmpliconNoise
version 1.25 [153] to remove 454 sequencing and PCR artifacts and PerseusD from the same
program package to remove PCR chimaeras, using default parameter values. The output
from each sample was further processed in QIIME (Quantitative Insights Into Microbial
Ecology) version 1.8.0 [95] if the number of processed high quality reads exceeded 3000 per
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sample. Otherwise, the sample was resequenced. OTU clustering and taxonomy as-
signment. The preprocessed dataset comprised of a total of 3,357,091 high quality reads.
The following analysis steps were performed using QIIME version 1.8.0. [95] OTUs were
picked at 99.3 % identity using the pick open reference otus.py command and uclust
1.2.22q [154]. Taxonomy was assigned using blast-2.2.22 [93]. The reference data files used
for both OTU clustering and taxonomy assignment were downloaded from the Greengenes
Database Consortium [92]). As AmpliconNoise did not perform very well in identifying
chimeric sequences in our dataset ChimeraSlayer [155] was applied here within the QI-
IME pipeline and identified chimeric sequences were removed from the OTU table and
the phylogenetic tree. Three samples of poor quality were removed from the OTU table.
Abundances were normalized using the Trimmed Mean of M-values method (TMM), im-
plemented in the edgeR Bioconductor package [102].” (MAARS consortium. Unpublished,
June 2016)
2.3.3 MAARS Transcriptome processing
“The tissue samples were stored in RNAlater and total RNA was extracted from the tis-
sue samples using the RNeasy Fibrous Tissue Mini kit (Qiagen). Tissue samples were
homogenized using the FastPrep-24 instrument (Nordic Biolabs AB), and RNA was ex-
tracted according to the manufacturers instructions. The yield and purity of RNA in the
samples were controlled using a Nanodrop spectrophotometer and Qubit fluorometer to
verify absence of inhibitors (R260/280: 2.1; R260/230nm: 1.3). RNA integrity was quan-
tified by electrophoresis and performed using Agilent dedicated Lab-on-chip (RNA6000
Nano and Pico kits). RNA Integrity numbers and 28S/18S ratio averages were respec-
tively 8.6 and 2. 100ng of total RNA were amplified according to Affymetrix protocols
(Affymetrix GeneChip Whole Transcript (WT) Expression Arrays). Based on expertise
of Institut Curie genomic platform, MAQC A RNA samples (Universal RNA, Stratagene,
P/N: 740000) were implemented to series of RNA amplification in order to monitor target
preparation. In practice, series of 47 RNA (from healthy volunteers, and patients) and 1
Universal RNA were amplified, monitored and labelled. During synthesis steps, purified
molecules were quantified using a multichannel Nanodrop (ND8000, Thermo) to normalize
amount of molecules used for DNA synthesis (10g) and hybridization (5.5g). Molecules
were also controlled on high throughput electrophoresis (QIAxcel DNA, Qiagen) in order
to monitor size of complementary RNAs (average: 500nt), and fragmented DNA (average:
50nt), to ensure quality of targets and hybridization of microarrays. Series of 96 targets
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were hybridized onto Affymetrix Gene ST 2.1 96 array plates, including in total two Univer-
sal RNA, using an Affymetrix Genetitan MC system. Quality of raw data and normalized
data were monitored to control dynamics of the measurements, across series of synthesis,
and series of hybridization using bacterial spike in controls added to total RNA, and using
Universal RNA. An automated quality control pipeline based on the arrayQualityMetrics
method [156] was used to capture quality failures in microarray data. Data were then
normalized using the Robust Multi-array Average (RMA) [132] approach implemented in
the affy Bioconductor package [157].” (MAARS consortium. Unpublished, June 2016)
Chapter 3
The skin microbiome in homeostasis
and disease
3.1 Introduction
The skin is a primary interface and acts as a first line of defence against invading pathogens,
preventing infection and exposure to harmful compounds. The vast resident population
of microrganisms which cohabit the human skin exist in symbiosis and have convolved
with their human hosts [18]. It is now accepted that some of these commensal species are
beneficial and help to maintain a state of homeostatic equilibrium on the skin, promoting
host health and preventing infection of pathogenic species [31, 22].
Studies of the healthy skin microbiota indicate that community composition is dominated
by 4 main phyla consisting of Firmicutes, Proteobacteria, Actinobacteria and to a lesser
extent, Bacteroidetes [38, 31, 158, 41]. A diverse and healthy microbiota is thought to
promote host immunity [159] and as the skin contains a plethora of immune cells [160],
it is possible that host-microbiota interplay is associated with immune system training
[161]. In the event of dysbiosis, which reflects a loss of diversity, this balance is disrupted
which could lead to inappropriate immune response and inflammation. Currently it is un-
known whether dysbiosis of the commensal bacteria is either a cause or effect of disease [31].
Host factors such as body site, age, gender [40, 31, 41, 38] and geographic location [117]
have been shown to be associated with community composition. Furthermore, studies have
shown that healthy skin harbours a complex and diverse ecosystem and is one of the organs
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with the most heterogenous microbiota [1, 39].
Atopic dermatitis is an allergic disease characterised by increased IgE levels, dysbalance of
the Th1/Th2 axis, and abundance of Th2 cytokines [44]. Barrier dysfunction in AD [51]
may increase permeability to microbial antigens [52] resulting in improper immune cell po-
larisation; thus, is plausible that dysbiosis could result in inappropriate immune activity.
Studies of resident bacteria have shown high abundances of Staphylococcus aureus on both
the lesions and uninvolved skin of AD patients [62]. As with other diseases, AD is char-
acteristic of a dramatic loss in species diversity [64]. Furthermore, Staphylococcus aureus
has been shown to be of higher abundance during an inflamed state compared to the pre
and post-flare phases [64]. Moreover, it has been proposed that S. aureus abundance may
increase from baseline during the pre-flare phase.
Psoriasis is characterised by extreme quantities of antimicrobial peptides (AMPs) and
increased infiltration of Th1, Th17 and innate immune cells [73]. Previous analysis of
the psoriatic microbiota have presented variable and inconsistent results. An early study
[84] identified an expansion of Firmicutes compared to healthy skin, and a reduction of
Proteobacteria and Actinobacteria. Furthermore, a strong under-representation of Propi-
onibacterium acnes was found on lesional skin which the authors suggested may play a
beneficial role, or may be displaced by more dominant species. More recent results showed
that psoriatic skin was characteristic of reduced species richness and increased abundance
of four genera including Corynebacterium, Propionibacterium, Staphylococcus and Strepto-
coccus [85]. Contrasting results from a study of the microbiota isolated from skin biopsies
identified reductions in Actinobacteria as well as increases in Proteobacteria [86].
Given the inconsistencies of previous analyses, further study of the disease associated and
inflamed microbiome could provide important insights into understanding the role of mi-
crobiota in health and disease. Previous analysis of the inflammatory microbiome consisted
of small sample sizes, and no other study has directly compared the microbial composition
of AD and PSO in a single analysis. Here using the MAARS cohort, this chapter presents
an exploratory analysis into the largest microbiome cohort to date consisting of 87 patients
with Atopic dermatitis, 128 patients with Psoriasis and 117 healthy volunteers to highlight
core differences with respect community composition in disease.
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Parts of this chapter are extensions to preliminary unpublished analysis performed in col-
laboration with MAARS consortium members. In these cases, the analyses have been
extended and modified to address my own research questions. Species diversity analysis,
specifically the comparisons of α-diversity in Figure 3.3 B, O2 tolerance in Figures 3.3
E-G, and analysis of β-diversity in Figure 3.4, build upon previous works by Stefanie
Prast-Neilsen, Björn Anderrson and Marine Jeanmougin. These analyses have been ex-
tended to assess the association with disease severity, as well as incorporation of higher
order taxonomy and non-lesional disease cohorts.
Differential abundance of OTUs build upon collaborative unpublished analyses by Ste-
fanie Prast-Nielsen, Mauricio Barrientos-Somarribas and Björn Anderrson. The original
analysis compared OTU relative abundances between healthy volunteers, AD-lesional and
PSO-lesional samples and then significant OTUs were evaluated and corrected post-hoc for
associations with non-clinical factors. The work presented in this chapter was extended to
include higher order taxonomy from the Phylum, Class, Order, Family and Genus levels as
well as inclusion of non-lesional samples. All differential analysis was subject to a parallel
analysis using MaAsLin which was used to estimate the differential abundance of all taxa
whilst controlling for potential confounding factors. Paired comparisons between lesional
and non-lesional tissue were also incorporated. All implementation, interpretations, fig-
ures, and text was performed by myself.
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3.2 Methods
3.2.1 Data acquisition and sampling
Raw and TMM normalised 16S rRNA sequencing reads were obtained from the Karolinska
Institutet and Institut Curie as part of the MAARS consortium project. Briefly, consent-
ing patients with mild-to-severe chronic AD and plaque type PSO and healthy volunteers
were recruited from three university hospitals in Dusseldorf (HHU), London (KINGS)
and Helsinki (UH). Diagnosis was made by a dermatologist using the Hanifin and Rajka
criteria. Patients were excluded based upon antibiotic use and presence of autoimmune
diseases. Swabs were taken from the skin surface using a ring and glass rod in 1.5 ml of
PBS which was swabbed 10 times to the right and 10 times to the left. The 16S rRNA
gene was amplifed from DNA extracted from surface swabs with PCR and sequenced on a
Genome Sequencer FLX-Titanium instrument in Stockholm at the Karolinska institutet.
After demultiplexing and removal of chimaeras, QIIME [95] was used to pick open reference
OTUs at 99.3% identity. Taxonomy was assigned to OTUs with blast-2.2.22 [93] with the
Greengenes reference database [92]. Three samples of poor quality were removed from the
dataset. Raw OTU counts were normalised using the Trimmed Mean of M-values method
(TMM) [102]. A detailed description of the patient recruitment and sampling performed
by the MAARS consortium is described in (Section 2.3.1), and for 16S rRNA sequencing
and microbiome processing refer to (Section 2.3.2).
All available samples in the MAARS dataset were considered in the analysis; however, a
body site-matched cohort was also defined. This analysis considered a subset of healthy
and disease samples which were more balanced with respect to body sites. AD and PSO
tend to occur at different body sites, therefore, for analysis of the AD and healthy control
(CTRL) microbiota, the matched cohort consisted of samples originating from the thigh
and upper back which accounted for 98% of the available ADL samples and 52% of the
available CTRL samples. The PSO matched cohort consisted of samples from the lower
and upper back accounting for 85% of available PSOL samples and 54% of CTRL samples.
An overview of the whole cohort and the matched AD and PSO cohorts are shown in
Table 3.1 and Tables 3.3 and 3.4 respectively.
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3.2.2 Species Diversity
The Chao1 richness estimator [104] and Shannon diversity was calculated within R pack-
age Vegan [162] with the functions estimateR() and diversity(). Calculation of commu-
nity dissimilarities (β-diversity) was performed with Bray Curtis at all taxonomic levels.
NMDS was performed within Vegan [162] on Bray Curtis dissimilarities with the function
metaMDS(). For calculation of weighted and un-weighted UniFrac distances [107], samples
were rarefied to an even sequencing depth of 3500 reads within the phyloseq package [163].
Aerobic or anerobic status for OTUs was characterised by Jens Schröder with reference to
Bergey’s Manual of Systematic Bacteriology [164].
3.2.3 Statistical analysis
Association of taxa with body site and sampling institution was performed with Kruskal-
Wallis ranked sum tests. Associations with age were calculated using Spearman’s cor-
relation, and tests involving gender were performed with Wilcoxon ranked-sum tests. To
determine if species diversity or species richness was associated with clinical group or global
assessment score, Kruskal-Wallis tests were applied and post-hoc Dunn’s tests were per-
formed to identify significant pairs in the case of a null rejection. Unless otherwise stated,
significant associations were considered as those with a Benjamini Hochberg adjusted p
value < 0.05.
3.2.4 Differential abundance analysis
OTU counts were summed at the Phylum, Class, Order, Family and Genus levels where
possible and relative abundances were calculated. OTUs not annotated to a specific tax-
onomic level were binned into an unassigned group. At each taxonomic level, a filtering
step selected features that were non-zero in at least 10% of samples and with a minimum
mean relative abundance of 0.001. Differential analysis between cohorts was performed
with two approaches. In the first, a standard non-parametric Wilcoxon’s ranked sum test
was applied to the TMM normalised counts. In the second, linear models implemented
in the MaAsLin package [5] were applied to taxa relative abundances. MaAsLin was used
to estimate the disease effect whilst controlling for potential confounding factors using the
formula: OTU ∼ clinical group + gender + anatomical location + sampling institution
+ age. OTU relative abundances were arcsine square root transformed [5]. Differentially
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abundant taxa were identified as a consensus set, i.e., those significant with a Benjamini-
Hochberg adjusted p value of < 0.05 by both MaAsLin and Wilcoxon’s tests. Analysis
between lesional and non-lesional pairs within disease groups was performed using paired
Wilcoxon tests and with patient as a random covariate in MaAsLin. Unless otherwise
stated, the -log(pvalue) reported within figures is the signed -log(BH pvalue) from the
MaAsLin analysis. This corresponds to the sign of the linear regression coefficient multi-
plied by -log10(pvalue) to retain the direction of association.
3.2.5 Classification
A supervised learning approach based upon Random Forest classification models was im-
plemented to identify discriminative sets of taxa. The pipeline was used to train models for
two comparisons (CTRL vs ADL, CTRL vs PSOL) with the aim of identifying the features
that best discriminate disease groups. To identify the most stable predictors of disease,
under-represented species were removed by filtering out those that were present in less
than 15 samples in each comparison. Next, to select the most discriminant OTU features,
Random Forest feature selection implemented in the R package Boruta [165] was used
under a 10 cross fold validation framework with 10 randomised repeats. Selected features
were ranked by Boruta according to the variable importance Z score. OTUs with a mean
Z score greater than 0.2 were considered for further analysis. The fold change between
healthy and disease patients was calculated to identify depletion or increased abundance
in disease. After selection of features, the classification model was trained within the R
package randomForest [166]. The performance of the model was evaluated using the R
package ROCR [167], and the mean area under the curve (AUC) across all folds was re-
ported. NMDS with Bray-Curtis distance using the selected feature sets with the function
metaMDS from the R package Vegan [162] was used for visualisation of the predictive fea-
tures. Selection frequency was calculated as the percentage of times a variable was selected
by Boruta across all folds over all randomisations.
3.2.6 Co-occurrence network analysis
Co-occurrence networks were constructed on all OTUs present in more than 5 percent of
samples resulting in a core microbiota of 569 OTUs. Compositionality-robust correlations
were calculated with SparCC [124] on the raw OTU counts, which calculates a corrected
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correlation coefficient designed specifically for assessing the correlation between taxa in mi-
crobiome studies. The statistical significance of correlations was evaluated against an em-
pirical null distribution obtained with 100 bootstrap iterations and p values were corrected
using the Benjamini Hochberg method (p <0.05, SparCC >0.2). Network visualisations
were generated in Cytoscape [168].
3.3 Results
3.3.1 Study population
Healthy and diseased patients were recruited from three clinical institutions as previously
described (Section 3.2.1). After quality control, 87 matched atopic dermatitis lesional
(ADL) and non-lesional (ADNL) samples, 224 healthy control (CTRL) samples from 117
individuals, and 128 matched psoriasis lesional (PSOL) and non-lesional (PSONL) sam-
ples remained in the analysis (Table 3.1). Overall, PSO samples corresponds to a higher
percentage of males (79%) and may reflect reports suggesting that severe disease is more
prevalent in males than females [169].
Table 3.1: MAARS cohort study population
ADL ADNL CTRL PSONL PSOL
Patients (n) 87 87 117 128 128
Samples (n) 87 87 224 128 128
Gender (n) Female 39 39 146 27 27
Male 48 48 78 101 101
Anatomical Location (n) Buttocks 0 0 0 18 18
Lower Back 2 3 107 87 99
Thigh 45 45 104 1 1
Upper Back 40 39 13 22 10
Institution (n) HHU 36 36 66 49 49
KINGS 14 14 89 43 43
UH 37 37 69 36 36
Age Mean 43.7 43.7 35.8 48.7 48.7
SD 14.6 14.6 14.2 13.4 13.4
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3.3.2 Characteristics of the skin microbiota
A total of 7532 unique OTUs were identified across five cohorts. The resultant OTU table
was 98.5% sparse indicating that the vast majority of OTUs are rare (Figure 3.1 A). Only
297 OTUs were present in more than 10% of the dataset, and most samples were sparsely
populated (Figure 3.1 B) with each sample on average consisting of 143 non-zero OTUs.
Control samples had the greatest number of unique OTUs found across clinical group and
approximately double the number of those found in ADL lesional samples (Figure 3.1 C).
No genus-level taxa were present in all samples, except Staphylococcus in ADNL (Table
3.2). Only four genera were present in 95% of samples on healthy skin. The most common
genus was Corynebacterium, followed by Staphylococcus, Acinetobacter and Burkholderia
representing a core component of the skin microbiota.
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Figure 3.1: Microbiota summary statistics. (A) The frequency of OTUs present in a
proportion of samples (with singletons removed). (B) Frequency of individual OTUs. The
red line corresponds to the mean number of OTUs per sample of 143 (C) The number of
unique taxa at each taxonomic level for each clinical group.
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Table 3.2: Percentage occurrence of core genera across the MAARS cohort. (Genera
present in at least 95% of control samples are shown)
ADL ADNL CTRL PSONL PSOL
Staphylococcus 96.6 100.0 98.7 97.7 97.7
Corynebacterium 93.1 96.6 99.1 95.3 95.3
Acinetobacter 88.5 94.3 97.3 96.1 94.5
Burkholderia 83.9 93.1 97.3 97.7 95.3
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Figure 3.2: Abundant taxa at all phylogenetic levels across clinical groups.
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To further define the core cutaneous microbiota, the most abundant taxa at each phylo-
genetic level and for each cohort were identified. Healthy skin was dominated by 4 main
phyla (Figure 3.2 A). Proteobacteria (47%), Firmicutes (25%), Actinobacteria (23%) and
Bacteroidetes (4%) accounted for approximately 99% of the healthy skin microbiota which
is in concordance with published analysis of the cutaneous microbiota [85, 84]. A major
reduction in the relative abundance of Proteobacteria (23%) and a drastic increase in the
abundance of Firmicutes (59%) was observed on atopic skin, whereas psoriasis was char-
acteristic of moderate increases in Firmicutes (35%) and Actinobacteria (27%). A striking
peak at each taxonomic level was observed in AD samples corresponding to Bacilli, Bacil-
lales, Staphylococcaceae, Staphylococcus and Staphylococcus aureus at the Phylum, Class,
Order, Family, Genus and OTU levels respectively (Figure 3.2 A-F). Changes in PSO
were much more subtle, and the most abundant taxa closely resembled healthy skin.
3.3.3 Community diversity in health and disease
3.3.3.1 Associations with α-diversity
The composition of a sample can be described in terms of α-diversity indices which rep-
resent the evenness and richness of a sample. The Shannon index and Chao1 species
richness estimator [104] was calculated and Kruskal-Wallis was used to test for system-
atic differences in α-diversity between clinical groups. Post-hoc Dunn’s tests revealed a
significant difference in species richness between ADL and PSOL (p = 0.0002). No signif-
icant differences were identified between both diseases and control samples (Figure 3.3
A). Significant differences in Shannon diversity across clinical groups were identified (p
<0.05, Figure 3.3 B). Post-hoc tests revealed atopic samples were of reduced diversity
compared to healthy microbiota (ADL: p <0.0001, ADNL: p <0.0001, Figure 3.3 B). As
others have reported, no significant change in Shannon diversity was observed in psoriatic
samples compared to healthy samples [86], however, diversity was significantly higher in
PSO than in AD (p <0.0001).
Studies of the microbiome have shown that in some conditions, disease severity can be
linked to microbial diversity [110]. To test this hypothesis on the skin, Kruskal-Wallis tests
within lesional disease revealed that species diversity was significantly associated with the
physicians’ global assessment score in both PSOL (p = 0.007, Figure 3.3 C) and ADL
(p = 0.02, Figure 3.3 D). Post-hoc tests revealed that diversity was significantly reduced
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in severe AD compared to mild disease (p = 0.008), and severe psoriatic lesions had lower
diversity than both mild (p = 0.0024) and moderate disease (p = 0.008). These results
indicate that severe disease exists in a heightened state of dysbiosis. Lastly, the abundance
of anaerobes, aerobes and facultative anaerobes across clinical groups was evaluated. Both
anaerobes and aerobes were of reduced abundance in AD (p <0.0001, Figure 3.3 E-F) as
well as a vast expansion of facultative anerobes (p <0.0001, Figure 3.3 G). No significant
associations were identified with O2 tolerance status in PSO.
3.3.3.2 Associations with β-diversity
Next, compositional differences in the cutaneous microbiota (Figure 3.4) were evaluated
between samples using measures of (β-diversity). Pairwise Bray Curtis dissimilarity was
calculated between samples and ordination was performed with non-metric multidimen-
sional scaling (NMDS) using the Vegan package [162]. At the OTU level, ADL and to a
lesser extent, ADNL samples clustered with each other (Figure 3.4 A) indicating that
the atopic microbiota is compositionally dissimilar from healthy and psoriatic communities.
Involved and uninvolved psoriatic samples were indiscernible from healthy communities.
To determine if compositional differences on Psoriatic skin were could be better represented
at a higher phylogenetic level, the analysis was repeated (ordination of Bray Curtis dissim-
ilarities) at each taxonomic level, as well as the top 100 most abundant OTUs (Figure 3.4
B-G). In each case, ordination revealed a degree of clustering of amongst atopic samples
which were compositionally dissimilar to the remaining clinical groups however, psoriatic
communities were inseparable from healthy controls.
To determine if these findings were reproducible with different distance metrics, ordination
of weighted and un-weighted UniFrac distances on samples rarefied to a depth of 3500
reads was performed. Unweighted UniFrac (Figure 3.4 H), which only takes into account
phylogenetic relationships, showed little evidence of clustering amongst clinical groups,
whereas weighted UniFrac (Figure 3.4 I) which takes into account both abundance and
phylogeny, produced an ordination similar to those calculated with Bray Curtis dissimi-
larity. Therefore, these results indicate that the atopic microbiota is dissimilar to healthy
and psoriatic communities, of which species abundance is an important factor, and that
any compositional differences in psoriasis are subtle.
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Figure 3.3: Clinical group association with species richness, diversity and microbiota O2
tolerance. (A-B) Between-group comparison of α diversity. (A) Chao1 richness. (B)
Shannon diversity. (C-D) Within-disease comparison of Shannon diversity across severity
states (C) Shannon diversity stratified by global assessment score in PSOL samples. (D)
Diversity stratified by severity in ADL. (E-G) Between-group comparison of abundance of
specific O2 tolerant species. (E) Association with anaerobes. (F) Association with Aerobes
(G) Association with anaerobes. Stars represent Bonferroni corrected p value (Dunn’s test,
* p <0.05, ** p <0.005, *** p <0.0005)
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Figure 3.4: Community composition and β diversity. NMDS analysis of Bray Curtis dis-
similarity of the MAARS cohort. Point colors and shape correspond to different clinical
groups. (B-G) NMDS analysis of Bray Curtis dissimilarity at all phylogenetic levels and
the top 100 most abundant OTUs. (H) NMDS of unweighted UniFrac distance on samples
rarefied to 3500 reads. (I) Weighted UniFrac analysis.
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3.3.4 Differential Abundance Analysis
A major objective of clinical microbiome studies is to identify species which are over-
represented on diseased tissue. Before differential abundance analysis, a filtering step was
first implemented to focus the analysis on highly abundant taxa. This step was performed
as rare taxa are susceptible to under-sampling which results in spurious counts and could
increase type I error. Further, filtering enables a reduction in the number of performed
hypothesis tests, increasing the power to detect changes amongst abundant species. All
OTUs were also aggregated at the Phylum, Class, Order, Family and Genus levels allowing
for rarer taxa to contribute at higher levels of the taxonomic tree. Taxa at all levels were
considered if they were present in 10% of samples, with a mean relative abundance of at
least 0.001. Across all taxonomic levels, this filtering resulted in a total set of 285 taxa
which were tested for differences in abundance. These included 8, 17, 30, 61, 65, and 104
taxa at the Phylum, Class, Order, Family, Genus and OTU levels respectively.
3.3.4.1 Non-clinical factor analysis
It is well known that microbial composition is associated with non-clinical factors such as
age, gender [40] and body site [38]. To establish the relationship with non-clinical factors
in the MAARS dataset prior to differential analysis, the changes in OTU abundance with
respect to body site, gender, age and sampling institution were first evaluated at the OTU
level using non-parametric statistics.
Of the 104 OTU level features evaluated, many were associated with non-clinical factors.
Amongst the healthy controls, 28 OTUs were significantly associated with at least one
factor (p < 0.05, Appendix A.1). Six OTUs were significantly associated with gender,
all of which were of higher abundance in females, except for Corynebacterium sp which
was of higher abundance in males. Of particular interest were OTUs mapping to the
Lactobacillus genus for which 3 were significantly of greater abundance in females. Five
OTUs were associated with body site including Staphylococcus aureus which was of higher
abundance on the upper back, and Finegoldia sp, which was of reduced abundance on the
upper back. Across all clinical groups, several significant associations were identified with
sampling institutions indicating potential sampling bias, or that geographic location and
or climate [117] may impact upon the abundance of some species.
In light of this observation, to identify a robust set of disease associated taxa, both
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Wilcoxon’s tests and linear models implemented in the MaAsLin package [5, 118] were
applied (see Methods Section 3.2.4). As non-clinical factors were associated with taxa
abundance, the factors age, gender, sampling institution and body site were included in
the linear model to control for extraneous sources of variation. To minimise false positives,
a consensus set was defined such that a taxon was only considered to be differentially abun-
dant if it was significant (Benjamini Hochberg p <0.05) in both models. The models were
then applied to identify differences in taxa abundances for ADL-CTRL, ADNL-CTRL,
PSONL-CTRL and PSOL-CTRL.
3.3.4.2 Differential taxa at the phylum level
An evaluation of the phylum level taxa was performed first to identify higher-level vari-
ability between healthy and inflamed communities. At the phylum level, a gradient in
the relative abundance of the three most abundant phyla across the whole dataset was
observed (Figure 3.5 A) where some samples were dominated by Proteobacteria, and
some by Firmicutes. A visual clustering of ADL samples towards the Firmicutes-high
tail of the phylum distribution was observed suggesting that AD may be associated with
increased abundance of Firmicutes. No distinct clustering of psoriatic or healthy samples
was apparent. The expansion of Firmicutes and reduction of Proteobacteria in AD was
also evident in the overall proportions of phyla stratified by clinical group (Figure 3.5
B). Wilcoxon ranked sum tests confirmed a significant reduction of Proteobacteria in both
ADL (p = 1.12e-10) and ADNL (p = 4.62e-03) (Figure 3.5 C) along with significant
increases in Firmicutes (ADL: p = 4.0e-14, ADNL: p = 5.67e-4, Figure 3.5 D). ADL
was also characteristic of a reduction in Actinobacteria (p = 1.02e-05). Lesional psoriasis
was associated with a moderate increase in abundance of Firmicutes (p = 5.58e-03) along
with a reduction of Proteobacteria (p = 7.69e-05). No significant difference in Firmicutes
or Proteobacteria was identified in non-lesional Psoriasis. A complete list of differentially
abundant phyla is shown in Appendix A.
3.3.4.3 Differential taxa at the Class, Order, Family and Genus levels
Next, differences in taxa abundance were evaluated at lower taxonomic levels. At all taxo-
nomic levels in atopic lesions, 106 taxa were found to be significantly different compared to
healthy controls (p < 0.05). The most significant taxa were of increased abundance in AD
including Bacilli at the class level (p = 8.83e-28), Bacillales at the order level (p = 3.22e-
34), Staphylococcaceae at the family level (p = 3.22e-34), and Staphylococcus at the genus










































































































Figure 3.5: Relative abundances of the top 4 phyla. (A) Skyline plot showing the relative
abundance of Actinobacteria, Bacteroidetes, Proteobacteria, Firmicutes and other phylum
level taxa for each sample ordered by Proteobacteria abundance. The top of each column
corresponds to clinical group. (B) Mean relative abundance of top 4 phyla. (C) Boxplot
of Proteobacteria abundance across clinical groups. P values correspond to BH adjusted
Wilcoxon ranked sum tests. (D) Differential abundance of Firmicutes. Stars represent BH
corrected p value (Wilcoxon test, * p <0.05, ** p <0.005, *** p <0.0005)
level (p = 3.22e-34, Figure 3.6 A-D). These results correspond to the well documented
evidence of increased Staphylococcus abundance in atopic lesions [62]. The abundance of
these taxa was also significantly higher on non-lesional skin compared to controls (Figure
3.6 A-D). The vast majority of significant taxa were of reduced abundance on lesional
AD skin (Appendix A.2, A.3). These included Alpha and Betaproteobacteria at the
class level (p = 3.89e-10, 1.52e-08), Burkholderiales at the order level (p = 2.75e-08),
Burkholderiaceae (p = 1.63e-06) and Propionibacteriaceae (p = 1.80e-05) at the family
level, and Burkholdiera (p = 1.33e-06) and Propionibacterium (p = 2.19e-05) at the genus
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level. These results suggest that a range of microbiota are of lower abundance on atopic
skin and explain the dramatic loss of diversity. Many of the taxa found to be reduced
on lesional skin were also of reduced abundance on non-lesional skin suggesting that the

























































































Figure 3.6: Differential abundance at the Class, Order, Family and Genus levels across
clinical groups compared to control samples. Stars represent a significant association with
both Wilcoxon and MaAsLin analysis. Tile color corresponds to the sign of the coefficient
multiplied by -log10 of the adjusted p value. Positive values are of increased abundance in
disease.
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In comparison to AD, only thirty six taxa were found to be differentially abundant in PSOL,
most of which were of greater abundance on diseased skin. At the Family level, the most
significant included Peptostreptococcaceae (p = 5.12e-04) and Actinomycetaceae (p = 5.12e-
04) which were of increased abundance in disease. At the genus level, Peptostreptococcus
(p = 1.22e-07) and Actinomyces (p = 5.12e-4) were of increased abundance. As observed
in AD, the most significant features were also differentially abundant on non-lesional skin
(Figure 3.6 C-D) indicating that the uninvolved microbiota is already affected by changes
to the microbial community. The most significant taxa of reduced abundance in PSOL
included the family, Propionibacteriaceae (p = 5.12e-04) and the genus Propionibacterium
(p = 6.27e-04). Very few taxa were differentially abundant in PSOL at the Class and Order
levels (Appendix A.4) suggesting differences in microbiota are more specific. A complete
list of significant taxa is shown in Appendix A.
3.3.4.4 Differential taxa at the OTU level
At the most specific OTU level, the microbial landscape in AD was dominated by Staphy-
lococcus aureus which was over 150 fold greater in ADL compared to healthy (p = 1.72e-35,
Figure 3.7 A). As with other taxonomic levels, many OTUs were of reduced abundance
in disease such as Staphylococcus sp., Burkholderia sp., Corynebacterium sp., and Propi-
onibacterium acnes. In non-lesional atopic skin, a significant and dramatic increase in the
abundance of S. aureus compared to healthy was also observed (FC >50, p = 2.36e-16,
Figure 3.7 B). Some of the species depleted on lesional tissue were also of reduced abun-
dance on uninvolved skin including Staphylococcus sp., and Burkholderia sp. Overall these
results indicate that non-lesional communities in AD patients are already perturbed in
absence of inflammation.
Several OTUs were of increased abundance in PSOL (Figure 3.7 B). The most significant
was Corynebacterium simulans (p = 2.11e-09, FC >30). Other top psoriasis associated
species included Peptostreptococcus anaerobius, Neisseriaceae G. sp., Streptococcus sp.,
two Corynebacterium kroppenstedtii OTUs, and Peptostreptococcus sp. In contrast to the
atopic flora, only two species were found to be significantly depleted in disease by both
methods including Propionibacterium acnes and Burkholderia sp. Many of the top pso-
riasis associated species were also significantly different in non-lesional tissue including
Corynebacterium simulans, Neisseriaceae G. sp. and Peptostreptococcus sp. (Figure 3.7
D). Complete lists of differentially abundant OTUs are shown in Appendix A.





































































































Figure 3.7: Differential abundance at the OTU level compared to control samples. OTUs
shown were significant (p <0.05) in both the Wilcoxon and MaAsLin analysis. Bars corre-
spond to the sign of the coefficient multiplied by -log10 of the adjusted p value derived from
the MaAsLin analysis. Heatmap tile color corresponds to the sign of the coefficient multi-
plied by -log10 of the adjusted p value from the Wilcoxon analysis. (A) Differential OTUs
from the ADL-CTRL analysis. (B) PSOL-CTRL. (C) ADNL-CTRL. (D) PSONL-CTRL.
Positive values are of increased abundance in disease.
CHAPTER 3. THE SKIN MICROBIOME IN HEALTH AND DISEASE 57
3.3.4.5 Lactobacillus
Lactobacillus was one of the most significant species identified by Wilcoxon analysis. This
taxa was found to be of reduced abundance in ADL (p = 3.17e-06), ADNL (p = 4.24e-04),
PSONL (p = 8.85e-09) and PSOL (p = 9.31e-07), however, it was not identified as sig-
nificant p <0.05 by MaAsLin after controlling for covariates (ADL p = 0.051, PSOL p =
0.07, Figure 3.8 A). Lactobacillus is clearly associated with gender and has a significantly
higher abundance in female control samples (p = 2.4e-03, Table A.1, Figure 3.8 B).
Whilst this species is confounded by gender, it is also heavily depleted across all cohorts
(Figure 3.8 A). As studies have suggested a protective anti-inflammatory role for Lacto-
bacillus in the gut [170], further study is warranted to determine if this species is indeed
associated with homesostasis in the skin.
Lactobacillus sp. Lactobacillus sp.A B


































Figure 3.8: (A) Lactobacillus abundance across cohorts. (B) Lactobacillus abundance in
CTRL samples stratified by gender.
3.3.4.6 Body site matched cohort
Disease associated taxa were identified by comparison to a healthy control baseline in-
cluding all available samples; however, AD and PSO tend to occur on different body sites
which is reflected in the samples collected for this study (Table 3.1). Further, as in some
cases healthy patients contributed two or more samples across multiple body sites, it is
important to determine the degree to which within-subject similarity influences the dif-
ferential abundance analysis. The analysis was repeated considering only samples from
disease specific matched body sites (see Section 3.2.1). AD samples were approximately
balanced in the number of thigh and upper back samples and were compared to controls
at the same sites (Table 3.3). The matched PSO analysis considered samples from the
lower and upper back which accounted for 85% of PSOL samples (Table 3.4).
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Table 3.3: AD body site matched cohort
ADL ADNL CTRL
Patients(n) 85 84 113
Samples(n) 85 84 113
Gender (n) Female 39 39 73
Male 46 45 40
Anatomical Location (n) Buttocks - - -
Lower Back - - -
Thigh 45 45 100
Upper Back 40 39 13
Institution (n) HHU 34 33 34
KINGS 14 14 45
UH 37 37 34
Table 3.4: PSO body site matched cohort
PSOL PSONL CTRL
Patients(n) 109 109 115
Samples(n) 109 109 115
Gender (n) Female 23 23 74
Male 86 86 41
Anatomical Location (n) Buttocks - - -
Lower Back 99 87 102
Thigh - - -
Upper Back 10 22 13
Institution (n) HHU 48 48 37
KINGS 42 42 44
UH 19 19 34
The majority of differentially abundant taxa were identified in both the matched and
unmatched analysis except for a few differences. Considering ADL, 106 taxa were dif-
ferentially abundance across all taxonomic levels in the unmatched analysis, and 105 in
the matched analysis with an intersection of 96. Taxa which were not significant in the
matched analysis (Table A.6) included an OTU assigned to Anaerococcus and the Vari-
ovorax genus. Regarding PSOL, the analysis identified 36 and 23 for the unmatched and
matched analysis respectively, with an intersection of 20. Taxa which were not significant
in the matched analysis (Table A.7) included Corynebacterium kroppenstedtii (p = 0.063),
and Prevotella sp (p = 0.059). Furthermore, differences in Firmicutes (p = 0.059) and
Proteobacteria (p = 0.057) were no longer significant (p < 0.05). Across both diseases, the
most significant taxa were identified in both the matched and unmatched cohorts. Whilst
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it’s likely that some differences are related to body site and within-individual similarity,
most species that lost significance were already towards the lower levels of significance in
the unmatched cohort. This suggests that the differences are mostly due to a loss in power
by removal of 30% of samples. To retain as much information as possible, and to benefit
from having a single unified control cohort, the analysis was focused the entire dataset for
further analysis. Complete lists of taxa which were not identified in the matched analysis
are shown in Appendix A.
3.3.4.7 Differential taxa between involved and uninvolved cohorts
The cutaneous microbiota has been shown to be variable between individuals [39] there-
fore, differential abundance between involved and uninvolved tissue from the same patient
can be performed to account for this. Only minor differences were observed between non-
lesional and lesional AD. As others have found [64], the abundance of Staphylococcus aureus
was significantly higher on atopic lesions compared to susceptible skin (p = 3.92e-07). The
abundance of the Proteobacteria, Actinobacteria and Bacteroidetes phyla, as well as the
Finegoldia, Enhydrobacter and Micrococcus (Figure 3.9 A-F) generas were all reduced
on lesions. At the OTU level, the commensal Staphylococcus epidermidis was reduced on
inflamed skin. No significant differences in microbial abundances were identified between
PSONL and PSOL. This suggests that psoriasis patients are already subject to an altered
microbial composition on uninvolved skin which does not drastically change during a flare.
The abundance patterns of the top disease associated microbes in AD and PSO across
lesional and non-lesional disease was investigated further. Across paired AD samples, it
can be observed that the mean relative abundance of S. aureus in ADNL was 0.17 and
that 78% of pairs containing S. aureus increased in abundance on inflamed skin equalling
a mean relative abundance of 0.39 in lesions (Figure 3.9 G). In psoriasis, C. simulans
accounted for only 1.5% of the relative abundance in non-lesional tissue. Even though,
62% of pairs increased in C. simulans abundance across lesional status (Figure 3.9 H),
the mean abundance on lesional skin accounted for only 3% of the psoriatic microbiota.
It is therefore clear that the overall abundance profiles of the top pathogenic species are
strikingly different and suggest that AD is dominated by one major species of which is not
the case in psoriasis.
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Figure 3.9: Differential abundance comparing uninvolved to involved skin in AD. OTUs
shown were significant (p <0.05) in both the Wilcoxon and MaAsLin analysis. Bars cor-
respond to the sign of the coefficient multiplied by -log10 of the adjusted p value derived
from the MaAsLin analysis. Heatmap tile color corresponds to the sign of the coefficient
multiplied by -log10 of the adjusted p value from the Wilcoxon analysis. (A-F) OTUs of
differential abundance across taxonomic levels. No significant associations were identified
in PSO. (G) abundance of S. aureus across paired samples in AD. Red lines correspond
to a patient which increased in relative abundance from uninvolved to involved. Blue
lines correspond to those which decreased in abundance. (H) Corynebacterium simulans
abundance in PSO. P values correspond to paired Wilcoxon ranked sum tests.
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3.3.5 Classification and co-occurrence analysis
Next, to determine if the microbiota discriminates inflammatory skin pathologies, two clas-
sifiers were trained to explore the microbial taxa which differentiate diseased and healthy
samples. A set of 25 microbes discriminating ADL and CTRL cohorts was identified with
Boruta [165] to an AUC of 0.94 (class errors CTRL = 0.04, ADL = 0.26, Figure 3.10 A).
The most discriminative microbial taxa were of the genus Staphylococcus, including S. au-
reus (Z = 14.0), S. epidermidis (Z = 5.8), Staphylococcus sp. (Z = -6.89) and Burkholderia
sp. (Z = -7.4). Twenty six microbial taxa differentiated PSOL and CTRL with an AUC of
0.85 (class errors CTRL = 0.08, PSOL = 0.32, Figure 3.10 B). The top discriminating
microbes were C. simulans (Z = 15.5), Neisseriaceae g. sp. (Z = 6.9), C. kroppenstedtii
(Z = 5.5) as well as Lactobacillus sp. (Z = -8.4) and Lactobacillus iners (Z= -3.5).
To understand the interactions between communities of microbes under different disease
states, network principles were applied to express co-occurrence relationships between
disease-associated microbial taxa. Distinct differences between the community structures
of microbes associated with ADL and PSOL were observed. For microbes associated with
ADL, network inference with SparCC [124] resulted in 17 species with at least one sig-
nificant interaction with another predictive feature (SparCC >0.2, p <0.05, Figure 3.10
C). S. aureus displayed a negative correlation with Corynebacterium sp., S. epidermidis,
Tepidimonas sp. and Phyllobacterium sp.
Of the 23 microbes identified as important for PSOL classification (Figure 3.10 B), 14
species showed significant correlation (SparCC >0.2, p <0.05 Figure 3.10 D). Fewer con-
nections were observed in PSOL than in ADL and all correlations were positive. The most
informative taxa, C. simulans and C. kroppenstedtii displayed positive correlations with
Streptococcus sp., P. anaerobius and, Anaerococcus sp., Neisseriaceae g. sp., Neisseriaceae
g. sp. and Rothia dentocariosa respectively. Comparison across microbial interactions
in PSOL suggests that, rather than a single species dominating the microbial landscape
(as in ADL), multiple species are associated with this disease type. Lastly for visualisa-
tion purposes, ordination of OTUs identified by Boruta was performed with NMDS. In
ADL, the top 25 classifying microbes highlights the role of S. aureus in differentiating
ADL from CTRL samples (Figure 3.10 E). NMDS analysis of PSOL associated microbes
demonstrated a separation boundary between lesional and healthy samples (Figure 3.10
F).
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Figure 3.10: Classification models and co-occurrence network analysis. (A) Variable impor-
tance for the best set of discriminatory AD taxa identified with Boruta and classification
analysis. Bars are coloured by selection frequency (Red = OTU selected in all folds, blue =
OTU selected in 1 fold) (B) PSO taxa identified with Boruta. (C) Co-occurrence network
of AD associated OTUs selected by Boruta infered with SparCC. A connection represents
a correlation >0.2 and significant P <0.05 correlation. Solid and dashed lines respectively
represent positive and negative correlations. The size and colour of each node is propor-
tional to the log2 fold change between healthy and disease. (D) Correlation network of
PSO associated OTUs. (E) NMDS analysis considering only microbes identified through
feature selection for AD vs CTRL and (F) PSO vs CTRL.
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3.4 Conclusions and Discussion
This chapter presents the largest analysis to date of the healthy and inflammatory skin
microbiota. Overall, the skin harbours a complex and diverse ecosystem which is domi-
nated by four main phyla consisting of Proteobacteria, Actinobacteria, Firmicutes and to
a lesser extent Bacteriodetes confirming observations of previous studies in the cutaneous
skin microbiome [85, 84, 38, 31]. As the main components of the microbiota, it is likely
that these taxa exist in symbiosis with the human host to maintain a state of homeostatic
equilibrium on the skin. Whilst the top 4 phyla were in concordance with previous studies,
the overall proportions of these phyla conflict with results of a study which identified Acti-
nobacteria as the most dominant phyla [84]. Instead, the results of this study found the
most abundant taxa on healthy skin to be Proteobacteria which accounted for 47.4% of the
healthy microbiota. Despite differences in overall initial proportions of the most abundant
phyla, similar changes to their abundances was observed in disease. Proteobacteria was
under-represented and the proportion of Firmicutes was over-represented in both diseases,
although this was to a much greater extent in AD. Whilst changes in the abundance of
key phyla were similar to those found in the Gao et al. study [84], the results presented
here are the opposite to those found in psoriatic biopsies [86] indicating the need of further
studies to define a clear microbial landscape at the site of skin inflammation.
Psoriatic skin is characteristic of extreme AMP expression [73], and atopic skin is subject
to changes in pH and lower abundance of epidermal ceramides [44]. Therefore, given the
extreme environmental differences between inflamed and healthy skin, it is surprising to
find that samples did not cluster by clinical group at any taxonomic level. AD samples were
to some degree distinguishable from healthy and PSO samples although no clear boundary
existed, and the pattern more closely represented a gradient in community composition.
Psoriatic samples were inseparable from CTRL samples so it is clear that differences in the
atopic microbiome are more dramatic than those observed in PSO. Ordination of disease
associated OTUs identified by supervised feature selection resulted in a clearer separation
of clinical groups indicating that the skin microbiome does carry a signal of a diseased
environment.
The major features the atopic microbiota corresponded to increased abundance of Staphy-
lococcaceae, Staphylococcus and more specifically Staphylococcus aureus. S. aureus is a
well characterised pathogen known to be associated with atopic inflammation [51, 62, 171].
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Incredibly, the abundance of S. aureus was over 150 fold higher in lesional atopic skin
compared to healthy and this species completely dominated the microbiota of some pa-
tients. Many more species of increased abundance were identified on psoriatic skin in this
analysis than the previous largest study [85]. This could reflect differences in sampling
techniques, body site locations, geographic location or intra-individual variability which is
known to be a major factor influencing the cutaneous microbiota [39, 1]. As many of the
differentially abundant species had low effect sizes, it is likely that a large cohort increased
power to detect subtle differences in the cutaneous microbiota. Several taxa of increased
abundance were found in PSO including the genera Peptostreptococcus and Actinomyces.
The most significant OTU in PSO was C. simulans suggesting a potential pathogenic or
opportunistic role of this species. Whilst C. simulans was consistently the most signifi-
cant, it is unlikely that C. simulans can be considered a pathogen on a similar levels to S.
aureus. Many AD samples were completely dominated by S. aureus, whereas the average
relative abundance of C. simulans in PSO was approximately 3% of the total microbial
composition. Other species including Peptostreptococcus anaerobius and Neisseriaceae G.
sp. were also consistently over represented on psoriatic skin.
As well as Propionibacterium acnes which has been found to be under-represented in pso-
riasis [84], this species was also reduced on atopic skin. Furthermore, Burkolderia sp was
also depleted in both diseases. These species may reflect beneficial species which are lost
in disease, and coupled with the observation that species diversity was was reduced in
severe disease, it could be that loss of protective species exacerbates inflammation. Fur-
ther analysis could be performed to determine if these species interact with the host and
express anti-inflammatory properties, or if they provide resistance to pathogen colonisation.
A widespread depletion of Lactobacillus in all cohorts to high significance compared to
healthy via Wilcoxons tests was observed (ADL p = 3.17e-06, ADNL p = 4.24e-04, PSONL
p = 8.85e-09 and PSOL p = 9.31e-07). In fact, Lactobacillus sp. was the most significant
OTU of reduced abundance in PSO. In section 3.3.4, Lactobacillus was found to be signif-
icantly higher on female healthy skin compared to males. Consequently, the significance
of Lactobacillus was heavily impacted when controlling for extraneous sources of variation
within MaAsLin suggesting that the gender effect, and possibly other confounding factors
are associated with this species abundance. Given that the MAARS dataset is unbalanced
in terms of males and females, further analysis should be performed to identify if this
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species is associated with disease as it has already been implicated as a beneficial microbe
in the gut microbiome [170], and could play a protective role on skin.
One of the most surprising observations was that uninvolved skin shared many traits of
inflamed disease skin. Only moderate differences between ADNL and ADL were detected,
the most significant being the increase of S. aureus on lesional skin, and that 78% of pa-
tients displayed increased abundance in a lesional phase. It is therefore possible that S.
aureus may be associated with, or trigger an inflammatory event [64]. As well as increased
abundance of S. aureus, several species were of reduced abundance on lesional skin. Cou-
pled with the observation of reduced species diversity in lesions and severe disease, these
findings raise the possibility of probiotic treatments in AD to improve species diversity.
Interestingly, no significant differences between uninvolved and inflamed skin in psoriatic
patients were identified highlighting that the microbiota is already in a state of dysbiosis in
the absence of inflammation. One possible reason could be that changes in the microbiota
during an inflammatory phase are systemic and overwhelm the healthy resident community.
As disease patients in the MAARS cohort were sampled during a lesional phase, systemic
changes in the microbiome may have already occurred. Further work could investigate
this by sampling diseased patients in a non-lesional phase to determine if their microbial
composition more closely resembles healthy skin.
A progressive reduction of species diversity from healthy, through uninvolved, to lesional
atopic skin was observed. It is likely that this reduction is mostly related to the extreme
abundance of S. aureus which may overwhelm the resident commensal microbiota. Indeed,
it has been shown previously that S. aureus correlated with species diversity [64]. With
co-occurrence network analysis, it was clear in AD that S. aureus dominated the microbial
landscape and negatively correlated with several skin commensals such as S. epidermidis
and Corynebacterium sp. These results indicate that this dominant pathogen could be as-
sociated with the displacement of potentially regulatory or protective microbes. In contrast
to AD, multiple species which possibly organise into communities is a more representative
model of the psoriatic microbiota.
Taken together, this analysis presents a global picture of the skin microbiota across healthy
skin and two models of cutaneous inflammation. The healthy microbial landscape was
characterised and the components which were over-represented or depleted in disease were
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defined. This exploratory analysis places AD as a disease characteristic of loss in microbial
diversity which could be mediated by infection of S. aureus. On the other hand, micro-
bial differences in PSO whilst present, were considerably less extreme. Little evidence
was observed for dysbiosis, although this may be a factor in severe disease. Key potential
species in PSO corresponded to C. simulans, C. kroppenstedtii, Neisseriaceae G. sp., and
Peptostreptococcus anaerobius. Overall, this chapter defines key species of importance and
lays the foundation for study into host-microbe interactions.
Chapter 4
Transcriptomic profiles of skin
inflammation
4.1 Introduction
Comparing levels of gene expression by differential analysis is a powerful tool for identify-
ing core changes in the underlying transcriptome by finding differentially expressed genes
(DEGs). DEGs provide a global view of the systematic differences between cohorts and
can act as an entry point into understanding the biological processes which are perturbed
in disease. Genes of changed expression may be drivers of disease and are potential targets
for future study.
Several transcriptome analyses have been performed to compare the AD transcriptome
to baseline healthy samples [172, 61, 173, 174]. The most striking differences have been
identified in immune response, particularly relating to expression of Th2 cell products
[61]. This is also supported by differences in chemokine expression [174], altered IL36, and
upregulation of the Trem1 pathway signalling [173]. Other major differences have been
identified within epidermal compartment [61, 173] indicating that barrier weakness is a
major component of atopic inflammation. Researchers have also mined the transcriptiome
to identify changes which may correspond to the ‘dryness’ phenotype which accompanies
AD [171]. These include Olsson et al. [172] who identified differences in the expression
of the epidermal water retention gene aquaporin 3 (AQP3) and Plager et al. [174] who
suggested a role for lipid metabolism, indicating that PPARγ trended to be downregu-
lated in AD. A recent meta analysis [58] combined the datasets from several independent
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studies which increased statistical power to detect differences. Whilst a smaller number
of genes were identified than the union of all individual analysis, the authors argued that
the meta-analysis derived gene list is more biologically relevant and robust than any of the
individual counterparts. They found that the atherosclerosis signalling pathway was sig-
nificantly perturbed indicating that vascular inflammation is a component of AD. Whilst
these studies highlight the major areas of interest, they are limited by very small sample
sizes.
The psoriatic transcriptome has been analysed several times by microarray and RNA se-
quencing [175, 176, 177, 178, 179, 180, 181]. Most of these studies have identified increased
expression of IFNG and interferon inducible products [175, 176, 178, 180], thus, implicating
Th1 cells as a central component of psoriatic inflammation. Furthermore, transcriptome
studies have provided solid evidence for the involvement of Th17 cells by identifying con-
sistent up-regulation of IL17A and IL17 inducible transcripts [176, 175, 179, 180]. One
of the most striking observations is a heightened level of innate immunity as measured
by extreme levels of antimicrobial peptide expression [176, 177, 179, 180]. Another char-
acteristic of psoriatic transcriptomes is dysregulation within the epidermal compartment
[178, 177], particularly within the small proline rich protein (SPRR) and late cornified
envelope (LCE) families which is likely to result in structural weaknesses. Defects in lipid
metabolism pathways has also been identified by several studies [176, 177, 180] and may
relate to increased permeability in the skin barrier, or to comorbidities such as metabolic
syndrome which often accompanies psoriasis [182]. Two studies have linked psoriatic in-
flammation to Wnt signalling [181, 176]. Like AD, a meta-analysis combining 5 individual
transcriptome studies identified a core robust transcriptome that consisted of a strong im-
mune signature and enrichment for atherosclerosis signalling, and fatty acid metabolism
[140].
Several analyses have focused directly on the differences in transcript expression between
atopic and psoriatic skin. These comparisons have identified several transcriptomic compo-
nents which differ between diseases in comparison to healthy samples. The overwhelming
trend across these comparative studies indicate changes in the expression of T helper cell
signatures placing AD and PSO at opposing ends of the Th1/Th2 axis [183]. In this
early study, differences in chemokine expression were identified, emphasising that the CXC
chemokine family were expressed in PSO which attract Th1 and neutrophils, and the CCL
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chemokines were expressed in AD which attract Th2 cells. Interest into the role of Th17
cells in psoriasis increased [73] which challenged the hypothesis that psoriasis was primar-
ily a Th1 associated disease. Guttman-yassky et al. [184] found that psoriasis had higher
expression of the IL-23/Th17 pathway which was also corroborated by others [185, 186].
Psoriasis has been identified to have higher expression of certain antimicrobial peptides
compared to AD [77, 185, 187]. Furthermore, studies have also shown that there are
general expression differences in epidermal compartment, particularly within genes encod-
ing the cornified envolope [188] suggesting that whilst barrier defects are present in both
diseases, differences do exist. More recently, Guaranta et al. [185] compared a cohort
of patients with coexisting disease, i.e., patients suffering with both AD and PSO which
allowed comparisons to be performed within individuals increasing their power to detect
biological differences. They found changes in the expression of metabolic transcripts, epi-
dermal differentiation and further corroborated differences in T cell signatures showing
heightened expression of Th17 and Th2 cytokines in PSO and AD respectively. The most
recent study implicated IL36 as a psoriasis associated biomarker compared to other skin
diseases [187] potentially implicating this cytokine in the immunopathogenesis of PSO.
These studies have provided a basis for the main transcriptomic differences between AD
and PSO, however, they were underpowered with maximum sample sizes of 30. The analy-
sis performed in this chapter compares healthy, non-lesional and lesional skin with a cohort
of almost 3 times the size of previous largest comparative study which increases power to
detect subtle differences. Using the MAARS cohort, the transcriptomic profiles of atopic
dermatitis and psoriasis was refined and contrasted in the largest cohort to date.
Transcriptomics analysis in this chapter builds upon collaborative unpublished works by
Marine Jeanmougin. The original differential expression analysis contrasted healthy to dis-
eased samples and compared the AD-lesional and PSO-lesional associated DEGs to identify
disease specific and common signatures. The work presented in this chapter also includes
comparisons of healthy to non-lesional tissue and non-lesional to lesional tissue. The model
was modified to account for the non-independence of multiple samples contributed from
the same patient and a fold change criterion was incorporated ensuring that the analysis
is comparable to other published inflammatory skin transcriptomics studies. All analysis,
figures, interpretation and text was performed by myself.
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4.2 Methods
4.2.1 Data acquisition, sampling and processing
Quality controlled and RMA normalised expression data was obtained from Institut Curie
as part of the MAARS consortium project. Briefly, consenting patients with mild-to-severe
chronic AD and plaque type PSO and healthy voulenteers were recruited from three uni-
versity hospitals in Dusseldorf (HHU), London (KINGS) and Helsinki (UH). Diagnosis was
made by a dermatologist subject to the Hanifin and Rajka criteria. Patients were excluded
based upon antibiotic use and presence of autoimmune diseases. At the site of surface
swabs intended for DNA collection microbiomics profiling, 6mm punch biopsies were taken
under local anaesthesia and stored in RNAlater. RNA was extracted with the RNeasy
Fibrous Tissue mini kit (Qiagen) and hybridised to Affymetrix Gene ST 2.1 arrays. The
arrayQualityMetrics [156] method was applied to identify array failures. Data was subse-
quently normalised using the Robust Multi-array average (RMA) method implemented in
the affy package [157]. A detailed description of patient recruitment sampling is described
in Section 2.3.1, and for transcriptome profiling refer to Section 2.3.3.
4.2.2 Principal component analysis
Principal component analysis of the scaled and preprocessed expression data was performed
to identify major directions of variability within the transcriptome using the R function
prcomp. The variable loadings represent the contribution of each gene to the axis of PC1
and PC2 and were used as input to a pre-ranked GSEA [147] analysis of GO biological
processes [142]. The top process satisfying a Bonferroni corrected p value > 0.05 in both
positive and negative directions were used as a guide to annotate the major directions of
variability.
4.2.3 Differential analysis
Differential analysis was performed using preprocessed and RMA normalised expression
data. Contrasts of ADL-CTRL, ADL-ADNL, ADNL-CTRL, PSOL-CTRL, PSOL-PSONL,
and PSONL-CTRL were performed to identify genes associated with clinical groups. Within
the limma framework [137, 138], a linear model was fit to each gene to estimate the change
in expression between clinical groups. Gender, and sampling institution were included as
fixed effects, and patient was included as a random effect to account for non-independence
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of samples taken from the same individual. Differentially expressed genes were defined as
those with a Benjamini Hochberg adjusted P-value of < 0.05 and log2 fold change LFC of
> 0.58 (approximately equal to an absolute fold change of > 1.5).
4.2.4 Functional analysis
Genes identified as statistically significant were assessed for enrichment of canonical path-
ways and upstream regulators using Ingenuity pathway analysis (IPA) [143]. Enrichment
of GO biological processes was performed with Enrichr [189]. Up-regulated and down-
regulated gene sets were input into IPA and Enrichr separately. Disease specific gene sets
were identified by comparing the gene lists of ADL-CTRL and PSOL-CTRL. Genes com-
monly up-regulated and down-regulated in disease were determined as the intersection, and
those specific to each disease were identified as the difference. Oppositionally differentially
expressed genes were defined as differentially expressed in both ADL and PSOL compared
to CTRL and which LFC > 0.58, in opposite directions.
4.3 Results
A quality controlled and normalised transcriptomics dataset consisting of 83 ADL, 81
ADNL, 213 CTRL, 121 PSONL, and 120 PSOL samples was received from the MAARS
consortium as described in (Table 4.1).
PCA was performed to visualise sample scores in three dimensions which demonstrated
broad transcriptional differences between non-lesional and lesional groups (Figure 4.1).
The first and second principal components explained 11.7% and 4.95% of the variability in
the transcriptome respectively. In line with other studies [177], samples were progressively
distributed along a gradient defined by principal component 1 (PC1) suggesting this is an
important component associated with clinical group. This analysis revealed that lesional
groups of both diseases were distinct from uninvolved groups, however, non-lesional and
healthy samples were not linearly separable.
It is likely that PC1 represents high-level core transcriptomic differences between healthy
and inflamed skin. To further investigate this, GSEA [147] was performed using the prin-
cipal component loadings with GO biological process gene sets. As expected, the most
significant gene set enriched in the positive direction of PC1 was ‘immune response’ (p
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Table 4.1: MAARS Transcriptome study population
ADL ADNL CTRL PSONL PSOL
Patients (n) 83 81 113 121 120
Samples (n) 83 81 213 121 120
Gender (n) Female 36 37 135 25 26
Male 47 44 78 96 94
Anatomical Location (n) Buttocks 0 0 0 18 19
Lower Back 2 3 99 80 90
Thigh 44 42 100 1 1
Upper Back 37 36 14 22 10
Institution (n) HHU 34 32 58 45 44
KINGS 13 14 86 41 41
UH 36 35 69 35 35
Age Mean 43.5 44.3 35.0 48.6 48.8
SD 14.4 14.7 13.3 13.4 13.5
= 0.001) suggesting that the major transcriptomic gradient associated with inflamed skin
relates to perturbations within the immune system. Cell substrate adhesion was enriched
in the negative direction (p = 0.006) of PC1 towards healthy samples representing a state
of homeostasis.
4.3.1 Differential gene expression analysis
A series of differential analyses were performed to identify genes which were dysregulated
between inflamed, uninvolved and healthy skin. For both diseases, lesional disease was
compared to healthy, as well as lesional to non-lesional and non-lesional to healthy using
limma [137]. Differentially expressed genes were defined as those which were significant
(p < 0.05) with a log fold change (LFC) > 0.58 (equalling a fold change of approximately
1.5). The numbers of differentially expressed genes is shown in Table 4.2 and the top 10
most significant genes for each contrast is displayed in Table 4.3. After obtaining a global
view, transcriptomic signatures were further analysed and dissected to identify gene sets
preferentially expressed in AD or PSO in Section 4.4.
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PCA plot of MAARS transcriptome

























































Figure 4.1: Principal component analysis of the MAARS transcriptome cohort. Coloured
points correspond to different clinical groups. Terms along the arrows of PC1 and PC2
correspond to the top GSEA term identified using the ranked variable loadings.
Table 4.2: Differentially expressed genes (LFC > 0.58, p > 0.05)
Contrast DEG Up Down
ADL-CTRL 1260 797 463
ADL-ADNL 500 353 147
ADNL-CTRL 86 55 31
PSOL-CTRL 2516 1326 1190
PSOL-PSONL 2217 1164 1053
PSONL-CTRL 26 23 3
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Contrast logFC adj.P.Val Symbol
ADL-CTRL 1.5E+00 1.6E-121 ARNTL2
ADL-CTRL 3.6E+00 5.7E-119 LCE3D
ADL-CTRL 2.9E+00 1.4E-118 AKR1B10
ADL-CTRL 3.7E+00 1.2E-116 LCE3E
ADL-CTRL 3.0E+00 1.2E-116 C10orf99
ADL-CTRL 3.3E+00 5.7E-116 LCE3A
ADL-CTRL 7.5E-01 7.3E-115 PPP4R1
ADL-CTRL -2.3E+00 1.1E-113 BTC
ADL-CTRL 7.2E-01 2.3E-113 PGM2
ADL-CTRL 4.4E+00 4.4E-113 S100A9
ADL-ADNL 2.8E+00 5.8E-68 S100A12
ADL-ADNL 2.5E+00 5.8E-68 LCE3A
ADL-ADNL 2.1E+00 3.7E-66 AKR1B10
ADL-ADNL 2.9E+00 4.0E-61 S100A7A
ADL-ADNL 1.5E+00 1.0E-59 PRSS27
ADL-ADNL 9.5E-01 1.6E-58 LOC100507420
ADL-ADNL 2.6E+00 1.5E-57 KRT16
ADL-ADNL 9.6E-01 4.6E-56 CDH3
ADL-ADNL 9.6E-01 2.6E-54 GALNT6
ADL-ADNL 1.4E+00 3.6E-53 TMPRSS4
ADNL-CTRL 2.5E+00 7.1E-58 SPRR2G
ADNL-CTRL 2.0E+00 3.4E-50 LCE3D
ADNL-CTRL 2.4E+00 2.7E-48 S100A7
ADNL-CTRL 1.5E+00 5.2E-45 CCL13
ADNL-CTRL 1.1E+00 5.0E-38 TMC5
ADNL-CTRL -1.8E+00 5.0E-38 WIF1
ADNL-CTRL 1.2E+00 2.0E-36 CCL18
ADNL-CTRL 1.4E+00 1.4E-34 C10orf99
ADNL-CTRL -8.2E-01 1.4E-33 CHRM4
ADNL-CTRL 6.4E-01 5.0E-32 ARNTL2
PSOL-CTRL 3.7E+00 1.3E-286 KYNU
PSOL-CTRL 5.1E+00 2.0E-266 TMPRSS11D
PSOL-CTRL 6.4E+00 1.5E-237 S100A12
PSOL-CTRL 4.1E+00 8.3E-235 IL36G
PSOL-CTRL 5.7E+00 6.2E-229 IL36A
PSOL-CTRL 3.3E+00 3.8E-228 PLA2G4D
PSOL-CTRL 6.5E+00 5.2E-227 TCN1
PSOL-CTRL 6.6E+00 5.6E-223 S100A7A
PSOL-CTRL 2.6E+00 1.2E-216 KLK13
PSOL-CTRL 3.2E+00 1.4E-212 PRSS27
PSOL-PSONL 3.5E+00 1.6E-280 KYNU
PSOL-PSONL 5.0E+00 2.2E-268 TMPRSS11D
PSOL-PSONL 6.1E+00 1.3E-233 S100A12
PSOL-PSONL 5.7E+00 7.3E-233 IL36A
PSOL-PSONL 3.3E+00 4.8E-231 PLA2G4D
PSOL-PSONL 3.8E+00 9.7E-228 IL36G
PSOL-PSONL 6.1E+00 1.3E-222 TCN1
PSOL-PSONL 2.6E+00 6.4E-222 KLK13
PSOL-PSONL 6.2E+00 5.2E-216 S100A7A
PSOL-PSONL 1.9E+00 4.1E-215 VNN3
PSONL-CTRL 1.6E+00 1.1E-29 SPRR2G
PSONL-CTRL 1.6E+00 8.6E-27 S100A7
PSONL-CTRL 8.0E-01 1.7E-23 IFI27
PSONL-CTRL -1.0E+00 1.5E-15 WIF1
PSONL-CTRL 5.9E-01 2.1E-14 TMC5
PSONL-CTRL 1.2E+00 1.2E-09 CXCL10
PSONL-CTRL 6.5E-01 1.6E-08 C10orf99
PSONL-CTRL 9.6E-01 2.3E-08 S100A9
PSONL-CTRL 9.3E-01 4.1E-08 S100A8
PSONL-CTRL 6.9E-01 5.8E-08 CHI3L2
Table 4.3: Top 10 differentially expressed genes for each contrast
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4.3.2 Comparison of uninvolved skin between clinical groups
4.3.2.1 DEGs and pathways in non-lesional atopic skin
First, non-lesional skin was compared with healthy volunteers to identify genes which may
convey disease susceptibility in absence of inflammation associated transcriptomic disor-
der. Considering non-lesional skin, 86 genes were differentially expressed (55 up, 31 down,
Table 4.2) which were significantly dysregulated between ADNL and CTRL (Figure 4.2
A). Unlike [61], no significant downregulation of terminal differention genes FLG, IVL and
LOR was found. Instead, other members of the epidermal differentiation complex were
upregulated in non-lesional AD. These including members of the SPRR family, SPRR2B,
SPRR2G and members of the LCE family, LCE3A, LCE3D and LCE3E. Antimicrobial
peptides were also of increased expression in ADNL such as DEFB4A, S100A7, S100A7A
and S100A9.
As well as differences in epidermal barrier gene expression, several genes associated with
immune response were upregulated including AhR receptor translocator like 2 (ARNTL2),
BIRC3, interferon alpha inducible protein 27 (IFI27), the IL1 family member IL36G, and
genes associated with chemotaxis including CCL13, CCL18, CXCL9 and CXCL10. Inge-
nuity pathway enrichment showed that the top pathways were ‘Role of IL17A in Psoriasis’
which contained the S100A antimicrobial peptides and ‘Granulocyte Adhesion and Dia-
pedesis’ consisting of CXC and CC family cytokines as well as MMP3 (Figure 4.2 C).
The top down regulated gene in ADNL was WNT inhibitory factor 1 (WIF1) indicat-
ing that wnt signalling may be perturbed in non-lesional skin. Several of the downreg-
ulated genes corresponded to lipid and fatty acid metabolism such as ACOT1, FABP7,
AADACL3, AWAT2, and DGAT2L6 which suggests that deficiencies in lipid biosynthesis
are pre-existing in non-inflamed skin.
4.3.2.2 DEGs and pathways in non-lesional psoriatic skin
Transcriptional activity within non-lesional psoriatic tissue was perturbed to a smaller ex-
tent and more closely resembled healthy skin with only 26 differentially expressed genes (23
up, 3 down, Table 4.2, Figure 4.2 B). In a similar manner to that observed in AD, the
top genes included those associated with the epidermal differentiation complex including
SPRR2G, SPRR2B, the antimicrobial peptides S100A7, S100A9 and S100A8 as well as
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Figure 4.2: Genes differentially expressed in uninvolved skin compared to healthy. (A)
- heatmap of top 20 differentially expressed genes between ADNL (orange) and CTRL
(green). (B) DEGs between PSONL (brown) and CTRL (green). (C) Fold change com-
parison across uninvolved and lesional states. Top 10 genes from ADNL-CTRL. (D) Top 10
genes from PSONL-CTRL. (E) Enriched pathways amongst DEGs in both ADNL-CTRL
and PSONL-CTRL contrasts. Pathways shown are significant (BH p value < 0.1) in at
least one contrast.
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immune genes including IFI27, CXCL9 and CXCL10.
A significant enrichment for the ‘Role of IL-17A in psoriasis’ was identified which, like AD,
contained the S100A family antimicrobial peptides (Figure 4.2 C). Only 3 genes were
downregulated in PSONL including WNT inhibitory factor 1 (WIF1). WIF1 is known to
be strongly downregulated in lesional skin [190], however, this gene has not been described
in non-lesional psoriatic [177] or atopic skin. Many of the genes dysregulated in PSONL
were also significantly differentially expressed in ADNL, suggesting that skin susceptible
to inflammation share a proportion of the same characteristics.
Comparison of the fold changes of significant genes shows that transcriptomic dysregula-
tion within ADNL is ‘more-extreme’ than in PSONL (Figure 4.2 D-E). The fold changes
amongst the top 10 DEGs compared to healthy were found to be higher in uninvolved
atopic skin suggesting that non-lesional AD skin exists in a heightened state of disorder
compared to non-lesional psoriatic skin. In a lesional state, this pattern is reversed where
the same genes in PSOL skin were of greater expression.
Overall, analysis of non-lesional skin showed that there is a clear overlap in transcriptional
changes observed in both diseases, as well as several key differences. Dysregulation in
components of the EDC was observed in both diseases by upregulation of genes within the
SPRR and S100A families. Further, common processes involving genes associated with
chemotaxis such as CXCL9 and CXCL10 were upregulated indicating that uninvolved skin
has heightened immune activation in the absence of inflammation. Further transcriptional
dysregulation was observed in ADNL including the up-regulation of CC family cytokines,
increased expression of LCE genes, and downregulation of genes involved in fatty acid
metabolism.
4.3.3 Genes and pathways upregulated in lesional skin
4.3.3.1 Genes and pathways upregulated in lesional atopic skin
Next, differential expression was evaluated in lesional samples. A total of 1260 (797 up, 463
down, Table 4.2) DEGs between ADL and CTRL samples were identified (Figure 4.3
A, B). Within the top DEGs, several known genes previously identified in published tran-
scriptomes were identified. These included genes corresponding to the epidermal barrier



















log2 FClog2 FC log2 FC log2 FC
CTRL ADL ADNL CTRL CTRL PSOL PSONL PSOL
ADL-ADNL PSOL-PSONL PSOL-CTRL
Figure 4.3: Differential expression analysis of lesional tissue. (A,C,E,G) Volcano plots.
Horizontal lines correspond to p = 0.05, vertical lines correspond to log2 fold change of -
0.58 and +0.58. (B,D,F,H) Heatmaps of contrasts including lesional tissue. The expression
of the top 40 most significant differentially expressed genes are shown
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such as LCE3D, LCE3A, LCE3E, SPRR2B and CNFN [188, 61]. Keratinocyte secreted
antimicrobial peptides were differentially expressed which are known to be associated with
AD [58, 188] including S100A7A, S100A9 and S100A12. Genes associated with immune
response were up-regulated including IL4R, NOD2, CLEC7A and CCL18 [61, 58]. The
interferon inducible gene, IFI16 was also found amongst the top 40 up-regulated genes.
ARNTL2 was highly ranked and was also expressed in non-lesional tissue suggesting a po-
tential role of the Aryl hydrocarbon receptor signalling pathway (AHR) in both uninvolved
and lesional atopic dermatitis. The matrix metalloproteinase MMP12 was differentially
expressed which is involved in ECM remodelling and is known marker of inflammation
expressed in atopic skin [61]. These results were mirrored in the comparison of lesional
atopic skin to non-lesional atopic skin which revealed 500 DEGs (353 up, 147 down, Table
4.2), 97% of which were also differentially expressed in ADL-CTRL (Figure 4.3 C,D).
Several of the most highly DE genes were also amongst the top genes in lesional disease
including antimicrobial peptides of the S100 family, IL4R and epidermal barrier associated
genes LCE3A, and CNFN.
Pathway analysis of the most up-regulated genes in both ADL-CTRL and and ADL-ADNL
revealed a set of enriched pathways that was highly concordant (Figure 4.4 A). The most
significant pathways included Atherosclerosis signalling pathway (ADL-CTRL p = 5.01e-
15) which is associated with vascular inflammation and has recently been associated with
AD [58]. Most of the top enriched pathways corresponded to the immune system and
included Granulocyte Adhesion and Diapedesis (ADL-CTRL, p = 1.56e-14), T Helper cell
differentiation (p = 1.58e-08) and iCOS-iCOSL signalling in T helper cells (p = 8.7e-08)
which is associated with the activation of Th1 and Th2 cells. Nine genes were differ-
entially expressed between ADL-CTRL which were involved in the ‘complement system’
(ADL-CTRL, p = 1.2e-04) which has not been shown in previous analysis of the atopic
transcriptome suggesting the classical complement system may also contribute towards
atopic inflammation. A significant enrichment for Hepatic Fibrosis / Hepatic Stellate cell
activation (p = 2.29e-07) was found indicating that genes involved in fibrotic processes are
up-regulated in lesions [48].
4.3.3.2 Genes and pathways upregulated in lesional psoriatic skin
A total of 2516 (1326 up, 1190 down) genes were significantly differentially expressed in
PSOL samples compared to healthy with a mean log fold change of 1.0 (Table 4.2). The
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Figure 4.4: Enriched Ingenuity pathways upregulated in disease for contrasts involving
lesional disease. (A) Top upregulated AD pathways enriched in ADL-CTRL (red) and
ADL-CTRL (gold) contrasts. (B) Top upregulated PSO pathways enriched in PSOL-
CTRL (blue) and PSOL-PSONL (gray) contrasts. All pathways shown are BH adjusted p
value < 0.1 in at least one contrast. Red and black lines correspond to p = 0.1 and 0.05
respectively.
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top 40 genes revealed a picture of transcriptional dysregulation in concordance with several
published transcriptomes (Figure 4.3 E,F). Strikingly high expression levels of antimi-
crobial peptide genes were observed including S100A12, S100A7A and DEFB4A which
were all up-regulated with log2 fold changes > 6 [77, 177, 179, 180]. Genes encoding for
components of the epidermal barrier were upregulated including CNFN, TGM1, LCE3A,
and SPRR2B [185, 188, 179].
As well as epidermal barrier and antimicrobial peptides; genes associated with inflam-
mation and the immune system were up-regulated. IL36G and IL36A were expressed to
extreme levels in psoriatic skin (LFC > 4) [185, 187, 179]. Other upregulated immune
genes included OASL, OAS2 and TCN1. Also amongst the top genes were those asso-
ciated with energy and lipid metabolism [176] including PLA2G4D [179], KYNU [140],
GDPD3 and RHCG. As observed in AD, the differentially expressed genes between PSOL-
PSONL closely resembled those identified in PSOL-CTRL (Figure 4.3 G,H) including
IL36, antimicrobial peptides, EDC genes and those corresponding to lipid metabolism.
Interferon signalling was the top enriched pathway amongst genes upregulated in PSOL
(p = 2.34e-09, Figure 4.4 B). Several other immune pathways were enriched including
‘Communication between innate and adaptive immune cells’ (PSOL-CTRL; p = 6.76e-
09), which contained TLR2 and was specifically expressed in PSO. ‘iNOS signalling’ (p =
6.76e-06) contained the highly up-regulated NOS2 (LFC = 2.8) and indicates activation of
macrophages, ‘TREM1 signalling’ (p = 2.13e-05) which was recently identified in an AD
transcriptome study [173] and ‘IL10 signalling’ (p = 3.81e-06). Significant enrichment for
‘LXR/RXR activation’ (p = 6.76e-06) was found and included apolipoprotein 1 (APOL1)
suggesting potential disruption of processes involved in lipid and cholesterol biosynthesis.
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4.3.4 Genes and pathways downregulated in lesional skin
4.3.4.1 Genes and pathways downregulated in lesional atopic skin
Differential analysis revealed 463 genes downregulated in ADL compared to healthy indi-
viduals (Table 4.2). Few pathways were enriched amongst down regulated genes (Figure
4.5 A). The top pathway was ‘Oleate Biosynthesis II’ (ADL-CTRL; p = 0.009) and con-
tained the genes FADS1, FADS2, SCD5 and ALDH6A1. These results reflect previous ob-
servations of abnormal lipid composition in the stratum corneum of patients with AD [59].
Further enrichment was observed in ‘wnt-catenin signalling’, establishing a link between
this pathway in atopic inflammation. Five genes involved in circadian rhythm signalling
(ADL-CTRL; p = 0.03) were identified including PER3, PER1, NR1D1, BHLHE41, CRY2.
Circadian rhythms have recently been shown to control the expression of proinflammatory
cytokines [191] thus this pathway could play a role in atopic inflammation. As cover-
age of enriched pathways was poor amongst downregulated pathways, enrichment of GO
[142] biological processes with enrichR [189] was performed (Figure 4.5 B). This analysis
revealed enrichment amongst several processes involved in fatty acid and lipid metabolic
processes improving support for a transcriptional profile associated with disruption to lipid
functionality. Circadian regulation of gene expression was also enriched providing further
support for disruption of this process in AD.
4.3.4.2 Genes and pathways downregulated in lesional psoriatic skin
Comparison of lesional PSO to healthy revealed no Ingenuity pathways which were enriched
(p < 0.1) however several pathways were enriched in the PSOL-PSONL contrast. Enriched
pathways were associated with lipid biosynthesis including (Figure 4.5 C) ‘LPS/IL1 Me-
diated inhibition of RXR function’ (PSOL-PSONL; p = 0.033) and ‘Oleate Biosynthesis II’
(PSOL-PSONL; p = 0.044). The same four genes involved in ‘Oleate Biosynthesis II’ found
in AD, were also downregulated in PSO suggesting lipid biosynthesis is also dysfunctional
in psoriatic tissue. Pathways relating to energy metabolism including ‘AMPK signalling’
(PSOL-PSONL; p = 0.03) and ‘leptin signalling in Obesity’ (PSOL-PSONL; p = 0.03)
were significantly down and was further supported by GO enrichment of energy metabolic
processes such as ‘regulation of glucose’, ‘carbohydrate metabolic process’ and ‘fatty acid
metabolic process’ (Figure 4.5 D). ‘Axonal guidance signalling’ (PSOL-PSONL; p =
0.08) was enriched amongst downregulated genes. It been suggested that neurons and
neuropeptides may be associated with pruritus in PSO [192, 193]. Mild to severe pruritus
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Figure 4.5: Enriched Ingenuity pathways downregulated in disease for contrasts involving
lesional disease. (A) Top downregulated AD pathways enriched in ADL-CTRL (red) and
ADL-CTRL (gold) contrasts. (B) Top enriched GO terms amongst downregulated genes
in ADL-CTRL. (C) Top downregulated PSO pathways enriched in PSOL-CTRL (blue)
and PSOL-PSONL (gray) contrasts. (D) Top enriched GO terms amongst downregulated
genes in PSOL-CTRL. All pathways shown are BH adjusted p value < 0.1 in at least one
contrast. Red and black lines correspond to p = 0.1 and 0.05 respectively
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affects approximately 60-90% of psoriasis patients [194]. An increase in nerve growth factor
(NGF) with ELISA has been found in psoriatic individuals with pruritus [195] and whilst
NGF was not found to be differentially expressed (in either AD or PSO), 34 down-regulated
genes associated with neuronal guidance were down-regulated in psoriatic lesions. These
included members of the Ephrin family and receptors, EFNB2 and EPHB1, Semaphorins
including, SEMA3D and SEMA3E, Plexins including PLXNA3, and SLIT2. Further sup-
port was identified by enrichment for the ‘synapse organisation’ GO term (Figure 4.5 D)
and potentially relate to a neurological axis which relate to the mechanisms of pruritus.
‘Wnt β-catenin signalling’ was found to down-regulated (PSOL-PSONL; p = 0.08) and
supports previous reports of dysfunctional Wnt signalling in psoriasis [190, 181].
4.4 Disease specific gene sets
To gain insight into transcriptional processes that are common between diseases, and those
which are preferentially expressed in either AD or PSO, signatures were defined by inter-
secting the lists of differentially expressed genes (Figure 4.6). To evaluate differences in
immune activation, cytokines and chemokines preferentially up-regulated in AD or PSO
were identified (Figure 4.7).
4.4.1 Common and disease associated inflammatory signatures
4.4.1.1 Common inflammatory gene signatures and pathways
Six hundred and forty one genes were commonly up-regulated between both diseases
(Figure 4.6 A). The most significant pathways included Atherosclerosis Signalling (p
= 1.99e-08) which was identified in a recent AD meta-analysis [58], Granulocyte Adhesion
and Diapedisis (p = 3.63e-07) and T helper cell differentiation (p = 5.62e-06). To determine
core similarities and differences in immune response, cytokine and chemokine signatures
of the commonly upregulated genes were identified (Figure 4.7) using the same DEG
sub-setting approach employed by Guaranta et al. [185]. IL22, IL36A and IL36G were
up-regulated in both diseases, as well as an array of cytokine receptors. These included
IL36RN, IL4R, IL7R, IL10RA and IL2RA. A chemokine profile of CXC family CXCL8,
CXCL9, CXCL10, CXCL11, CXCL17, and CC family CCL2, CCL22, CCL18 and CCL19
were up-regulated in both diseases. The pathways, as well as proinflammatory genes iden-
tified reflect a core disease signature associated with vascular inflammation, immune cell
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Figure 4.6: Cohort specific gene sets and pathway analysis. (A) Venn diagrams showing
overlap of upregulated and downregulated genes between ADL and PSOL compared to
control. (B) Top significant pathways for up-regulated gene sets. Heatmap tile colors
represent -log of the adjusted p value for pathway enrichment. Gray tiles are not significant.
(C) Enriched pathways amongst genes downregulated in both ADL and PSOL.
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chemotaxis and lymphocyte activation (Figure 4.6 B). It is important to note that for
many of commonly upregulated immune genes, the expression in PSO was higher than
that in AD except in the cases of: IL2RG, IL2RA, IL10RA, CCR4, CCR1 and the CC
chemokines CCL2, CCL18, and CCL19.
4.4.1.2 Genes and pathways preferentially expressed in AD
To identify biological processes associated with a specific disease, pathway enrichment
of gene sets preferentially expressed in in either AD or PSO was performed. Despite a
high degree of overlap, several pathways were enriched within PSO and AD specific DEGs
(Figure 4.6 B). 156 genes were specifically up regulated in atopic lesions (p < 0.05, LFC
> 0.58). The chemokine and cytokine profile of AD specific genes was evaluated (Figure
4.7) revealing a Th2 signature including cytokines IL10 and IL24, as well as IL13RA2 and
the chemokine receptor CCR8. TGFB was found to be of increased expression in AD along
with a panel of CC family chemokines associated with immune cell migration including
CCL17, CCL8, CCL26, CCL1 and CCL13. With upstream regulator analysis, the Th2
cytokine IL4 (p = 1.67e-28) was found to be the most significant candidate.
The most significant up-regulated pathway was ‘Granulocyte Adhesion and Diapedesis’ (p
= 1.25e-07) which is involved in migration of immune cells and contains several CC family
chemokines (as described above) indicating differences in immune cell chemoattraction be-
tween AD and PSO (Figure 4.7). These findings support previous observations that AD
is associated with over expression of CC family, and PSO with CXC family chemokines
[183]. This pathway also included VCAM1 which is a cell adhesion molecule induced by
Th2 cytokines [196].
Hepatic Fibrosis / Hepatic Stellate Cell activation’ (p = 1.86e-06) was enriched in AD spe-
cific genes and consisted of collagen transcripts, COL4A1, COL6A3, COL6A5, COL6A6,
the TIMP metallopeptidase 1 (TIMP1) and immune genes IL10 and TGFB1. TGFB was
expressed specifically in ADL and is known to be pro-fibrotic. Furthermore, it has been
suggested that extracellular matrix remodelling in AD could be driven by TGFB [197].
These results indicate that ECM remodelling may be associated with skin thickening that
accompanies AD [198]. As TGFB was preferentially expressed in AD, it could be that
TGFB is a differentiator which drives this response. AD specific genes were also strongly
enriched for complement system (p = 2.45e-05) establishing a link between this pathway
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and atopic inflammation.
4.4.1.3 Genes and pathways preferentially expressed in PSO
The psoriatic transcriptome was characterised by 685 specifically up-regulated genes (Figure
4.6 A). Evaluation of cytokine and chemokine profiles identified an up-regulated Th17
signature including IL17A, STAT3 and CCL20 (Figure 4.7). The Th1 cytokine IFNG
was up-regulated in PSO, as well as high expression of interferon inducible gene IFIT1.
Several proinflammatory cytokines including IL19, IL20 and IL33 were up-regulated in
PSO, as well as a panel of chemokines mediating immune cell trafficking; these consist
of CXCL1, CXCL16, CXCL13 and CCL20. IL1B was specifically expressed in psoriasis
samples. Whilst the IL1 family cytokines IL36G and IL36A were differentially expressed
in both AD and PSO, they were amongst the most up-regulated genes in PSO with log
fold changes > 4, therefore, these results confirm recent reports emphasising the impor-
tance of this family in the pathogenesis of psoriasis [199, 179]. Top upstream regulators of
up-regulated PSO genes were INFG (p = 6.12e-24) and STAT3 (p = 9.16e-24).
Pathway enrichment amongst genes preferentially expressed in PSO revealed Th1 and pso-
riasis associated pathways such as ‘Interferon Signalling’ and ‘Role of JAK1, JAK2, and
TYK2 in Interferon signalling’ (Figure 4.6 B). ‘Interferon signalling’ contained INFG
which is produced by Th1 cells and is considered to be one of the main differentiators
between AD and PSO [184]. Psoriasis associated genes were enriched for ‘Acute phase re-
sponse signalling’ (p = 0.003, Figure 4.6 B). This pathway included an array of immune
transcripts including the IL1 family cytokines IL1B, IL36B, and IL33, together with the
receptor IL1RN. The authors of [200] found up-regulated serum levels of IL33 in AD com-
pared to psoriasis, however, here the opposite trend was observed in the skin transcriptome
(AD LFC = -0.04, PSO LFC = 0.72). Other genes in this pathway consisted of STAT3
and NFKBIB, all of which were preferentially up-regulated in PSO.
Genes involved in ‘LPS/IL-1 Mediated inhibition of RXR function’ were over-represented (p
= 0.006) and contained IL1 family cytokines and genes associated with lipid and xenobiotic
metabolism, as well as enrichment for ‘LXR/RXR Activation’ (p = 0.006) which included
NOS2, a known biomarker in PSO [201], thus, enrichment of this pathway may correspond
to the metabolic syndrome which accompanies patients with psoriatic lesions [72].
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Table 4.4: Genes expressed in opposite directions
Gene LFC AD-CTRL P AD-CTRL LFC PSO-CTRL P PSO-CTRL Description
CEACAM5 -0.62 3.0e-09 0.77 9.4e-16 Carcinoembryonic Antigen
ASPN 0.60 4.9e-17 -0.83 8.6e-36 Asporin
PPP1R3C 0.69 2.6e-22 -0.86 5.09e-38 Protein Phosphatase subunit
4.4.1.4 Commonly downregulated pathways
There were 439 down-regulated genes in both AD and PSO (Figure 4.6 A). These genes
were associated with lipid biosynthesis pathways (Figure 4.6 C) including ‘Oleate Biosyn-
thesis’ (p = 0.007) and ‘LPS/IL-1 Mediated inhibition of RXR function’ (p =0.03). The
genes involved in ‘Oleate Biosynthesis’ were SCD5, FADS2, FADS1 and ALDH6A1 indicat-
ing that lipid biosynthesis is dysfunctional in both diseases. ‘Circadian rhythm signalling’
was significantly downregulated in both diseases (p = 0.03) which has recently been shown
to regulate expression of proinflammatory cytokines [191] therefore, this finding could es-
tablish a general link with skin inflammation. Whilst no strong enrichment of immune
system processes was found, cytokines of reduced expression in both diseases included
IL34 and IL37.
4.4.2 Genes expressed in opposite directions
Genes were filtered for those which were differentially expressed in opposite directions
i.e., genes which were significantly up-regulated in AD (p < 0.05, LFC > 0.58), however,
were significantly down-regulated in PSO (p < 0.05, LFC < -0.58, Table 4.4). Only
three genes satisfied these criteria including CEACAM5, which is involved in cell adhesion,
Asporin (ASPN) which was up-regulated in AD but down regulated in PSO, is an ECM
protein which is capable of inhibiting TGFB signalling in cartilage [202]. ASPN was also
found to be significantly up-regulated in non-lesional atopic skin and therefore could be an
interesting candidate for further study. PPP1R3C is involved with protein phosphorylation
with a wide range of functions. The function of these genes in the skin is currently unknown,
thus further investigation may provide insights into the mechanisms which differentiate
disease.










































































































Figure 4.7: Common and specific cytokine expression. Up in ADL corresponds to DEGs
which were LFC > 0.58, p > 0.05 in ADL-CTRL and not in PSOL-CTRL.
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4.5 Conclusions and Discussion
PCA showed that lesional samples had distinct transcriptomes from uninvolved and healthy
skin, and that the major axis of variability was associated with immune response. Fur-
thermore, non-lesional samples were almost indistinguishable to healthy controls. This
was supported by the finding that PSONL had very few DEGs (26) suggesting that non-
inflamed skin closely resembles healthy tissue. On the other hand, transcriptional dys-
regulation in lesional skin was vastly perturbed with over 2500 genes. A different pattern
emerged in AD as uninvolved tissue had 86 genes of altered expression whereas lesions were
perturbed to a smaller extent than PSO. Atopic lesions were characterised by fewer DEGs
than psoriasis which is in concordance with other comparative studies [185, 183]. The fold
changes of uninvolved DEGs tended to be higher in AD; however, in a lesional phase, the
expression in PSO was greater than in AD suggesting that susceptible AD skin exists in a
heightened state of disorder, however during a flare, transcriptional dysregulation in PSO
overshadows AD.
4.5.1 Uninvolved skin
Epidermal barrier dysfunction is characteristic of skin susceptible to disease
Considering the non-lesional tissue of both diseases, most DEGs in PSONL were also sig-
nificant in ADNL. Amongst the overlapping genes, those encoding components of the epi-
dermal barrier including SPRR2G, SPRR2B along with the antimicrobial peptides S100A9
and S100A7 were identified. These genes were significantly up-regulated clearly suggesting
that barrier dysfunction precedes a flare event.
Heightened immune activation in non-lesional AD
An overlapping immune signature within uninvolved skin was identified which included
up-regulation of interferon inducible genes CXCL10, CXCL9, and IFI27. These genes rep-
resent a component of the immune system which is activated in the absence of inflammation
of both diseases. Further immune system activation was observed in non-lesional AD with
the specific up-regulation of the chemokines CCL18 and CCL13. CXCL10 and CCL18
have been identified in the non-lesional skin of AD patients [61], however, to the best of
our knowledge CXCL9 and CCL13 have not been reported. The expression of CCL18 is
enhanced by the expression of Th2 cytokines [203], therefore, it could represent a Th2
signature within the uninvolved skin of AD and indicates that non-lesional skin exists in
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a state of heightened immune activation. Taken together, this analysis indicates that sus-
ceptible AD skin is associated with Th1/Th2 immune activation, increased antimicrobial
peptide presence and increased expression of genes involved in terminal differentiation. Un-
involved psoriasis more closely resembled healthy skin, but displayed evidence of increased
Th1 activity and dysregulation amongst genes encoding for the epidermal barrier.
4.5.2 Lesional skin
The epidermal barrier is significantly disrupted during inflammation
Both AD and PSO were associated with transcriptional changes to integral components
of the epidermal barrier. Several members of the LCE3 family along with members of the
SPRR family were up-regulated in both diseases as well as CNFN. Disruption to barrier
gene expression has been identified in previous studies [185, 188] and is a major area of
interest in AD as barrier weakness may convey increased susceptibility to transepidermal
allergen transfer [204, 205] and colonisation of pathogens like Staphylococcus aureus [206].
Interestingly, disruption to the barrier in PSO was potentially greater as fold changes were
more extreme, therefore, barrier weakness alone does not explain AD. It is also possible
that increased expression of epidermal genes in PSO is reflective of increased proportion
of keratinocytes in psoriatic biopsies due to hyperproliferation [207].
Common immune system dysregulation
The immune system was vastly perturbed in both diseases as shown by the common up-
regulated genes. A common inflammatory signature was enriched for immune processes
including ‘Granulocyte adhesion and diapedesis’ and ‘Atherosclerosis signalling’. This com-
mon immune signature consisted of CCL22, CCL2, and CXC family chemokines as well as
IL22, ICOS, IL36A and IL36G. Whilst IL36 was differentially expressed in both diseases,
the expression of IL36 was at strikingly high levels in PSO, as others have shown [179].
The common signature also included several cytokine receptors including IL36RN, IL10RA,
IL2RA, IL7R and IL4R. The top upstream regulator was IFNG (p=1.8e-46), therefore, the
common inflammatory immune signature is likely to be associated with Th1 activity which
is characteristic of PSO [73], and also characteristic of AD in the chronic phase [44].
Many antimicrobial peptides were up-regulated in both diseases and including S100A7A,
S100A7, S100A2, S100A12, S100A8, S100A9 and DEFB4A. Whilst AMPs were dysregu-
lated in both, they tended to be of greater expression in PSO as others have found [77].
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Th2 activation in AD and Th1/Th17 activity in PSO
The underlying immunological consensus places AD as a disease associated with a Th2 cell
response in the acute phase [44], whereas PSO is thought to be associated with interferon-γ
producing Th1 cells and IL-17A producing Th17 cells [73]. The cytokine profile preferen-
tially expressed in AD, included IL10, IL24 and IL13RA2 along with an array of CC-family
cytokines and CCR8. Upstream regulator analysis identified IL4 as the top candidate
amongst genes preferentially expressed in AD, therefore, these findings support the hy-
pothesis of Th2 disbalance in AD.
In psoriasis, preferential up-regulation of IL1B, IL19, IL20, IL33, INFG and IL17A was
found along with an array of CXC family cytokines. Pathways associated with PSO specific
genes were classic Th1 pathways such as ‘Interferon signalling’. Top upstream regulators
were INFG and STAT3, thus, these results suggest that PSO is of higher expression in
Th1/Th17 cytokines and inducible products, and supports the current consensus model of
these diseases.
Disruption to lipid biosynthesis in AD and PSO
Disruption to lipid biosynthesis has been associated with both AD and PSO previously
[58, 140]. Pathways involved in lipid biosynthesis including ‘Oleate biosynthesis II’ were
found to be enriched amongst down-regulated genes in AD compared to healthy samples
supporting observations of reduced lipids and ceramides in AD [60, 59]. As a larger number
of downregulated genes were found in PSO (1190 vs 463), this pathway was not found to be
significant, however, the same genes were dysregulated suggesting that this characteristic
is also likely to be present in psoriatic skin.
Further analysis of GO terms showed a downregulation of genes involved in fatty acid
metabolism for both diseases. Within the epidermis, keratinocytes synthesise lipids which
are a necessary component of the cornified layer and as lipid bioysnthesis has been linked
to barrier dysfunction, this could also be associated with the colonisation of Staphylococ-
cus aureus [206]. Wnt signalling is known to be disrupted in psoriasis [181, 190] although
downregulated genes were enriched in both diseases establishing a general link between this
pathway and skin inflammation. Core genes involved in the circadian clock were also found
to be downregulated in both diseases. Expression of certain cytokines have been shown to
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be under clock control, and mutations within clock inhibitors can result in a psoriasiform
inflammation in mice [191].
High expression of ECM genes in AD
AD was characterised by high expression of extracellular matrix genes and was enriched for
pathways such as a Hepatic ‘Fibrosis/Hepatic Stellate Cell Activation’. Several members of
the matrix metalloproteinases family; MMP3, MMP19, TIMP1, as well as members of the
collagen family; COL4A1, COL6A3, COL6A5, COL6A6, were preferentially up-regulated
in AD. On the other hand, only weak enrichment for ECM terms was found amongst
all upregulated PSO genes compared to healthy (p = 0.06, pathway rank = 90). Th2
cytokines as well as TGFB were preferentially expressed in ADL and can induce fibrosis
[198, 197, 208] which may explain the differential expression of these genes.
Down-regulation of axonal guidance signalling and energy metabolism in PSO
Genes downregulated in PSOL were enriched for ‘axonal guidance signalling’ which was also
identified by GO enrichment analysis. Neurological factors are thought to be associated
with pruritus [192, 195] in the skin, therefore, this pathway may correspond to differences
in itch mechanisms. Furthermore, these findings could relate to the recent association
between a set of nociceptors required to drive IL-23-mediated psoriasiform inflammation
in mice [209]. Genes downregulated in PSO were also enriched for ‘AMPK signalling’ and
‘glucose metabolism’ which reflects perturbation to energy metabolism and could be asso-
ciated with the metabolic syndrome which is often associated with psoriasis [72].
Lastly, the increased power due to the size of our cohort allowed us to find three genes
(CEACAM5, ASPN and PPP1R3C) which were differentially expressed in opposite direc-
tions between AD and PSO. To the best of our knowledge, this is the first time these
genes have been reported. Due to unique expression profiles of these genes, they are candi-
dates for further investigation as their functional roles in the skin are not well characterised.
Overall, this analysis presents a comprehensive overview of the transcriptional differences
between both lesional and uninvolved skin from AD and PSO. Common transcriptomic
components were identified, and signatures which were preferentially expressed in AD and
PSO were established. This analysis has confirmed several dysregulated processes which
have been identified in previous studies such as Th1/Th17 and Th2 polarisation in PSO
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and AD respectively, as well as disruption to the epidermal barrier and lipid bioysynthesis
pathways. Several other components which are less established and have not been reported
in previous transcriptome analysis were identified such as disruption to the ECM, neuro-
logical components and circadian rhythms. This transcriptome wide exploratory analysis
places AD as a disease characteristic of heightened Th2 immunity, increased ECM remod-
elling and with disruption to the epidermal barrier. On the other hand, PSO was associated
with increased activity of Th1/Th17 immunity, extreme antimicrobial peptide expression,
abnormal epidermal barrier expression and with potential disruption to energy metabolism
and axonal guidance signalling pathways. Both diseases showed traits of disrupted lipid
and fatty acid metabolism. The gene sets identified in this chapter characterise the major




It is now generally accepted that the resident microbiota plays a role in shaping the im-
mune system and helps with the maintenance of homeostatic equilibrium [22, 21]. When
the delicate balance in the microbiota is disrupted, the composition of microbial commu-
nities enters a state of dysbiosis which has been linked with chronic inflammatory diseases
[87] such as Crohn’s disease [4, 5], atopic dermatitis [64] and asthma [120]. If dysbiosis
does indeed exacerbate or trigger inflammation, establishing the links between resident
microbiota and host response is a critical step towards development of therapeutics which
can modulate the commensal microbiota.
Several previous studies have attempted to integrate the microbiome with host derived
parameters such as the metabolome and transcriptome. These include Schwartz et al.
[116], who used a strategy based upon canonical correlation analysis (CCA) to express a
relationship between metagenomic virulence factors and intestinal host-immune gene ex-
pression in the context of diet amongst formula and breast-fed infants. Investigation of
host-microbe associations with linear modelling is popular due to its ability to control
for extraneous sources of variation such as age, antibiotic usage, gender and body site
[33, 40, 41] which are known to impact upon microbial abundance. One such study found
a trend for increased Proteobacteria abundance with the expression of host IL1A in the
context of asthma [120]. Another study used linear models to investigate the influence of
phylum level microbiota on the expression of the genes APOA1 and DUOX2 [119] reveal-
ing clinically relevant interactions in the context of Crohn’s disease and ulcerative colitis.
95
CHAPTER 5. HOST-MICROBE INTEGRATION 96
A more recent application simultaneously reduced dimensionality in both microbiome and
transcriptome datasets to maximise power, and then used linear models to identify associa-
tions between host transcriptional and microbiomic factors in the inflamed ileal pouch [29].
In previous chapters, the overall properties of resident community composition, as well as
the host transcriptional architecture of skin inflammation were determined. Given that
the MAARS consortium data consists of both microbiome and transcriptome resources
sampled at the site of inflammatory disease, this provided a unique opportunity to study
host-microbe interactions. This chapter presents an exploratory analysis into microbe-
associated host-transcriptional pathways. To investigate host-microbiome associations, a
power analysis was performed to approximate an appropriate number of possible hypoth-
esis tests given an assumed covariance of 0.5 between host transcripts and taxa whilst
retaining 80% power [29]. Next, dimensionality reduction schemes were performed to si-
multaneously reduce the number of transcripts and species subjected to hypothesis testing.
Several strategies were implemented to detect host-microbe interactions. In an unbiased
analysis to identify global patterns, abundant taxa and disease associated genes (as identi-
fied in Chapter 4) were hierarchically clustered and then linear models were implemented
to identify relationships between gene clusters and taxa clusters [29]. Targeted approaches
for identifying transcriptomic patterns associated with candidate OTUs were also imple-
mented. For key species such as S. aureus in AD and C. simulans in PSO, patients were
stratified into discrete groups based upon median OTU abundance, and then differential
analysis of the transcriptome using limma [138] was performed to identify pathogen asso-
ciated transcriptomic signatures. In an alternative approach, host transcriptomic factors
were derived by principal component analysis and pairwise linear models were applied
comparing the relative abundance of selected species with the set of principal components
(PCs) that explained 50% of the total variance in the transcriptome [29].
Initial discovery of the S. aureus associated gene signature via dichotomisation of the host
transcriptome was performed by Marine Jeanmougin. A reimplementation of this analysis
is presented in Figure 5.7 and has been extended to determine the association with dis-
ease severity.
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5.2 Methods
5.2.1 Sample selection
Quality controlled and RMA normalised gene expression data, was obtained from Institut
Curie, and quality controlled and normalised 16S microbiome sequencing data was obtained
from the Karolinska institutet and Institut Curie as part of the MAARS consortium project.
Details of patient recruitment, sampling and data processing are detailed in (Sections
2.3.1, 2.3.2 and 2.3.3). For integrative analysis, only samples with both microbiome
and transcriptome samples were selected as described in (Table 5.1).
5.2.2 Power analysis
To guide the scale of dimensionality reduction required, a power analysis was performed
under the framework described by Morgan et al. [29]. It was used to determine the number
of possible pairwise tests to detect a true covariance of 0.5, whilst retaining 80% power
given the available 82 ADL and 119 PSOL samples. Ten thousand correlated variable pairs
of length 82 in ADL and 119 in PSOL were sampled from a bivariate normal distribution
with covariance ranging from 0-1 using the R function rmvnorm. The 80th percentile of p
values for each value of covariance was calculated representing 80% of the p values at given
covariance. Then, to account for the family wise error rate (FWER) at an alpha level of
0.05, the estimated number of possible pairwise tests was calculated as 0.05 divided by the
80th percentile of p values [29].
5.2.3 Transcriptome dimensionality reduction
First, the 32633 genes present on the array were filtered to those that were associated
with disease by performing differential analysis between healthy and diseased cohorts us-
ing the limma package [138] as described in Chapter 4 and Section 4.2.3. This initial
filtering resulted in a total of 1260 AD and 2516 PSO associated genes (p < 0.05, LFC
> 0.58). DEGs were then split into upregulated and downregulated groups, and were in-
dependently clustered with hierarchical clustering using 1 - Pearson correlation distance
and Ward’s linkage method. To further reduce DEGs, the optimal number of clusters in
each set was estimated. For clusters, 2 ≤ k ≤ 50, the average silhouette width was cal-
culated, and k was selected as the cluster with the maximum silhouette width. A single
representative of the differential gene cluster was calculated as the cluster centroid, i.e., the
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average expression of genes within the differential gene cluster (Figure 5.2). Calculation
of gene centroids have been performed in a similar way by Kivela et al. [210]. In a parallel
analysis, the cluster representative was calculated as the first principal component where
the same conclusions were reached.
In an additional strategy to perform host transcriptome dimensionality reduction, genes
were filtered to those with at least the median variance across the transcriptome resulting in
16316 genes. Principal component analysis of the scaled and centred transcript expression
was performed and the number of components which explained 50% of the variance were
retained [29].
5.2.4 Microbiome dimensionality reduction
To select taxa for integration, all OTUs were summed up at each taxonomic level and
minimum abundance filtering was performed to remove rare species. Each taxon was
required to be present in at least 20% of samples with a mean relative abundance of
at least 0.005. Average linkage hierarchical clustering of arcsine square-root transformed
relative abundance of taxa was performed using 1 - Pearson correlation distance and the
dendrogram was cut at a fixed height of 0.5. A cluster representative from each was selected
as the taxon with the lowest mean abundance [29] (Figure 5.2).
5.2.5 Host-microbe associations
To estimate host-microbe associations between dimensionality reduced microbe cluster
representatives and transcript cluster centroids, pairwise linear models were applied. To
account for potential confounding factors known to be associated with microbial rela-
tive abundances, the formula: gene centroid ∼ taxa cluster representative + body site +
sampling institution + gender + age was used. Relative abundances were arcsine square
root transformed [5]. Significant associations were considered as those with a Benjamini
Hochberg corrected p value < 0.1 with a correlation coefficient > 0.4 (Figure 5.2). The
same model formula was used to identify associations between expression principal com-
ponents and taxa of interest.
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5.2.6 Microbe associated transcriptional signatures
For taxa of interest, patients were grouped into ‘High’ and ‘Low’ groups based upon median
OTU abundance. Using the high and low groups, the transcriptome was dichotomised and
differential analysis was performed with the limma package [138]. Differentially expressed
genes between OTU-high and OTU-low were considered as those with an adjusted p value<
0.1. Dichotomised taxa groups were also used to test for differences in principal component
scores. Association of high and low groups with local SCORAD was performed with a
Wilcoxon ranked sum test.
5.2.7 Functional analysis
Over representation of pathways was performed with Ingenuity Pathway Analysis [143].
Gene ontology enrichment was performed with enrichR [189]. Annotation of gene princi-
pal components was performed by selecting the top 20 loadings of the greatest magnitude
in both positive and negative directions. A pre-ranked gene set enrichment analysis [147]
was performed to attribute functions to the principal component loadings using the RE-
ACTOME database [145].
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5.3 Results
To uncover potential host-microbe interactions in lesional disease, samples were first re-
stricted to matched lesional AD and PSO samples, i.e., those which had both a microbiome
and transcriptome in the MAARS cohort as described in (Table 5.1).




Gender (n) Female 36 26
Male 46 93
Anatomical Location (n) Buttocks - 18
Lower Back 2 90
Thigh 43 1
Upper Back 37 10
Institution (n) HHU 34 44
KINGS 13 41
UH 35 34
Age Mean 44.5 48.8
SD 14.5 13.6
5.3.1 Power analysis
Exhaustive pairwise comparisons between taxa and host transcripts would require a total of
32633 (transcripts) * 7532 (taxa) = 2.45e8 hypothesis tests, therefore, an association would
require a raw p value of <2e-10 to be declared significant after accounting for the FWER.
Such levels of significance between the microbiome and host parameters are unobtainable
as reflected in the results of previous integrative studies [120, 119, 29], therefore, a suitable
scheme of dimensionality reduction is required to reduce the number of pairwise tests.
As discussed earlier, performing a power analysis is an important step in estimating the
required magnitude of dimensionality reduction [29]. Power analysis performed as described
in [29], showed that for a true covariance of 0.5 and to retain 80% power, approximately 230
tests in ADL for a sample size of 82, and 10000 in PSOL for a sample size of 119 could be
performed (Figure 5.1). Given the disparity between the estimated number of possible
tests between ADL and PSOL, the exploratory analysis was designed to accommodate
CHAPTER 5. HOST-MICROBE INTEGRATION 101
the constraints of ADL, where the objective was to reduce the the number of taxa and
transcript components to approximately 15 in both microbiome and transcriptome.





























Figure 5.1: Power analysis. For an estimated true covariance of 0.5 and to retain 80%
power, the approximated number of possible hypothesis tests after correcting for the FWER
was estimated.
5.3.2 Integration pipeline
Given the limited number of pairwise tests available, a stringent dimensionality reduction
scheme was applied to both the microbiome and transcriptome datasets. For both the
microbiome and transcriptome, hierarchical clustering was applied to identify groups of
similar features. Then, an appropriate representative from each cluster for linear mod-
elling was selected (Figure 5.2).
First, dimensionality reduction of the transcriptome was performed in a semi-supervised
manner. If microbiota are associated with inflammation and or diseased status, then it is
likely that microbially induced transcriptional candidates will also be disease associated
genes. The total number of transcripts on the array was initially reduced to those found to
be differentially expressed between healthy and disease samples as described in (Chapter
4). This first reduction step reduced the total number of genes from 32633 to 1260 AD
associated, and 2516 PSO associated transcripts. Next, DEGs were split into upregulated
and downregulated groups and hierarchical clustering was performed using 1 - Pearson
correlation as the distance measure with Ward’s linkage method. The optimal cut height
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Filtering of rare taxa
(present in > 20% samples,
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Figure 5.2: Flow diagram of integration pipeline.
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was identified by clustering DEGs from k = 2 through 50 and picking k as the number of
clusters which maximised the average silhouette width. For each cluster the centroid was
calculated which was then used for testing microbe host-transcriptome associations in a
linear model (Figure 5.2).
Next, the scale of unsupervised dimensionality reduction in the transcriptome was used to
guide the magnitude of dimensionality reduction in the microbiome. OTUs were summed
up at each taxonomic level and then filtered to retain only abundant taxa which were
present in at least 20% of samples with a mean relative abundance of 0.005. Summation
at each taxonomic level was performed to allow higher order taxa which may not be well
represented at the OTU level under the stringent filtering criteria. Filtered taxa were
then hierarchically clustering using 1 - Pearson correlation as the distance measure. The
dendrogram was cut a height of 0.5 and the taxa with the lowest mean abundance was
selected [29] (Figure 5.2).
5.3.3 Host-microbe associations in AD
Genes differentially expressed in lesional AD were identified with limma as described in
(Chapter 4). According to the silhouette width, the optimal numbers was 9 clusters for
upregulated genes (denoted as U-, silhouette width = 0.21), and 7 clusters for downreg-
ulated genes (labelled as D-, silhouette width = 0.17, Figure 5.3 A-B). Abundant taxa
were then hierarchically clustered and the dendogram was cut at a height of 0.5 revealing
15 clusters (Figure 5.3 C). A cut height of 0.5 was selected as to keep the total number of
hypothesis tests close to the approximate number of 230 possible pairwise tests estimated
from the power analysis (Section 5.3.1). From each of these clusters, the representative
with the lowest mean was selected, which for the majority of taxa was at the OTU level
except for three at the genus level, one at the family level and one at the order level.
Pairwise linear models were then implemented to determine the association between the
16 disease associated gene expression centroids and the 15 microbe cluster representatives.
Three significant associations were identified (p < 0.05, r > 0.4), all of which involved
Staphylococcus aureus (Figure 5.4 A). The strongest association identified was between
S. aureus and the downregulated cluster D1, (r = -0.49, p = 0.03, Figure 5.4 B). To
identify top gene candidates within a cluster, the correlation of each member to the cluster
centroid was calculated. Top genes associated with D1 (Figure 5.4 E), included genes










































































































Figure 5.3: Dimensionality reduction of the Atopic transcriptome and microbiome. (A)
The optimal number of clusters amongst upregulated genes is shown in a heatmap. Row
colors correspond to clusters. (B) Clusters amongst downregulated genes. (C) Dendrogram
of microbes. The black line corresponds to a cut height of 0.5. Font colour correspond
to microbe clusters and the microbe in black for each cluster is the selected lowest mean
representative.
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corresponding to immunity such as IL34 and RORC which displayed some of the strongest
(negative) correlations with S. aureus. IL34 is associated with the survival and differentia-
tion of langerhans cells and has recently been implicated in lesional AD where it has been
suggested that it may play a role in the inhibition of the inflammatory cascade [211]. The
top enriched GO terms associated with D1 were ‘circadian regulation of gene expression’
(p = 2.0e-04) and ‘rhythmic process’ (p = 2.0e-04, Table 5.2). Several genes within D1
were central components of the mammalian circadian clock including PER1, PER3, CRY2
and CIART. Whilst these genes were not amongst that most highly correlated with the
cluster centroid, they were amongst the group of genes which had the strongest correlation
with S. aureus.
Staphyococcus aureus positively correlated with the U1 cluster (r = 0.46, p = 0.09, Figure
5.4 C). The top enriched GO terms for U1 were ‘positive regulation of NF-κB transcription
factor activity’ (p = 1.8e-05), ‘positive regulation of defence response’ (p = 3.4e-04), and
‘regulation of cytokine production’ (p = 7.6e-04, Table 5.2) demonstrating a heightened
state of innate immune activity with increasing abundance of S. aureus. Several of the top
genes within the U1 cluster encoded for antimicrobial peptides such as the members of the
S100A family and DEFB4A, as well as other features of the epidermal compartment such
as KRT6C and DSG3 (Figure 5.4 F). The IL4R gene was also amongst the top S. aureus
associated genes; the product of this gene has Th2 cytokines IL-4 and IL-13 as ligands [212].
The final S. aureus associated gene cluster was U9 (r = 0.44, p = 0.09, Figure 5.4 D). This
cluster was enriched for immune system processes such as ‘activation of immune response’
(p = 1.9e-02, Table 5.2). Study into the composition of U9 revealed that immunological
GO terms were enriched mostly due to the presence of five transcripts encoding components
of the classical complement system pathway including C1QB, C1QA, CR1, C3AR1 and
C1QC (Figure 5.4 G). This was further supported by GO enrichment for ‘complement
activation’ (p = 2.09e-02) which is known to play a role in opsonization of S. aureus
[213]. Other top genes within U9 corresponded components of the ECM such as COL6A3,
COL4A1 and TIMP1 (Figure 5.4 E) which also was indicated as an enriched GO term
(Table 5.2).





































































































































































































































































































Centroid - microbe associations
Figure 5.4: Associations between the ADL microbiome and transcriptome. (A) associations
between gene clusters and microbe cluster representatives. Heatmap tile color corresponds
to the correlation, and a point within a tile represents a significant association (p < 0.1, r
> 0.4). (B) S. aureus vs D1 centroid expression. (C) S. aureus vs U1 centroid expression.
(D) S. aureus vs U9 centroid expression. (E) The top 30 members of D1 measured by
pearson correlation to the cluster centroid. (F) Top 30 genes for U1. (G) Top 30 for U9.
CHAPTER 5. HOST-MICROBE INTEGRATION 107
5.3.4 Host-microbe associations in PSO
The same exploratory analysis pipeline was applied in psoriasis to identify potential host
microbe interactions. The initial 2516 DEGs optimally clustered into 6 upregulated (Figure
5.5 B), and 5 downregulated clusters (Figure 5.5 C). Next, taxa were hierarchically clus-
tered and the dendrogram was cut at the same height of 0.5 used in AD which identified 25
microbe clusters (Figure 5.5 A). As observed in AD, for most clusters, the lowest mean
representative was selected at the OTU level resulting in 18 at the OTU level, 2 at the
genus level and 5 at the family level. Pairwise linear models were then implemented to
determine the relationship between the psoriasis associated gene expression centroids and
selected taxa cluster representatives.
Cluster Term Adjusted.P.value
D1 circadian regulation of gene expression (GO:0032922) 2.0E-04
D1 rhythmic process (GO:0048511) 2.0E-04
D1 regulation of fat cell differentiation (GO:0045598) 2.0E-03
D1 regulation of phosphatase activity (GO:0010921) 3.9E-03
D1 regulation of dephosphorylation (GO:0035303) 9.9E-03
U1 positive regulation of NF-kappaB transcription factor activity (GO:0051092) 1.8E-05
U1 positive regulation of defense response (GO:0031349) 3.4E-04
U1 positive regulation of sequence-specific DNA binding transcription factor activity (GO:0051091) 7.9E-04
U1 regulation of cytokine production (GO:0001817) 7.9E-04
U1 positive regulation of cytokine production (GO:0001819) 9.7E-04
U9 activation of immune response (GO:0002253) 1.9E-02
U9 complement activation (GO:0006956) 2.9E-02
U9 protein activation cascade (GO:0072376) 3.2E-02
U9 extracellular matrix disassembly (GO:0022617) 3.8E-02
U9 regulation of extracellular matrix disassembly (GO:0010715) 4.3E-02
Table 5.2: Enriched GO terms amongst S. aureus associated gene clusters
A lack of concordance between the microbiota and host transcriptome in PSO was observed
with no significant associations (Figure 5.5 D). The correlations across all pairwise tests
were low, and the maximum correlation was 0.26 between the family Xanthomondaceae
and the upregulated gene cluster U6 (Figure 5.5 E). In Chapter 3, analysis of the mi-
crobiota identified strong associations between Corynebacterium simulans and psoriasis
status, however, no significant transcriptomic signal was identified for this species and the
top correlation with any centroid was 0.14 (Figure 5.5 F). Overall, these results indicate
a surprisingly low concordance between the psoriatic microbiota and transcriptome.






































































































































































































Figure 5.5: Dimensionality reduction and associations between the PSOL transcriptome
and microbiome. (A) Dendrogram of microbes. The black line corresponds to a cut height
of 0.5. Font colour correspond to microbe clusters and the microbe in black for each cluster
is the selected lowest mean representative. (B) The optimal number of clusters amongst
upregulated genes is shown in a heatmap. Row colors correspond to clusters. (C) Clusters
amongst downregulated genes. (D) Associations between microbes and gene clusters. (E)
F. Xanthomonadaceae vs U6 cluster expression. (F) C. simulans vs U5 cluster expression.
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5.3.5 Covariation of Staphylococcus aureus with transcriptome
factors
To further analyse S. aureus associated transcriptomic signatures, an unsupervised feature
reduction of the transcriptome was performed using principal component analysis. The
complete AD transcriptome (32633 transcripts) was reduced to genes with greater than
the median variance leaving 16316 genes. Principal component analysis was performed to
further reduce 16316 variable genes to 17 factors which explain 50% of the transcripomic
variability in AD [29]. Linear models were then utilised to determine the association be-
tween principal components and S. aureus relative abundance.
One significant association was identified with PC1 (Figure 5.6 A) which explained 9.5%
of the variation in ADL transcriptome. S. aureus was positively correlated with PC1 (cor
= 0.42, p = 0.07, Figure 5.6 C) indicating that the transcriptomic architecture under-
lying AD and S. aureus are closely related. To investigate the functional properties of
PC1, the top 20 positive and negative loadings were analysed (Figure 5.6 B). The top
loadings correspond to genes which are the most highly weighted and represent the most
variable genes along the direction represented by the principal component. Within the top
loadings of PC1, genes corresponding to the epidermal compartment such as DSG3, DSC2,
KRT6A, KRT16 and KRT6C were positively weighted. The Th2 cytokine receptor IL4R
was also found to the amongst the top weighted genes. In the negative direction, IL34 and
RORC were amongst the most weighted, further supporting a negative association between
S. aureus and these genes.
To assign functional annotations to PC1, a pre-ranked gene set enrichment analysis [147]
of the REACTOME database [145] was performed using the PC1 loadings (Figure 5.6
D). As expected, this analysis revealed a strong enrichment for immune categories such as
‘Immune System’ and ‘Adaptive Immune System’ in the positive direction. In the negative
direction, ‘Generic transcription pathway’ as well as ‘Metabolism of Lipids and Lipopro-
teins’ were enriched. These results demonstrate that Staphylococcus aureus is positively
associated with heightened immune system activity and may be associated with deficien-
cies in lipid metabolism, a process known to be characteristic of AD [58]. Many of the top
weighted genes in PC1 were also found to be significantly associated in the exploratory
analysis described in (Section 5.3.3) further supporting a host-pathogen interaction.




























































































Figure 5.6: Association between principal components and S. aureus. (A) PC1 signifi-
cantly correlated with S. aureus relative abundance (p < 0.1, r > 0.4) Heatmap tile colour
corresponds to the correlation and a point within a tile indicates a significant association.
(B) Top 20 positive and negative loadings of PC1. (C) S. aureus abundance vs PC1 scores.
(D) Pre-ranked GSEA of REACTOME pathways using PC1 loadings.
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5.3.6 A Staphylococcus aureus transcriptomic signature
In order to determine a direct S. aureus transcriptomic signature. The total 82 ADL sam-
ples were dichotomised into equal groups of 41 samples based upon the median abundance
of S. aureus (Figure 5.7 A). Differential analysis of the two groups, ‘S. aureus-High’ and
‘S. aureus-Low’, was performed with limma [137] which revealed a signature of 578 genes
(330 upregulated, 248 downregulated, p < 0.1, Figure 5.7 B). The top upregulated genes
included the antimicrobial peptides S100A7A, S100A9, S100A8, S100A12 and DEFB4A as
well as the Th2 cytokine receptor IL4R, and components of the ECM including COL6A3,
COL4A1 and COL4A2, many of which were also identified in the exploratory analysis.
Genes downregulated in the presence of S. aureus included those associated with the cir-
cadian clock such as RORC, PER and CRY2 as well as the cytokine IL-34.
Enrichment of upregulated genes with Ingenuity Pathway Analysis [143] identified the top
pathway as ‘Hepatic Fibrosis/Hepatic Stellate cell activation’ (p = 0.015, Figure 5.7 C).
This pathway included genes encoding for collagen, COL4A1, COL4A2 and COL4A2, as
well as profibrotic immune genes TGFB1, IL4R and MMP1 suggesting that S. aureus may
be associated with ECM remodelling in the dermis which is thought to play a role in in-
flammation [214]. The ‘role of IL17A in psoriasis’ pathway was also enriched, however,
this pathway was enriched due to up-regulation of the S100A8, S100A9, S100A7A and
DEFB4A antimicrobial peptides and not due to differential expression of IL17A. Enrich-
ment of downregulated genes revealed only weak associations. ‘PXR/RXR activation’ was
enriched (p < 0.1, Figure 5.7 D) and may reflect an association between S. aureus, skin
dryness and epidermal lipid deficiencies [59, 58]. As a separate isolated test, the stratified
‘S. aureus high’ group cohort was shown to have higher expression levels of PC1. Lastly,
differences in disease severity was tested between the ‘S. aureus high’ and ‘S. aureus low’
groups. Patients with high abundances of the ‘S. aureus-high’ group had a significantly
higher Local SCORAD than those in the ‘S. aureus-low’ group (Figure 5.7 E, p = 0.006).
This stratification analysis was also performed for PSO candidates such as C. simulans
and C. kroppenstedtii in PSO lesional samples which revealed no significant genes.
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Figure 5.7: Transcriptome stratification analysis. (A) Samples were stratified into S. au-
reus-high and S. aureus-low groups based upon median abundance. (B) Heatmap of dif-
ferentially expressed genes between S. aureus-high and S. aureus-low. (C) Upregulated
pathways as identified by IPA. The black line corresponds to p = 0.05, and the red line
corresponds to p = 0.1. (D) Downregulated pathways. (E) Association with Local SCO-
RAD tested with Wilcoxon ranked sum test.
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5.4 Conclusions and Discussion
Several studies have analysed both the skin inflammation associated host transcriptome
and microbiome, however, this is first time that both datasets have been simultaneously
analysed and integrated to identify potential host-microbe interactions. It has been hy-
pothesised that psoriasis may be triggered by microbiota stimuli due to its overall similarity
to Crohn’s disease [215], in which chronic inflammation is thought to be associated with
dysbiosis in the intestine [80]. Mutations within genes of both the innate and adaptive
immune system, as well as the epidermal barrier are characteristic of PSO [73] therefore,
it was surprising to find a lack of concordance between taxa on psoriatic skin and the
expression of disease associated transcripts. In Chapter 3 the psoriatic microbiota was
unchanged between uninvolved and lesional states, yet in Chapter 4, extreme transcrip-
tional differences were identified. The lack of concordance observed in the current chapter
may suggest an inability of the host transcriptome to shape community composition (or
vice versa) in the short term, and it may be the case that changes are accumulated over
the course of disease development.
Staphylococcus aureus is a known pathogen infecting the lesions of patients with AD as
confirmed in Chapter 3. Here using several integrative approaches, it can be seen that
the relative abundance of S. aureus is clearly related to significant proportions of the
atopic transcriptomic signature. S. aureus positively correlated with proinflammatory
gene clusters which define AD, and negatively correlated with genes downregulated in le-
sions. Perhaps the most interesting finding, was the positive association with IL4R which
is the receptor of the Th2 cytokines IL4 and IL13 [212] which are of key importance in
the pathogenesis of AD [44]. It was also clear that S. aureus was associated with the
innate immune system via expression of anti-microbial peptides as well as the complement
system. Whilst host defence mechanisms were of heightened activity, patients with greater
abundance of S. aureus were also characteristic of severe disease. S. aureus was also posi-
tively associated with components of the extracellular matrix such as COL6A3, COL4A1
and TIMP1. The ECM plays important roles involving immune cell activation, prolifer-
ation and migration [214] and it may be that S. aureus possesses pro-fibrotic properties,
or is associated with Th2 activity which can induce fibrosis and is associated with AD [208].
Interestingly, the strongest association found was an inverse correlation between genes in
a cluster enriched for circadian clock genes. Circadian rhythms have recently been shown
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to control the expression of proinflammatory cytokines and that mutations within clock
genes results in a psoriasiform inflammation in mice [191]. Furthermore, IL34 was inversely
correlated with S. aureus which is important for the development of Langerhans cells [216].
Overall, whilst no significant associations were detected in psoriasis, the results presented
in this chapter provide an insight into the transcriptional imprint of Staphylococcus aureus
in AD and provides a foundation for further mechanistic studies.
Chapter 6
Co-expression networks analysis of
skin inflammation
6.1 Introduction
Understanding transcriptional dysregulation is key to unravelling the mechanisms which
cause disease. Differential analysis provides only a reductionist view of the information
contained within large scale transcriptome datasets. In such analysis, genes are considered
as independent entities whereas in reality, genes together with other biomolecules interact
within highly complex and intricate systems.
One method to investigate biological systems is to model gene expression data as a graph
in which nodes correspond to transcripts, and edges correspond to the interactions between
gene pairs allowing the relationships between genes to be studied. Interaction networks
facilitate the analysis of systems using techniques based upon graph theory, such as clus-
tering or centrality measures for hub gene detection. The concept of cluster detection, also
known as community or module detection can be used to identify sets of genes which may
be involved in similar biological processes. Thus, it is a powerful technique to identify new
candidate genes by exploiting the principle of guilt by association [217, 218].
The goal of transcriptional network reconstruction is to infer gene-gene interactions directly
from gene expression measurements. Several methods for network inference have been pro-
posed in literature. The simplest approaches calculate a similarity measure between genes,
typically via correlation, where an edge connects gene pairs if the correlation satisfies a
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certain threshold [219]. Other methods to reconstruct gene-gene interaction networks in-
clude those which calculate mutual information between gene pairs such as ARACNe [220],
and others such as those based upon partial correlations [221] or bayesian methods [219].
Despite several available approaches, the high dimensionality of transcriptome data has
resulted in popularity for correlation based methods as they are intuitive and computa-
tionally inexpensive compared to partial correlation and Bayesian methods which do not
scale well with large datasets [222]. The most established co-expression network inference
method, Weighted Gene Co-expression Network Analysis (WGCNA), has been used to re-
construct co-expression networks numerous times since its initial publication in 2005 [150].
WGCNA has been applied to transcriptomics data in many contexts. These include, relat-
ing co-expression modules to specific brain regions [223], between species [224], in diseases
such as Huntington’s disease [225], autism [226], heart disease [227], hepatitis [228] and
cancer [229, 230]. Furthermore, in a recent study, the WGCNA and ARACNe methods
were suggested to be the most robust methods for constructing global co-expression net-
works [222].
The analysis presented in this chapter investigates the reconstruction of skin associated
co-expression networks within the WGCNA framework [150, 231]. The reconstructed net-
works were then used to identify genes and gene modules which play important roles in
skin inflammation. By performing a large scale genome-wide integrative network analysis,
the objective was to identify interacting communities of genes to find processes which may
be relevant in the pathogenesis of Psoriasis (PSO) or Atopic dermatitis (AD). Identifying
gene communities significantly reduces dimensionality allowing host transcriptomic profiles
to be integrated with microbial abundance to find modules which covary with pathogens
such as Staphylococcus aureus or Corynebacterium simulans, as well as those which are
associated with clinical severity.
Independent co-expression networks were reconstructed for each cohort, and then two main
analyses were performed. In the first, module preservation analysis [232] was performed
to identify differentially co-expressed modules between healthy and diseased states. The
second involved associating co-expression modules to clinical variables and a selection of
potentially pathogenic microbes in order to uncover host-microbe interplay.
CHAPTER 6. INTEGRATIVE CO-EXPRESSION NETWORK ANALYSIS 117
6.2 Methods
6.2.1 Data selection and preprocessing
Quality controlled and RMA normalised gene expression data was obtained from Insititut
Curie as well as quality controlled and normalised 16S microbiome sequencing data was
obtained from the Karolinska institutet and Institut Curie as part of the MAARS consor-
tium project. Details of patient recruitment, sampling and data processing are described in
(Sections 2.3.1, 2.3.2 and 2.3.3). As a major objective of this analysis was to identify
host-microbe interactions, only samples with both microbiome and transcriptome samples
were considered as described in Table 6.1.
The objective of comparative network analysis was to compare the structure of gene-gene
correlations between lesional, non-lesional and control networks, therefore, for each disease
(AD, PSO) a body site matched cohort was defined to remove under-represented body
sites (in either the control or disease groups). This step was performed to reduce potential
sources of non-clinically associated variation, so that when disease and control groups
are compared, biopsies from specific body sites in each network are more appropriately
balanced. For Atopic dermatitis, ADL, ADNL and an AD body site matched control
group (CAD) were defined from upper back and thigh samples. The psoriasis datasets,
PSOL and PSONL as well as a body site matched PSO group (CPSO) were defined from
lower back and upper back samples.
6.2.1.1 Transcriptome preprocessing
Co-expression analysis can be sensitive to array outliers, therefore, the initial step in the
WGCNA pipeline is to remove potential array outliers. For each cohort (ADL, ADNL,
CAD, PSOL, PSONL, CPSO), the Euclidean distance between samples was calculated
and samples were clustered with average linkage hierarchical clustering. Samples which
did not cluster within the main body of samples (Appendix Figure B.1 - B.2) were
removed. A complete overview of the samples used in network construction are described
in Table 6.1. Genes with less than the median variance across all cohorts were removed
ensuring that networks for each cohort were constructed on the same set of genes.
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6.2.1.2 Microbiome preprocessing
For matched microbiome samples, a variance stabilising arcsine square root transformation
[5] was applied to OTU relative abundances. Specific microbes of relevance in the inflam-
matory skin microbiome were selected and tested for association with the transcriptome
including Corynebacterium simulans, Staphylococcus aureus, Staphylococcus epidermidis,
Propionibacterium acnes, Peptostreptococcus anaerobius, and Neisseriaceae. G. sp.
6.2.2 Network construction and module detection
6.2.2.1 Definition of the adjacency matrix
Networks were reconstructed independently for each cohort within the WGCNA framework
[150, 231]. First a similarity measure was calculated between all gene pairs resulting in
a correlation matrix between all genes. Typical correlation measures include Pearson,
Spearman or the biweight midcorrelation (bicor). The biweight midcorrelation is based
upon the sample median instead of the mean and is less sensitive to outliers [233]. A signed
co-expression network which retains information regarding the direction of co-expression
was constructed, thus the correlation between nodes i and j was defined as:
cij = |0.5 + 0.5× bicor(xi, xj)| (6.1)
where xi and xj are the expression profiles of nodes i and j across all samples.
Setting the threshold for the correlation matrix using a hard threshold, for example, con-
necting gene pairs with correlation strengths greater than 0.8 may result in loss of infor-
mation as a gene pair with correlation of 0.79 would not be connected [150]. To overcome
this, a weighted adjacency matrix is defined [150]. The weighted adjacency defines the
connection strengths between genes. For each network, the signed correlation coefficients
were iteratively raised to a power β through values 2 to 30. The soft thresholding pa-
rameter, β, is applied because transcriptome data is noisy and correlations may arise due
to technical error [231]. Higher values of β exponentially penalise weaker correlations by
shrinking them closer to 0 and emphasises stronger correlations by influencing them less.
Biological networks are assumed to be of scale free topology where the degree distribution
of a network follows a power law [234, 218]. To test for a scale free topology, the degree
distribution (fraction of nodes which have degree k) is plotted against k in a log-log plot.
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If a straight line with a negative slope is observed, the network topology approximates
a scale free topology, i.e., many nodes with low connectivities and characterised by few
highly connected hubs. The parameter β is selected to ensure that network adopts a scale




Next the Topological Overlap Measure (TOM) [150] is defined. As the overall objective
of WGCNA is to find modules of genes which are highly interconnected, i.e., genes which
share many of the same interaction partners, a node similarity measure is calculated which
quantifies how similar two nodes a, b are with respect to how similar the neighbours of a
are to the neighbours of b. TOM takes into account the connection strengths between gene
pairs whilst also considering connection strengths between paired neighbours. Topological
overlap also has the added benefit of reducing the influence of spurious correlations due to





min(ki, kj) + 1− |aij|
(6.3)





For a gene pair, TOM values lie between 0 (completely unconnected) and 1 (fully con-
nected) and the TOM dissimilarity matrix (1-TOM) is used in conjunction with a com-
munity detection algorithm to identify groups of highly interconnected genes. Average
linkage hierarchical clustering was performed and branches of the dendrogram were clus-
tered into co-expression modules with the cutreeDynamic function [235]. The dynamic tree
cut method does not cut at a static threshold and independent branch cutting is performed
based upon branch shape as a static tree cut cannot identify nested modules of genes [235].
6.2.2.2 Module eigengenes
For each module after branch cutting, the module eigengene (ME) [236, 237] is calculated.
The module eigengene is the first right singular vector of the standardised module expres-
sion matrix [238] and is equivalent to the first principal component. Module detection
can result in multiple modules which express similar expression patterns and the authors
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suggest merging modules to reduce redundancy [238]. The pairwise Pearson correlation
between module eigengenes was calculated and modules with similar expression patterns
corresponding to a correlation of greater than 0.8 were merged. After merging, module
eigengenes were recalculated using the merged module definitions. To ensure modules
constituted only genes with similar expression patterns, all genes were correlated to the
module eigengene, and those with a correlation (kME) < 0.4 were reassigned to the ‘gray’
module for genes with no clear module membership (see Section 6.2.2.4). For readability
reasons only, modules in every network were relabelled such that they matched the colour
of the module with the most significant overlap defined by a Fisher’s exact test within the
ADL network.
6.2.2.3 Functional enrichment
Modules were annotated using functional enrichment analysis. Unless otherwise stated,
gene ontology functional enrichment of biological processes was performed with cluster-
Profiler [239]. Further analysis was performed with IPA [143] and consensusPathDB [240]
to obtain knowledge of enriched pathways and upstream regulators. P values were adjusted
using the Benjamini Hochberg method.
6.2.2.4 Identification of hub genes
Hub genes were defined using the eigengene based connectivity measure kME [241], also
known as module membership. kME is calculated as the correlation of the expression
profile of gene i with a module eigengene ME and thus represents the extent to which a
gene follows the expression profile of a module. Genes with a high kME, i.e., close to 1
tend to be highly connected to genes within a module and have a similar expression profile
to the module eigengene. To determine the importance of a gene within a module, genes
were ranked on their kME values.
Alternatively, hub genes can be identified using connectivity based measures. The whole





Module hub genes, can be identified by Intramodular connectivity, kIM [150]. Intramodu-
lar connectivity is defined as the sum of the weighted adjacencies between gene i in module
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To enable comparison of kIM across modules, kIM was scaled by the gene with the
maximum connectivity. Reports show that kIM and kME are highly related [231].
6.2.2.5 Differential connectivity
Differential connectivity of genes between networks was performed to identify differentially
regulated hubs using the method described in [151]. Within each network the connectivity
of each node was calculated as the sum of all weighted adjacencies with other genes in
the network. Then, the the scaled weighted connectivity of node i was calculated as the
connectivity of node i divided by the connectivity of the most highly connected node in
the network. The difference in weighted scaled connectivities, kDiff, between networks A
and B was calculated as kA - kB. Using the thresholds suggested by [151], differentially
connected genes were considered those for which kDiff > 0.4.
6.2.3 Statistical analysis
To determine if modules overlapped with differentially expressed genes, differential analysis
was performed using limma as described in (Chapter 4). Association between module
eigengenes and traits was performed using a linear model to account for sources of extrane-
ous variation. The lm function in R was used with the formula, ME ∼ trait + anatomical
location + institution + age + gender. The traits evaluated included clinical severity
(SCORAD, PASI) and arcsine square root transformed OTU relative abundances [5]. Sig-
nificant associations were those with a Benjamini Hochberg adjusted p value < 0.1 with
a correlation > 0.3. Correlation coefficients between traits and eigengenes were calculated
with Pearson correlation.
6.2.4 Network visualisation
Network subgraphs for module preservation analysis were created by selecting edges with
correlation> 0.65 between the top 25 hub genes as identified by kME. Module subnetworks
were visualised in either Cytoscape [168] or Igraph [242]. For the network diagrams of S.
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aureus associated modules, the top 20 hub genes identified in each module by kME were
selected and the top 10% of edges were retained.
6.2.5 Module preservation
Module preservation analysis was performed using two main categories of preservation
statistics. The first, and most naive approach, is the application of cross tabulation statis-
tics, where given module definitions in two networks, the overlap of genes across modules
was evaluated with Fisher’s exact tests. This approach is intuitive for observing a general
overview of module preservation between two networks, however, cross tabulation statistics
do not take into account information regarding the correlations, or density of connections
between modules [232]. Furthermore, as cross tabulation statistics require module def-
initions in both networks, these are likely to be somewhat dependent on the network
construction procedure and parameter selection in which the modules were defined [232].
The second approach corresponds to network based statistics. Network based preservation
statistics require module definitions in only one network, known as the reference network.
To assess module preservation, the module definitions and adjacency matrix for the ref-
erence network are used to determine if clusters can be identified within the adjacency
matrix of the test network. This addresses the pitfall that preserved clusterings can only
be identified based upon the parameters of the module detection algorithm [232]. Two
types of network based preservation statistics were considered: ‘density’ and ‘connectivity’
based. Density preservation determines if the connections within a module are of similar
structure and quantity, whereas connectivity statistics are used to test if the interaction
patterns between nodes are retained across two networks. The network based statistics
used in this analysis are summarised in the following sections, however, for a detailed
description refer to [232].
6.2.5.1 Density based preservation metrics
Density measures assume that if the density of connections within the test network are
high, then it is likely that the reference module is preserved within the test network. The
following density measures were considered [232]:
meanCor measures the correlation density, and is defined as the mean correlation of all
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genes within the test network module, multiplied by the sign of the correlation in the
reference network module. When the sign of the reference and test network are opposing,
this decreases the value for meanCor.
meanKME is calculated in a similar way to meanCor however the correlation between
neighbours is replaced with the correlation to the module eigengene, kME.
meanAdj is calculated as the mean adjacency of a module in the test network, thus,
meanAdj represents the adjacency density. A module with a high mean adjacency in the
test network suggests that the module is preserved.
propVarExpl uses the proportion of variance explained by the module eigengene as a
density measure. The kME values are derived for the genes in a module by correlation
with the module eigengene. The propVarExpl measure is defined as the mean squared
kME values within the test network. [232]
6.2.5.2 Connectivity based preservation metrics
Connectivity measures work on the principle that the connectivity profiles of nodes within
a reference network module should be similar within a test network if a module is preserved.
To estimate the concordance, the correlation of connectivity measures between reference
and test networks is calculated, thus, a high correlation indicates a preservation of node
specific properties. The following connectivity preservation measures were considered [232]:
cor.cor corresponds to the correlation preservation which measures the concordance of
correlations between genes in a co-expression network module. For genes in a module,
the correlation matrix is defined in both reference and test sets. Cor.cor represents the
correlation between the vectorised reference and test correlation matrices. For a highly
preserved module, the correlation coefficients between genes should remain similar across
reference and test networks.
cor.kIM refers to intramodular connectivity preservation. cor.kIM calculates the corre-
lation between intramodular connectivities, defined in equation 6.6, in the test and ref-
erence networks. For a preserved module, hub genes within the reference network should
remain highly connected within the test network, thus, one would expect a high correlation
between intramodular connectivities.
cor.kME refers to the correlation of module memberships. The correlation of each gene
and the module eigengene kME is calculated in both reference and test networks and
the correlation is computed. Highly connected genes tend to have high kME values,
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whereas peripheral genes tend to have low or negative kME values thus one would expect
a preserved module to have a high cor.kME. [232]
6.2.5.3 Significance of module preservation
To assess the significance of module preservation, the observed value, obs, of a preservation
metric a, is calculated between the reference and test network. Next the module definitions
within the test network are randomly permuted nperm times to construct an empirical null
distribution of random modules of the same size. Then for the network statistic a, the





To capture the degree of preservation represented by multiple connectivity and density
statistics, the following composite measures are calculated.
Zdensity = median(ZmeanCor, ZmeanAdj, ZpropV arExpl, ZmeanKME) (6.8)
Zconnectivity = median(Zcor.kIM , Zcor.kME, Zcor.cor) (6.9)
and finally for an overall general view of module preservation, the Zsummary score is cal-
culated as the average of Zdensity and Zconnectivity. The authors of [232] suggest that a
Z score > 10 indicates strong preservation, < 10 indicating weak preservation and < 2
that the module is not preserved. As there is more power to detect connectivity patterns
between large numbers of genes compared to smaller numbers [232], the Z score is highly
associated with module size. In the current analysis where modules vary in size, it can
be more appropriate to measure preservation using the ranks of the obtained values. The
medianRank was used to supplement Zsummary statistics which are calculated in the same
way as described above but with observed statistic rankings instead of permutation Z
scores.
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Table 6.1: Matched body site and network construction cohorts
ADL ADNL CAD CPSO PSONL PSOL
Patients (n) 74 72 107 101 96 98
Samples (n) 74 72 107 101 96 98
Gender (n) Female 33 35 68 66 19 22
Male 41 37 39 35 77 76
Anatomical location (n) Lower back 0 0 0 89 76 89
Thigh 41 38 95 0 0 0
Upper back 33 34 12 12 20 9
Institution (n) HHU 30 27 31 30 43 41
KINGS 13 12 44 38 37 40
UH 31 33 32 33 16 17
Age Mean 43.4 43.4 34.3 35.3 47.1 47.8
SD 13.3 14.3 12.7 13.8 13 13.5
6.3 Results
6.3.1 Data selection and preprocessing
Six individual networks were constructed corresponding to ADL, ADNL, Control-AD
(CAD), PSOL, PSONL and Control-PSO (CPSO). Network construction was limited to
arrays with available microbiome samples and AD networks were restricted to thigh and
upper back, and PSO networks were constructed on lower and upper back samples. Next,
to ensure co-expression networks were robust, samples which did not cluster within the
main body of the samples were identified and removed by average linkage hierarchical
clustering of the Euclidean distance matrix. The dendrograms and sample removals are
shown in (Appendix B, Figures B.1, B.2). After sample removal, a total of 74 ADL,
72 ADNL, 107 CAD, 101 CPSO, 96 PSONL and 98 PSOL samples were used for network
construction. A complete description of samples is shown in (Table 6.1) Next, the tran-
scriptome was filtered to remove genes with low variability across all cohorts. All of the
32,632 genes present on the array are unlikely to be expressed in the skin, and genes that
are of low variability are unlikely to correspond to systematic differences between diseases.
Furthermore, construction of a genome wide co-expression network is computationally ex-
pensive, therefore, network construction was restricted to the top 50% of variable genes
leaving a total of 16316 genes.
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Table 6.2: Global network statistics
Network SFTfit Beta Slope Modules Med connectivity
ADL 0.852 12 -2.12 22 15.8
ADNL 0.900 12 -2.72 13 15.5
CAD 0.943 12 -2.58 10 12.2
CPSO 0.990 12 -2.17 10 12.0
PSONL 0.980 12 -2.24 11 10.9
PSOL 0.902 12 -3.08 16 11.3
6.3.2 Network construction and module detection
Weighted gene co-expression networks require the selection of the correlation matrix expo-
nent β. To identify the optimal value for the soft power threshold β, the signed biweight
midcorrelation (bicor) matrix was calculated for each network and was then iteratively
raised to powers 3 through 30. For each value of β, the degree distribution p(k) and con-
nectivity k of the network is calculated and a linear regression is performed to quantify
the fit of the network to the scale free topology criterion, i.e., following a power law with
a negative slope. To allow for comparisons between networks, a common value of β was
selected for which all networks were approximately scale free with comparable median con-
nectivities. A β value of 12 was selected as at this value the connectivity of all networks
fit the scale free topology criterion with an R2 of greater than 0.85 (Figure 6.1). Scale
free fit, median connectivity and general network statistics are presented in (Table 6.2).
The topological overlap matrix was calculated to highlight gene pairs with similar inter-
acting partners, and modules were defined using the cutreeDynamic method [150] inde-
pendently in each network. Within each subnetwork, the module eigengene was calculated
and pairwise correlations between module eigengenes was performed to identify highly re-
lated modules. As modules with similar expression patterns may represent redundancy,
subnetworks with a correlation of greater then 0.8 were merged into a single module. Mod-
ules were labelled with a colour for interpretation, and genes which did not belong in any
module were grouped into an unassigned ‘grey’ module. Modules for each network were
then matched to modules in the ADL network by calculating the overlap in gene members
and performing Fisher’s exact tests. Modules with the most significant overlap were rela-
belled to have the same colour. As labels are arbitrary, this step has no significance on the
analysis, and only aids the interpretation of modules across networks.
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Figure 6.1: Scale free topology fit for all cohorts at varying levels of β. The horizontal line
corresponds to a scale free topology fit of 0.85. Colours correspond to the cohort and at β
= 12, all cohorts fit the scale free topology criterion > 0.85.
6.3.3 Atopic Dermatitis associated networks
Construction of the ADL, ADNL and CAD networks revealed 22, 13 and 10 modules respec-
tively (Figure 6.2 A). The final networks and module definitions showed that networks
were comparable in terms of slope and median connectivity (Table 6.2). Qualitatively,
a concordance in module assignments can be observed across the ADL, ADNL and CAD
networks by the tracks below the gene dendrogram (Figure 6.2 A).
6.3.3.1 CAD network modules
Modules identified within the skin co-expression networks must be annotated with a bio-
logical function to aid in interpretation. An enrichment of GO biological processes in each
module using clusterProfiler [239] was performed which revealed a set of modules enriched































370 extracellular matrix organization 1.4e−14
793 anterior/posterior pattern specification 0.00092
675 leukocyte activation 6.3e−63
185 extracellular matrix organization 3e−09
75 response to type I interferon 1.9e−28
620 ncRNA metabolic process 2e−43
267 monocarboxylic acid metabolic process 4.8e−16
9087 sensory perception of smell * 1.2e−36
149 activation of immune response 9.9e−12
150 nuclear−transcribed mRNA catabolic process * 3.3e−24
136 molting cycle 9.2e−11
79 glycolipid metabolic process 0.45
316 synapse assembly 0.0067
183 keratinization 5.6e−05
317 anatomical structure regression 0.29
298 inflammatory response 7.8e−06
486 mitotic cell cycle 1.1e−91
76 triglyceride metabolic process 0.00079
214 protein methylation 0.25
217 keratinization 9.3e−09
971 RNA splicing 7e−24






















636 extracellular matrix organization 7.4e−16
816 immune effector process 6.8e−65
119 actin filament bundle assembly 0.0012
99 muscle contraction 7.5e−18
994 monocarboxylic acid metabolic process 2.1e−33
9891 sensory perception of smell * 9.4e−28
158 molting cycle 2.9e−15
527 tube formation 0.00012
388 mitotic cell cycle process 5.5e−86
170 response to peptide hormone 0.02
325 skin development 1.7e−16
1981 RNA processing 7.6e−32




















Figure 6.2: Module definitions of AD co-expression networks, gene tree and enrichment
analysis. (A) Hierarchical clustering of TOM dissimilarity and module assignments. Tracks
below the dendrogram correspond to module definitions in the ADL, ADNL and CAD
networks as well as differential status (p < 0.05, LFC > 0.58). (B) Module size and top
GO biological process term for each module in the ADNL network. (C) Module size and
GO terms for the ADL network.
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for key skin associated functions.
First, considering the control network (CAD), 10 modules were identified and all subnet-
works were over-represented for a GO BP (p < 0.05, Appendix B, Figure B.3). Two
modules were associated with skin development processes (salmon, lightgreen), and one
was associated with the extracellular matrix (yellow). Housekeeping terms such as ‘RNA
processing’ and ‘monocarbocylic acid metabolic process’ were highly enriched. There were
no modules which were enriched for immune system processes suggesting that co-expression
relationships between immune genes in a state of homeostasis are less defined.
6.3.3.2 ADNL network modules
Regarding ADNL, 13 modules were identified, and all were enriched for a GO biological
process (p < 0.05, Figure 6.2 B). One module was enriched for immune processes (brown),
three modules were enriched for the extracellular matrix (black, yellow, cyan) and two
modules were associated with skin specific development processes (tan, lightgreen). Several
modules were enriched for housekeeping functions such as ‘RNA processing’ (turquoise) and
‘mitotic cell cycle process’ (red).
6.3.3.3 ADL network modules
Next, GO analysis of lesional AD modules was performed (Figure 6.2 C). Of the 22 ADL
modules identified, 19 were enriched for a GO biological process (p < 0.05). Three modules
were strongly enriched for immune system processes. The brown module was enriched for
‘Leukocyte activation’ (p = 6.3e-63), the darkred module was enriched for ‘response to type
I interferon’ (p = 1.9e-28) and the purple module was enriched for ‘inflammatory response’
(p = 7.8e-06) demonstrating that co-expression amongst genes encoding immunity is a
key component in AD. As observed in ADNL, three modules were enriched for the ECM
(black, cyan, yellow) and three modules were associated with skin development processes
such as lightgreen which was enriched for ‘molting cycle’ (p = 9.2e-11), darkblue which
was enriched for ‘keratinization’ (p = 5.6e-05) and the tan module which was also enriched
for ‘keratinization’ (p = 9.3e-09). A complete list of the top GO terms enriched for each
module is shown in (Appendix B, Tables B.1 - B.6).




















99 lipid catabolic process 0.0041
317 leukocyte activation 1.2e−56
147 muscle contraction 3.7e−27
1034 monocarboxylic acid metabolic process 3.9e−32
11509 sensory perception of smell * 4.9e−19
152 molting cycle 3.5e−11
618 negative regulation of cell differentiation 0.00013
140 mitotic cell cycle process 5.1e−82
316 organelle assembly 3.7e−06
967 RNA processing 6.9e−35

























325 extracellular matrix organization 1.4e−29
788 skin development 0.00032
516 leukocyte activation 2.1e−66
57 muscle contraction 1.5e−21
53 B cell proliferation 0.0069
1097 ncRNA metabolic process 2.5e−19
150 fatty acid metabolic process 7.5e−14
10475 sensory perception of smell 1e−29
86 molting cycle 1.3e−13
399 growth 0.007
165 defense response to virus 1.9e−39
340 mitotic cell cycle process 1.6e−111
337 cilium assembly 3.6e−05
84 peptide cross−linking 6.7e−10
1009 RNA processing 5.6e−33




Figure 6.3: Module definitions of PSO co-expression networks, gene tree and enrichment
analysis. (A) Hierarchical clustering of TOM dissimilarity and module assignments. Tracks
below the dendrogram correspond to module definitions in the PSOL, PSONL and CPSO
networks as well as differential status (p < 0.05, LFC > 0.58). (B) Module size and top
GO biological process term for each module in the PSONL network. (C) Module size and
GO terms for the PSOL network.
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6.3.4 Psoriasis associated networks
The psoriasis co-expression networks were next analysed in terms of module composition.
The PSOL, PSONL and CPSO networks contained 16, 11 and 10 modules respectively
(Table 6.2, Figure 6.3 A). As observed in AD, a qualitative analysis of module definitions
as presented in (Figure 6.3 A) showed a general concordance across networks indicating
that there may be a degree of preservation in co-expression relationships.
6.3.4.1 CPSO network modules
To determine the biological function of co-expression modules, each module was subjected
to gene ontology enrichment analysis. Ten modules were identified in the PSO control
network (CPSO), all of which were over-represented with a GO BP term (p <0.05, Ap-
pendix B, Figure B.3). Two modules were associated with skin development processes
(tan, lightgreen), and one was associated with the extracellular matrix (yellow). Sev-
eral modules were enriched for housekeeping terms such as ‘RNA processing’ (turquoise),
‘inorganic ion transmembrane transport’ (magenta) and ‘monocarboxylic acid metabolic
process’ (greenyellow). There were no modules which were enriched for immunity, demon-
strating state of homeostasis in healthy samples.
6.3.4.2 PSONL network modules
Next, modules within the PSONL network were subjected to GO analysis (Figure 6.3
B). All modules were enriched for a GO BP term (p < 0.05), and like in AD, many
of the functions resembled core biological processes in the skin. The brown module was
highly enriched for ‘leukocyte activation’ (p = 1.2e-56) indicating that co-expression of
immune processes is well defined, even in non-lesional skin. Other key modules included
the lightgreen module which was was enriched for ‘molting cycle’ (p = 3.5e-11) and the
yellow module was enriched for ‘extracellular matrix organisation’ (p = 1.6e-30).
6.3.4.3 PSOL network modules
All lesional sub networks in PSO were enriched for a GO BP (p < 0.05, Figure 6.3 C).
Enrichment results revealed that three modules were enriched for immune system processes
including the brown module which was enriched ‘leukocyte activation’ (p = 2.1e-66), the
darkturquoise module which was enriched for ‘B cell proliferation’ (p = 0.0069) indicating
a potential role for B cells in PSO, and the purple module which was highly enriched for
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‘defence response to virus’ (p = 1.9e-39). Two modules were enriched for ECM processes
(black, cyan), and two modules were enriched for skin associated processes (lightgreen,
blue).
Overall, a lack of enrichment for immune system proccess in control networks was ob-
served reflecting a state of homeostatic equilibrium. In comparison, immune system mod-
ules were well defined in disease associated networks, even in a non-lesional state. This
general overview of the reconstructed networks revealed co-expression modules which were
highly relevant to skin disease and provide a basis for further analysis into the similarity
and differences in transcriptional architecture across cohorts, as well as the association of
subnetworks with microbial abundance.
6.3.5 Inflammatory network module preservation
In Chapter 4, differences in transcript expression were quantified by means of differential
gene expression analysis, however, this approach did not consider the relationship between
genes. A module preservation analysis was performed to determine the consistency and
robustness of gene-gene interactions across networks. Module preservation analysis allows
evaluation of the dynamic properties of gene modules and enables study into how commu-
nity structure changes in the context of disease [232]. In contrast to differential analysis,
the main objective of module preservation analysis is to to identify co-expression modules
which are disrupted indicating a potential rewiring of gene-gene interactions occurring be-
tween healthy, non-lesional and lesional status.
The preservation of modules across networks was analysed with two main strategies (see
Section 6.2.5 for a detailed discussion). The first, and most naive approach is the ap-
plication of cross tabulation statistics, which determines the significance of overlap in the
membership of gene modules between networks and does not take into account information
regarding the patterns of gene-gene interactions. The second strategy corresponds to net-
work based preservation statistics. As defined in [232], network based statistics relate to a
plethora of strategies designed to determine whether the connectivity and density patterns
within a reference network are preserved in a designated test network.
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6.3.5.1 Cross tabulation statistics for module preservation
Cross tabulation statistics were applied to obtain a general overview into the concordance
of module definitions between healthy, uninvolved and lesional networks. Regarding AD,
a remarkable degree of preservation was observed between the ADL, ADNL and CAD net-
works where each network module had at least one significant overlap with another module
(p < 1e-3, Appendix B, Figure B.4). A similar trend was observed in PSO where the
vast majority of modules were highly conserved (Appendix B, Figure B.5). The cross-
tabulation statistics were also applied between the ADL and PSOL networks which again
demonstrated a similar transcriptional architecture between these diseases (Appendix B,
Figure B.6).
Overall, a strong level of module preservation was observed across networks, however qual-
itatively, there were indications that a small number of modules may only by weakly
preserved. For example, the blue and green modules in the PSOL network appeared to
be split across several PSONL and CAD modules (Appendix B, Figure B.5). Cross
tabulation statistics are sensitive to the parameters which define the network as well as the
community detection strategy [232] and do not take into account correlation strengths be-
tween module members, therefore, further analysis of module preservation was performed
using network based statistics.
6.3.5.2 Preservation of network modules in AD
First, ADL was used as the reference network and preservation statistics were calculated
to determine if ADL modules could be identified within the ADNL adjacency matrix. Us-
ing the guidelines suggested by [232], a Zsummary threshold of < 10 was used to denote
weak preservation and Z > 10 reflected strong module preservation. As observed with
the cross-tabulation analysis, a remarkable degree of preservation of ADL modules was
observed (Figure 6.4 A). All of the ADL modules were preserved with a Zsummary > 10.
When considering the CAD network as the test network, and ADL as the reference net-
work, the green and purple modules were only weakly preserved (Z < 10, Figure 6.4 B).
Whilst the Zsummary statistic suggested a high degree of preservation, Zconnectivity in our
networks was strongly correlated with module size (Appendix B, Figure B.7). This is
a known limitation of the method, therefore, the Zsummary results were supplemented with
the medianRank statistic which is a robust way of reporting module preservation without
the influence of module size.
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Figure 6.4: Module preservation analysis of ADL modules. (A) Zsummary of modules using
ADL modules as reference and the ADNL expression matrix as the test set. (B) Z summary
of modules with ADL reference and CAD test set. (C-D) Median rank statistics, modules
ranked closer to 1 are highly preserved, and modules with high ranks are weakly preserved.
(C) MedianRank statistics with ADL reference and ADNL test. (D) ADL reference and
ADNL test. (E-F) Network diagrams depicting the correlations between hub genes of
weakly preserved modules. An edge represents a correlation > 0.65 in the ADL, ADNL
and CAD networks. (E) green module, (F) purple module.
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Analysis of module preservation statistics using the medianRank scoring method indicated
that the green module was the most weakly preserved within the ADNL network (Figure
6.4 C), and that the purple and green modules were the most weakly preserved within the
CAD network (Figure 6.4 D). Further investigation of these modules showed that the
connectivity patterns amongst the hub genes in the green module were severely depleted
in the ADNL and CAD networks (Figure 6.4 E). The top GO term for the green module
was for ncRNA metabolic process (p =1.97e-43, Figure 6.2 C) and the enriched pathways
reflect processes involved in protein and RNA processing (Appendix B, Figure B.1). A
similar pattern was observed within the purple module (Figure 6.4 F) which was enriched
for ‘inflammatory response’ (p = 7.8e-06) of which the Th2 cytokine receptor IL4R was
a hub gene, and contained key immune genes as well as antimicrobial peptides. Given
that the connectivity patterns amongst the green and purple modules were significantly
perturbed, these modules likely represent AD associated subnetworks.
6.3.5.3 Preservation of network modules in PSO
The same approach was applied using PSOL as the reference network, and the PSONL
and CPSO networks as the test sets. The vast majority of modules were preserved except
the green module which had a Zsummary statistic lower than 10 in both the PSONL and
CAD networks (Figure 6.5 A). No other modules had a Zsummary statistic lower than 10.
Given that the Zsummary statistic is sensitive to differences in module size, the results were
supplemented with the medianRank. This analysis also indicated that the green module
was the least preserved module across networks (Figure 6.5 B-C). A complete breakdown
in the correlations amongst the top hub genes was observed across networks (Figure 6.5
D) demonstrating that interactions within this module undergo significant rewiring during
inflammation. The green module was significantly enriched for ncRNA metabolic process
(p = 2.5e-19, Figure 6.3 C) which has recently been associated with psoriatic inflamma-
tion [243]. Interestingly, the cytokine receptor IL4R was also amongst the hub genes of
this module suggesting that this subnetwork may also represent inflammatory component.
IL4R was found to be a hub gene within the ADL-purple module which was only weakly
preserved across AD networks. The PSOL green module was strongly enriched for genes
originating from both the green and purple ADL modules (Appendix B, Figure B.6)
which could indicate a relationship between inflammation and ncRNA processes.
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Figure 6.5: Module preservation analysis of PSOL modules. (A) Zsummary of modules using
PSOL modules as reference and the PSONL expression matrix as the test set (top), and
Z summary of modules with PSOL reference and CPSO test set (bottom). (B-C) Median
rank statistics. Modules ranked closer to 1 are highly preserved, and modules with high
ranks are weakly preserved. (B) MedianRank statistics with PSOL reference and PSONL
test. (C) PSOL reference and CPSO test. (D) Network diagrams depicting the correlations
between hub genes of the green module. An edge represents a correlation > 0.65 in the
PSOL, PSONL and CPSO networks. (E) Differential connectivity analysis of genes for
the ADL-PSOL comparison. kDiff was calculated as whole network connectivities in the
PSOL network subtracted from connectivity in the ADL network kADL-kPSOL. Genes
with kDiff > 0.4 are shown.
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In attempt to determine if differentially co-expressed modules were present between the
PSOL and ADL networks, the module preservation analysis was performed using the ADL
network as the reference network and PSOL as the test network. The same procedure was
performed using PSOL as the reference and ADL as the test network. In both cases, all
modules were highly preserved Zsummary > 20 (data not shown) demonstrating a strong
relationship between the co-expression relationships which underlie inflammation in the
skin. Whilst module structure was preserved between ADL and PSOL, individual genes
could display different connectivity patterns which may provide insight into the master
transcriptional regulators which underlie the Atopic and Psoriatic systems. A differential
connectivity analysis was performed between ADL and PSOL by calculating the difference
in network connectivity across all genes. That is, in the context of lesional disease, the
overall weighted connectivity of a gene with other nodes in the network is calculated
independently for both networks; kA and kP . For each gene the connectivity difference,
kA − kP , is calculated [151]. Seven genes were of greater connectivity in AD and 33
genes in PSO (kDiff > 0.4, Figure 6.5 E). Genes differentially connected in AD related
to genes associated with T cells such as the differentiation regulator RORC, as well as
TRAJ23 and CLEC7A. The cholesterol transporter Apolipoprotein E (APOE) was also
differentially connected in AD. Three genes of greater connectivity in PSOL were associated
with negative regulation of NFKB signalling including NOS2, TNIP3 and PYDC1.
6.3.6 Association of co-expression modules with the microbiome
The expression profile of a co-expression network module can be summarised into a single
representative vector known as the module eigengene. This module eigengene can then be
used to link the expression of a module to clinical traits. In this section the relationship
between eigengene expression and microbial abundance as well as disease severity (SCO-
RAD in AD, PASI in PSO) was evaluated in attempt to unearth potential host-microbe
associations of clinical relevance.
Only associations between module eigengenes and traits were significant within the ADL
network (Appendix B, Figure B.8). Regarding the lesional ADL network, 6 modules
were significantly associated with microbial abundance, two of which were also significantly
associated with SCORAD (Figure 6.6 A). Regarding the microbiota, only associations
between Staphylococcus aureus and co-expression modules were identified, in line with
previous results presented in Chapter 5.
























































































































































































Figure 6.6: Associations between co-expression modules, disease severity and microbial
abundance in AD. (A) Association between module eigengenes, microbes and SCORAD.
Significant associations with an adjusted p value < 0.1 and r > 0.3 are shown. (B) Pearson
correlation between kME and S. aureus gene significance in the tan module. (C) Heatmap
of the top 20 hub genes ranked by kME in the tan modules. Samples are ordered by
increasing S. aureus abundance. Black column labels correspond to S. aureus negative,
and red labels correspond to S. aureus positive. (D) kME vs gene significance for blue
module. (E) heatmap of hubs in the blue module. (F) Network visualisation of the tan
and blue modules. The top 10% of correlations between the top 20 hub genes in the tan
and blue modules.
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6.3.6.1 Tan module
First, negative relationships were investigated of which the tan module was inversely corre-
lated with S. aureus (r = -0.37, p = 0.015, Figure 6.6 A). This module was was strongly
enriched for GO processes associated with skin development such as keratinization, ker-
atinocyte differentiation, and epidermal cell differentiation (p < 9.5e-09, Appendix B,
Table B.1). To identify potential hub genes within this module, module membership val-
ues (kME) were calculated for each gene as the correlation between the gene member and
module eigengene. A measure of gene significance for S. aureus was also calculated as the
correlation between the gene and S. aureus. The correlation between kME and gene signif-
icance showed a highly significant inverse relationship indicating that key genes within the
tan module are negatively correlated with S. aureus abundance (Figure 6.6 B). Genes
were then ranked by kME value to identify hub genes, and the top ranking genes were se-
lected and presented in a heatmap whereby samples were ordered by S. aureus abundance
(Figure 6.6 C). The heatmap represents a pattern by which hub genes of the tan module
are of lower expression in the presence of high S. aureus relative abundance.
The top genes within the tan module clearly reflect genes associated with the epidermal dif-
ferentiation complex. Several members of the late cornified envelope family (LCE) includ-
ing LCE1C, LCE1A, LCE1B, LCE2D, LCE6A, LCE1F and LCE4A, as well as ACER1,
and KPRP were amongst the top hub genes. The tan module also included other key
components of the epidermal barrier which were highly ranked including FLG2, FLG and
Loricrin (LOR). Barrier defect is known to be a characteristic of AD [44], and is specifically
associated with mutations with the FLG gene [50], therefore, this finding demonstrates that
transcriptional activity of the skin barrier is associated with the colonisation of pathogens
such as S. aureus.
6.3.6.2 Blue module
The blue module was negatively associated with S. aureus abundance (r = -0.44, p < 0.05,
Figure 6.6 A). The top GO terms associated with this module were anterior/posterior
pattern specification and regionalization, however, the significance of enrichment for the
blue module was one of the lowest across the whole ADL network indicating that the
genes in this module are likely to be heterogeneous and may represent currently unknown
processes (p < 9e-04 Appendix B, Table B.1). S. aureus gene significance and kME
for blue module members were correlated and highly significant (r = -0.54, p = 3.1e-62,
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Figure 6.6 D) indicating that hub genes are associated with S. aureus abundance.
Top hub genes included several candidate genes identified in Chapter 5 including GAN,
PARD3, HS3ST6, TMEM116, BOC, CHP2 (Figure 6.6 E). Other key genes identified in
Chapter 5 were also present in the blue module and highly ranked such as IL34 (rank
= 45) and RORC (rank = 34) strengthening the relationship between these genes and
association with S. aureus in ADL. An inverse association with disease severity (p < 0.05,
Figure 6.6 A) was observed, therefore, the genes in this module could be of clinical
relevance and further study could elucidate their function in the pathogenesis of AD.
6.3.6.3 Green module
One of the larger modules with 620 genes in the ADL network, green, was strongly enriched
for the GO term ‘ncRNA metabolic process’ (p = 1.97e-43, Appendix B, Table B.1) and
pathways such as ‘Ribosome biogenesis in eukaryotes’. A significant association between
S. aureus and the green module was found (Figure 6.6 A) and the top hub genes were of
greater expression in the presence of S. aureus (Figure 6.7 A-B). There is an increasing
appreciation for the relationship between non-coding RNAs and inflammation [244], and
psoriasis has recently been associated with long non-coding RNAs [243], although the
mechanisms are poorly understood. Several of the top hub genes were associated with
ribosomal RNA (Figure 6.7 B-C) which is traditionally considered to play a housekeeping
role. Whilst the interpretation of this module in the context of AD is challenging, further
investigations into the role of ncRNA, protein metabolism and the association with S.
aureus could provide insight into this relationship.
6.3.6.4 Purple module
The purple module was an immune system related subnetwork and was enriched for ‘in-
flammatory response’ and ‘innate immune response’ (p < 5e-05, Appendix B, Table
B.1). This module significantly correlated with S. aureus (r = 0.45, p = 0.018, Figure
6.6 A) and module membership showed a positive trend with GS (r = 0.56, p = 2.2e-26,
Figure 6.7 D). Many of the top hub genes within the purple module were associated
with antimicrobial defence including S100A9, S100A12 and S100A7A and also included
the Th2 cytokine receptor IL4R (Figure 6.7 E-F). DEFB4A was also highly ranked by
kME (rank = 39). As well genes encoding for immunity, other hubs included KRT6C,
KRT16, DSG3, GJB2 and the serine protease SERPINB13 which are critical for structural










































































































































































Figure 6.7: Co-expression modules positively associated with S. aureus.(A) kME vs S.
aureus gene significance for the green module. (B) Heatmap of the top 20 hub genes ranked
by kME in the green module. Samples are ordered by increasing S. aureus abundance.
Black column labels correspond to S. aureus negative, and red labels correspond to S.
aureus positive. (C) Network diagram of the top hubs in the green module. The top 10
% of correlations between the top 20 hub genes in green module are shown. (D) kME vs
gene significance for the purple module. (E) heatmap of hubs in the purple module. (F)
network diagram in the purple module. (G) kME vs gene significance for the cyan module.
(H) heatmap of hubs in the cyan module. (I) Network diagram for the cyan module.
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integrity and homeostasis of the epidermal barrier.
Pathway analysis of module members revealed further enrichment for innate pathways
including ‘NF-κB signalling’ and ‘cytosolic sensors of pathogen-associated DNA’ (p < 0.01,
Figure 6.8), therefore, this module represents components of the innate immune system
and epidermal barrier which are active in the presence of S. aureus. As this module was
significantly associated with disease severity (p = 0.015 , Figure 6.6 A), it clinically is a
relevant module and could represent a crosstalk between the immune system and epidermal
barrier and may provide insights into host response to S. aureus infection in AD.
6.3.6.5 Cyan module
The cyan module was strongly enriched for GO terms associated with the extracellular ma-
trix such as ‘extracellular matrix organisation’ and ‘extracellular structure organization’
(p < 3e-9, Figure 6.2 C, Appendix B, Table B.1). The top enriched pathways also
reflected ECM association with enrichment of ‘ECM-receptor interaction’ and ‘collagen
biosynthesis’ (Figure 6.8). A significant association between the cyan module eigengene
and S. aureus (r = 0.46, p = 0.015, Figure 6.6 A) as well as a positive (non-significant)
trend for disease severity was observed. As with other S. aureus associated modules, kME
and GS were significantly correlated (r = 0.56, p = 6.8e-17, Figure 6.7 G).
Genes within the cyan module (Figure 6.7 H-I) included the collagen family proteins
COL15A1 and COL6A3. Several other collagen family genes were highly ranked within
the cyan module including COL4A1, COL4A2, COL6A2 and COL6A1. Other ECM genes
were amongst the top hubs including VCAN which is involved in cell-cell adhesion, NID2,
which binds collagen and is associated with the structure of the basement membrane, and
the serine proteinase inhibitor SERPINH1. Several of the ADAM family of disintegrin
and metalloproteases were present in the cyan module, including ADAM9, ADAMTS12
and ADAM12 which are involved in wound healing and possess anti-angiogenic properties
[245, 246]. The ECM plays an important role within inflamed tissues and influences immune
cell signalling, migration, activation and T cell polarization [214]. The association of
this module with S. aureus establishes a link between between the ECM and pathogen
abundance which could relate to the remodelling and fibrosis which occurs in atopic lesions
[208].
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(Reactome) Collagen formation
(Reactome) Collagen biosynthesis and modifying enzymes
(KEGG) ECM−receptor interaction − Homo sapiens (human)
(Wikipathways) miRNA targets in ECM and membrane receptors
(Reactome) Extracellular matrix organization
(Reactome) STING mediated induction of host immune responses
(Reactome) EPHB−mediated forward signaling
(Wikipathways) Apoptosis Modulation and Signaling
(Reactome) Cytosolic sensors of pathogen−associated DNA 
(KEGG) NF−kappa B signaling pathway − Homo sapiens (human)
(KEGG) Proteasome − Homo sapiens (human)
(Reactome) Mitochondrial protein import
(BioCarta) proteasome complex
(Reactome) Metabolism of proteins
(KEGG) Ribosome biogenesis in eukaryotes − Homo sapiens (human)
(Reactome) Diseases of signal transduction
(Wikipathways) Neural Crest Differentiation
(Reactome) Generic Transcription Pathway
(KEGG) Basal cell carcinoma − Homo sapiens (human)
(KEGG) Hippo signaling pathway − Homo sapiens (human)
(Reactome) Transport of glucose and other sugars*





Figure 6.8: Top 5 enriched pathways for modules of interest as identified by consensus-
PathDB. The black line corresponds to p = 0.05, and the red line to p = 0.1.
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6.4 Conclusions and Discussion
In the analysis presented, independent co-expression networks were constructed to inves-
tigate the complex systems underlying skin inflammation. These co-expression networks
allowed for investigation into core sets of genes which interact during atopic and psoriatic
inflammation. Furthermore, dimensionality reduction via the calculation of module eigen-
genes facilitated the mapping of host-microbe interactions identifying gene sets related to
pathogen abundance, and enabled the identification of those which covaried with disease
severity. The vast majority of modules identified across networks were strongly enriched
for biological processes relevant to skin biology.
First, a module preservation analysis was performed, and despite the considerable expres-
sion differences described in Chapter 4, it was surprising to find that the transcriptional
architecture was remarkably preserved across networks. Despite an overall state of preser-
vation, two modules were found to be weakly preserved in AD and one module in PSO
compared to controls and their non-lesional counterparts. One of these modules, the green
module, was highly enriched for non coding RNA metabolic processes as well as ‘ribosome
biogenesis’ (in both PSO and AD). Recent studies in psoriasis have shown that lncRNAs
were significantly enriched amongst psoriasis associated modules and could play important
roles in the regulation of inflammatory pathways [243]. In ADL, the green module was also
associated with S. aureus abundance and indicates an interesting relationship between S.
aureus abundance and housekeeping RNA processes.
In atopic dermatitis, the purple module was associated with inflammatory response which
is not preserved in either of the ADNL or CAD networks. The top hub gene of the purple
module was IL4R, and whilst it is well established that genes associated with Th2 cells
are involved in atopic inflammation [44], this analysis demonstrated that genes within this
module form strong co-expression relationships during inflammation and are thus differen-
tially co-expressed. As IL4R was the top hub gene of this module, is it likely that the purple
module is associated with increased Th2 activity. Furthermore, this module was associated
with disease severity and Staphylococcus aureus abundance indicating that Th2 activity
exacerbates inflammation and is related to pathogen colonisation in AD. It was interesting
to find that all modules were highly preserved between ADL and PSOL indicating that the
transcriptional architecture of these diseases is similar. Despite this, several genes were
found to be differentially connected between diseases and may act as differential regulators.
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One of the main findings of this analysis is that only associations between Staphylococcus
aureus in the ADL network were identified. In Chapter 3 uninvolved atopic skin was
shown to be dominated by S. aureus, yet no significant associations between S. aureus in
uninvolved networks were identified. This suggests that S. aureus covaries with inflam-
mation yet it remains unclear how or if S. aureus triggers a flare. This observation could
reflect findings of higher abundances of staphylococcal enterotoxin isolated from S. aureus
strains on lesional skin than non-lesional skin [66]. Despite expansion in specific microbes
in PSO, no significant associations were identified between potential pathogens and tran-
scriptional activity in PSO.
Analysis of the ADL network showed a negative association between the tan module and
S. aureus abundance. This module contained a number of genes responsible for the struc-
tural integrity of the epidermal barrier and consisted of FLG, FLG2, LOR and LCE family
genes. Within the skin, the epidermis harbours a diverse range of specialised immune cells
including langerhans and dendritic epidermal T cells which along with keratinocytes, act
as the first line of defence against the external environment and invading pathogens [160].
It is well established that AD is associated with epidermal barrier deficiencies [51, 204],
the most well characterised being loss of function mutations within the FLG gene [49, 50]
which aggregates keratin filaments in the epidermis and is a key component of the stratum
corneum. Breakdown products of FLG are used to generate natural moisturising factors
which play roles in hydration of the skin barrier. FLG loss of function mutations are
therefore related to the dryness often characteristic of AD lesions [49]. Studies have shown
that barrier defects are associated with increased cutaneous infiltration of antigens, thus,
the increased permeability of the epidermal barrier could be a key component of atopic
inflammation [52]. The association of the tan module and S. aureus suggests that disrup-
tion to barrier integrity through reduced expression of this module is related to increased
abundance of pathogen.
As well as the epidermal compartment, the strongest host-S. aureus association involved
a module encoding for components of the ECM which makes up a large proportion of the
dermis. The cyan module represented a component of the ECM which was specifically per-
turbed in the presence of increased S. aureus abundance. Tissue and extracellular matrix
remodelling is characteristic of atopic inflammation [208] and Staphylococcus aureus has
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been shown to induce MMP expression in vitro in fibroblasts [247], therefore, it is possible
that S. aureus could be associated with ECM remodelling. Cytokines produced by Treg
cells such as TGFB and IL10 are upregulated in AD (see Chapter 3, Figure 4.7). TGFB
is an immunosuppresive cytokine which can induce fibrosis [248] and can be induced by
the Th2 cytokine IL13 [198]. Furthermore, Tregs are thought to possess both pro and
antifibrotic properties [248], thus S. aureus may be associated with a Th2 response [249]
which indirectly induces ECM remodelling.
S. aureus was also negatively correlated with the blue module and although enrichment
analysis was weak and inconclusive, it suggests that this module contains genes of un-
known function in the context of AD. Interesting candidates within this module included
IL34 which was also found to be associated with S. aureus in Chapter 5 and has recently
been associated with AD where it is thought to inhibit inflammatory cascades [211]. As
this module was also inversely correlated with disease severity, further analysis could be
performed to deduce the function of this potentially clinically relevant module.
In summary, a large scale integrative network analysis of the transcriptomic processes un-
derlying psoriatic and atopic inflammation was performed. Several co-expression modules
were related to S. aureus abundance and clinical severity in AD. Furthermore, although
not significant, in modules which were positively correlated with S. aureus, a trend for
increased disease severity was observed indicating that S. aureus exacerbates inflamma-
tory response. The co-expression modules identified were highly relevant to structural and
inflammatory processes underlying inflammation and further experimental analysis can
continue to unravel the complex interactions between pathogens and to identify potential
therapeutic targets.
Chapter 7
Conclusions and future perspectives
Advances in sequencing technologies have revolutionised our understanding of the resident
flora which envelop the surfaces of our bodies. In recent years, many 16S and metagenomics
surveys have been performed and it is now becoming increasingly clear that the relation-
ship between microbiota and host health is not as simple as once perceived. Many analyses
of the microbiota colonising the surface of diseased tissues have reported an apparent state
of dysbiosis which represents broad shifts in community composition. Collectively, these
analyses have shown that the relationship between the microbiome and host health is com-
plex, however, much of the evidence suggests that the resident microbiota and the host
immune system exists in delicate homeostatic balance which when disturbed, can provoke
an inappropriate immune response [31, 22]. Further work is still required to determine
the principles, however, as the cost of sequencing drops and the bioinformatics methods
to analyse the vast quantities of challenging data improve, greater understanding of host
microbiota interactions may enable modulation of the resident microbiota for therapeutic
applications.
Collectively the results presented in this thesis support the notion of a complex ecosys-
tem of microbiota colonising the healthy and inflamed cutaneous membrane. The largest
survey to date of the inflamed microbiota is presented in Chapter 3 which revealed the
major compositional differences between atopic dermatitis, psoriasis and healthy skin. This
analysis portrayed a diverse cutaneous microbiota with over 4000 unique OTUs present on
healthy skin, with each site consisting of approximately 143 different taxa.
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Clear compositional differences were observed between disease types, and dysbiosis is un-
doubtedly a major factor of the AD microbiome. Compositional shifts in psoriasis were
more subtle, however, in both conditions severe disease was characteristic of reduced diver-
sity thus, demonstrating a relationship between homestatic balance and cutaneous inflam-
mation. It has been suggested that S. aureus may be driving dysbiosis in AD [64], and the
co-occurrence network analysis presented in Chapter 3 supports this idea. Several nega-
tive interactions were observed and it suggests that S. aureus may competitively exclude
commensal species such as S. epidermidis. An alternative landscape of disturbances was
observed in PSO with several species such as Corynebacterium simulans, Peptostreptococ-
cus anaerobius and Neisseriaceae G. sp. displaying greater abundance on psoriatic skin,
thus, it may be the case that multiple species operating in concert contribute towards the
psoriatic phenotype.
Despite differences in pathogenic species, some general concepts of skin inflammation can
be determined. These include a loss of potentially beneficial taxa such as Propionibac-
terium which were reduced on diseased skin. This species often colonises sebaceous sites
[38] and it could be related to the the dryness associated with inflamed skin. Other possible
homeostatic candidates included Lactobacillus which were lost in disease, although further
work will need to be performed to determine its disease association with respect to gender
which clearly impacts upon the abundance of this species. Taxa such as Propionibacterium
were also reduced on non-lesional skin which suggests that potential probiotic treatments
could help to restore species diversity or be used as a possible preventative treatment com-
bating the onset of dysbiosis.
In comparison to healthy skin, the similarity between lesional and uninvolved skin was high.
The community composition was only marginally different between ADNL and ADL, and
no significant differences could be detected between PSONL and PSOL. A simple yet naive
explanation could be that the composition of disease susceptible skin is already in a state
of dysbiosis before an inflammatory triggering event. The data presented in this thesis
does not allow us to make this conclusion as it is possible that, either during, or preceding
a flare, the community composition may undergo a systemic shift such that the global
cutaneous microbiome is altered during a flare phase. Furthermore, unlike the microbiota
in which uninvolved sites closely resemble lesional skin, the transcriptomics analysis pre-
sented in Chapter 4, showed that uninvolved transcriptional profiles were much closer
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to healthy skin. This observed ‘lag’ between the microbiota and transcriptome supports
the idea that changes in the microbiome precede a flare and microbial dysbiosis could be
a required precursor to inflammation. Sampling of patients in a flare-free phase could
be performed to investigate this possibility, and if shifts in community composition occur
during a pre-flare phase, longitudinal analyses may be able to determine when this occurs
allowing for a causative analysis.
The findings in Chapter 4 defined the transcriptional architecture of disease and estab-
lished gene sets for integration with the cutaneous microbiota. The results demonstrated
broad transcriptional changes in the lesional skin of both diseases. This analysis indicated
that AD was characteristic of heightened Th2 activity, with disruptions to the epider-
mal barrier and extracellular matrix. Alternatively, PSO was associated with dysregula-
tion of IL36, Th1/Th17 cytokines, antimicrobial peptides as well as disruptions to energy
metabolism and axonal guidance signalling pathways. A considerable proportion of the in-
flammatory gene signatures overlapped which could be further investigated as therapeutic
targets potentially effective for both conditions.
The matched microbiome and transcriptome data generated by the MAARS consortium
provide a unique opportunity to study interactions between the host and resident mi-
crobiota, however, integration of high dimensional datasets is challenging. To achieve
appropriate levels of sensitivity, powerful dimensionality reduction methods must be ap-
plied [29]. The overwhelming host-microbiota signal identified was between S. aureus and
transcriptional profiles in AD. In Chapters 5 and 6, it was demonstrated that the impact
of most bacteria on the host transcritpome was low, and only significant associations were
identified between S. aureus and host transcripts in AD. These analyses point towards an
intimate relationship that exists between S. aureus and the pathogenesis of atopic der-
matitis. Negative associations were identified between S. aureus and IL34 which is critical
for the development of Langerhans cells and has recently been associated with AD [211].
A cluster of genes encoding integral components of the epidermal barrier such as FLG,
FLG2 and LOR were also negatively associated with S. aureus establishing a relation-
ship between barrier dysregulation and pathogen colonisation. Studies have indicated that
TEWL is significantly higher in AD patients colonised by S. aureus [206], and this analysis
describes a set of genes which may be involved in this process.
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Several positive associations with the immune system were identified which support a pro-
inflammatory role for S. aureus in AD. Relationships were identified with the complement
system, the expression of antimicrobial peptides and a gene cluster of which IL4R was the
top hub. These findings indicate that S. aureus is closely intertwined with host immune
activation and the Th2 response which drives AD. As well as associations with the immune
system, one of the strongest S. aureus associations involved genes encoding components
of the extracellular matrix. Fibrosis is a characteristic symptom of AD [208] and further
work could be performed to determine how S. aureus is associated with this response, or if
ECM remodelling is mostly due to increased immune activation [198]. Further associations
were identified within a module encoding processes for non-coding RNA. There is limited
literature regarding the role of ncRNAs in AD, therefore, this finding could represent a
component of atopic inflammation that may have been overlooked and could be clarified
through further research.
S. aureus is highly abundant on non-lesional skin, and accounts for approximately 17% of
the uninvolved microbiota. Despite clear host-microbe associations in the lesional phase,
no significant associations were identified on non-lesional skin. The reasons for this are
unclear, however, it could relate to the observation that a lower abundance of staphylococ-
cal enterotoxin is isolated from S. aureus strains on non-lesional skin, than from S. aureus
strains on lesional skin [66]. Further analysis with metagenomics sequencing will be able
to interrogate S. aureus at higher resolutions to the strain level enabling the investigation
of this hypothesis.
Psoriasis is associated with mutations of the innate and adaptive immune system [73].
Mutations within NFκB signalling are also a factor of Crohn’s disease and it is thought
that enteric inflammation may be driven by inappropriate immune responses to intestinal
microbiota [74, 80]. With the extreme transcriptional disturbances indicated in Chapter
4 to the immune system, epidermal barrier and AMPs, it was expected that this dysregula-
tion would be detectable in the relative proportions of the commensal microbiota. Instead,
little covariation between the psoriatic microbiota and host gene expression profiles was
observed and may represent an inability of the microbiome to shape host gene expression
in the short term. Despite mostly inconclusive results for host-microbe associations in
PSO, it cannot be concluded that the microbiome is unrelated to transcriptional profiles
in the skin. S.aureus completely dominated the microbiota in AD and despite an average
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relative abundance of > 40%, the effect sizes observed for this pathogen were still fairly
modest with maximum correlations of less then 0.5. When compared to C. simulans which
accounted for only approximately 3% of the lesional psoriatic microbiota, it is reasonable
to assume that effect size of this species amongst other potential pathogens in PSO would
be considerably lower than S. aureus. I expect that more samples would be required to
accurately elucidate host-microbe interactions in systems such as psoriasis where the com-
munity composition is only moderately disturbed.
It is important to note that 16S sequencing only profiles bacterial abundances and the cu-
taneous microbiome is also rich with fungal and viral microbiota [33]. Malassezia is one of
the most prevalent fungi species on the skin [33] and has been linked to skin inflammation
[206]. Further analysis could be performed to investigate the viral and fungal components
which may be relevant to dysbiosis in skin inflammation.
Overall the results presented in this thesis contribute towards a greater understanding into
the potential mechanisms which underlie dysbiosis in skin disease. The methods applied
for integration of omics’ datasets enabled the investigation into the relationships between
pathogens and host parameters and provided insight into how these interactions may relate
to inflammatory skin pathologies. Only with further validation and mechanistic studies
will it be possible to translate these findings into clinical applications.
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This appendix contains supplemental data for the independent microbiome analysis.
Group Gender (padj) Institution (padj) Bodysite (padj) Age (padj) OTU
CTRL 9.93E-06 ns ns ns Anaerococcus sp.
CTRL 5.46E-05 ns ns ns Corynebacterium sp.
CTRL 2.38E-03 ns ns ns Lactobacillus sp.
CTRL 5.67E-06 1.11E-02 ns 1.11E-02 Lactobacillus iners
CTRL 2.58E-02 ns ns ns Prevotella sp.
CTRL 4.56E-03 4.15E-03 ns ns Lactobacillus sp.
CTRL ns 5.04E-10 ns 5.66E-05 Corynebacterium sp.
CTRL ns 1.66E-03 ns ns Bradyrhizobium sp.
CTRL ns 1.89E-03 ns ns Anaerococcus sp.
CTRL ns 1.27E-02 3.70E-10 ns Herbaspirillum sp.
CTRL ns 6.58E-06 ns ns Paracoccus marcusii
CTRL ns 4.51E-03 ns ns Anaerococcus sp.
CTRL ns 7.46E-03 5.95E-05 ns Variovorax paradoxus
CTRL ns 7.90E-08 ns ns Acinetobacter sp.
CTRL ns 4.10E-03 ns 1.09E-03 Comamonadaceae G. sp.
CTRL ns 1.01E-03 6.53E-05 ns Phyllobacterium sp.
CTRL ns 2.73E-03 ns ns Corynebacterium sp.
CTRL ns 8.68E-06 ns ns Dermacoccus sp.
CTRL ns 9.28E-03 3.16E-03 ns Finegoldia sp.
CTRL ns 3.63E-03 ns ns Micrococcus sp.
CTRL ns 4.80E-04 ns ns Prevotella sp.
CTRL ns 4.08E-03 ns ns Acinetobacter johnsonii
CTRL ns 2.70E-03 ns ns Janibacter sp.
CTRL ns 3.89E-12 ns ns Methylophilaceae G. sp.
CTRL ns 1.86E-05 ns 9.33E-04 Dietzia sp.
CTRL ns 2.62E-04 ns ns Acinetobacter sp.
CTRL ns ns 7.49E-04 ns Staphylococcus aureus
CTRL ns ns ns 2.67E-02 Corynebacterium sp.
AD ns 1.56E-02 ns ns Acinetobacter sp.
AD ns 1.04E-03 ns ns Corynebacterium sp.
AD ns 7.93E-04 ns ns Acinetobacter sp.
AD ns 2.79E-03 ns ns Lactococcus sp.
AD ns 1.26E-02 ns ns Micrococcus sp.
AD ns 1.59E-02 ns ns Streptococcus sp.
AD ns 3.51E-02 ns ns Corynebacterium sp.
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AD ns 5.79E-05 ns ns Dietzia sp.
AD ns ns 4.41E-02 ns Variovorax paradoxus
PSO 2.06E-02 ns ns ns Corynebacterium sp.
PSO ns 7.10E-04 ns ns Corynebacterium sp.
PSO ns 2.87E-07 1.89E-02 ns Acinetobacter sp.
PSO ns 2.44E-04 ns ns Acinetobacter johnsonii
PSO ns 5.07E-05 ns ns Dietzia sp.
PSO ns ns 3.73E-02 ns Phyllobacterium sp.
PSO ns ns 4.24E-02 ns Kocuria palustris
PSO ns ns ns 4.78E-02 Corynebacterium kroppenstedtii
Table A.1: OTU-metadata associations
Tax Level Taxa Wilcoxon (padj) MaAsLin (padj) Coef
Phylum Firmicutes 4.00E-14 1.20E-22 5.10E-01
Phylum Proteobacteria 1.10E-10 9.50E-13 -3.90E-01
Phylum Actinobacteria 1.00E-05 2.90E-05 -1.60E-01
Phylum Bacteroidetes 1.10E-05 3.70E-05 -6.70E-02
Phylum Cyanobacteria 7.50E-03 2.50E-04 -2.30E-02
Class Bacilli 1.20E-15 8.80E-28 5.70E-01
Class Alphaproteobacteria 2.90E-09 3.90E-10 -1.50E-01
Class Betaproteobacteria 3.70E-13 1.50E-08 -2.80E-01
Class Actinobacteria 1.10E-05 2.90E-05 -1.60E-01
Class Clostridia 9.80E-07 6.10E-05 -8.30E-02
Class Deltaproteobacteria 4.90E-05 9.30E-05 -1.40E-02
Class [Saprospirae] 3.30E-04 3.30E-04 -1.30E-02
Class Cytophagia 4.00E-02 2.10E-03 -8.10E-03
Class Gammaproteobacteria 1.00E-04 7.20E-03 -1.20E-01
Class Flavobacteriia 3.60E-03 1.10E-02 -3.20E-02
Class Bacteroidia 2.10E-03 1.70E-02 -2.70E-02
Order Bacillales 3.90E-17 3.20E-34 6.20E-01
Order Burkholderiales 2.20E-13 2.80E-08 -2.70E-01
Order Rhizobiales 3.90E-08 3.70E-07 -1.20E-01
Order Actinomycetales 1.30E-05 2.90E-05 -1.60E-01
Order Caulobacterales 2.60E-08 6.50E-05 -2.60E-02
Order Sphingomonadales 1.10E-06 7.10E-05 -2.60E-02
Order Clostridiales 1.20E-06 8.10E-05 -8.10E-02
Order [Saprospirales] 3.30E-04 3.30E-04 -1.30E-02
Order Methylophilales 2.40E-04 5.60E-04 -1.50E-02
Order Lactobacillales 1.80E-05 7.60E-04 -8.50E-02
Order Cytophagales 4.00E-02 2.10E-03 -8.10E-03
Order Xanthomonadales 4.40E-04 2.30E-03 -2.20E-02
Order Rhodobacterales 2.80E-07 3.40E-03 -2.80E-02
Order Flavobacteriales 3.60E-03 1.10E-02 -3.20E-02
Order Bacteroidales 2.10E-03 1.70E-02 -2.70E-02
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Order Rhodospirillales 4.30E-02 2.40E-02 -8.80E-03
Order Pseudomonadales 2.10E-06 2.70E-02 -7.30E-02
Order Pasteurellales 2.10E-02 3.50E-02 -1.10E-02
Family Staphylococcaceae 6.30E-17 3.20E-34 6.30E-01
Family Burkholderiaceae 2.00E-05 1.60E-06 -6.80E-02
Family Propionibacteriaceae 7.30E-09 1.80E-05 -2.50E-02
Family Brucellaceae 3.30E-04 2.00E-05 -1.80E-02
Family Comamonadaceae 6.10E-11 6.50E-05 -2.00E-01
Family Caulobacteraceae 2.60E-08 6.50E-05 -2.60E-02
Family Sphingomonadaceae 4.90E-06 1.70E-04 -2.50E-02
Family [Tissierellaceae] 3.50E-07 2.20E-04 -6.70E-02
Family Bradyrhizobiaceae 2.00E-09 3.30E-04 -4.10E-02
Family Chitinophagaceae 3.20E-04 4.70E-04 -1.30E-02
Family Methylophilaceae 2.40E-04 5.60E-04 -1.50E-02
Family Micrococcaceae 3.30E-05 7.60E-04 -8.70E-02
Family Oxalobacteraceae 2.00E-02 1.90E-03 -5.70E-02
Family Cytophagaceae 4.30E-02 2.00E-03 -8.10E-03
Family Nocardioidaceae 9.40E-05 2.10E-03 -9.30E-03
Family Clostridiaceae 6.60E-03 2.70E-03 -1.70E-02
Family Aerococcaceae 2.10E-04 3.00E-03 -2.20E-02
Family Xanthomonadaceae 6.80E-04 3.40E-03 -2.10E-02
Family Rhodobacteraceae 4.90E-07 6.00E-03 -2.60E-02
Family Rhizobiaceae 5.10E-04 6.80E-03 -1.30E-02
Family Lactobacillaceae 3.00E-07 7.50E-03 -4.70E-02
Family Corynebacteriaceae 2.30E-03 8.10E-03 -7.30E-02
Family Lachnospiraceae 8.70E-03 9.40E-03 -1.50E-02
Family Ruminococcaceae 2.80E-03 1.40E-02 -1.40E-02
Family [Weeksellaceae] 4.90E-03 1.50E-02 -2.90E-02
Family Microbacteriaceae 2.70E-02 3.10E-02 -9.30E-03
Family Pasteurellaceae 2.10E-02 3.50E-02 -1.10E-02
Family Moraxellaceae 4.00E-06 3.50E-02 -6.90E-02
Family Prevotellaceae 2.20E-02 3.50E-02 -1.90E-02
Genus Staphylococcus 9.60E-17 3.20E-34 6.30E-01
Genus Burkholderia 6.20E-06 1.30E-06 -6.90E-02
Genus Ochrobactrum 3.30E-04 1.90E-05 -1.80E-02
Genus Propionibacterium 7.30E-09 2.10E-05 -2.50E-02
Genus Anaerococcus 1.70E-07 4.10E-05 -5.70E-02
Genus Micrococcus 4.50E-05 1.20E-03 -8.10E-02
Genus Tepidimonas 2.20E-03 1.30E-03 -1.70E-02
Genus Finegoldia 1.10E-05 2.10E-03 -2.80E-02
Genus Bradyrhizobium 4.90E-08 2.70E-03 -3.50E-02
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Genus Thermoanaerobacterium 4.90E-03 3.00E-03 -9.90E-03
Genus Acinetobacter 1.40E-05 5.10E-03 -4.50E-02
Genus Lactobacillus 2.60E-07 7.50E-03 -4.70E-02
Genus Corynebacterium 2.30E-03 8.10E-03 -7.30E-02
Genus Variovorax 4.80E-02 1.10E-02 -3.10E-02
Genus Enhydrobacter 4.90E-05 1.10E-02 -5.40E-02
Genus Pelomonas 3.60E-07 1.20E-02 -2.50E-02
Genus Paracoccus 1.10E-05 1.40E-02 -2.40E-02
Genus Sphingomonas 4.40E-04 1.50E-02 -1.20E-02
Genus Facklamia 9.90E-04 1.60E-02 -1.20E-02
Genus Kocuria 1.30E-03 1.90E-02 -2.10E-02
Genus Prevotella 2.20E-02 3.50E-02 -1.90E-02
Otu Staphylococcus aureus 1.10E-29 1.70E-35 6.90E-01
Otu Burkholderia sp. 3.70E-09 7.60E-09 -7.60E-02
Otu Staphylococcus sp. 3.00E-11 3.30E-07 -7.50E-02
Otu Ochrobactrum sp. 7.50E-04 4.40E-05 -1.80E-02
Otu Sphingomonadaceae G. sp. 2.80E-03 6.50E-05 -1.40E-02
Otu Propionibacterium acnes 2.10E-07 9.40E-05 -2.30E-02
Otu Methylophilaceae G. sp. 6.30E-04 5.90E-04 -1.50E-02
Otu Anaerococcus sp. 3.10E-04 2.00E-03 -1.10E-02
Otu Corynebacterium sp. 1.30E-03 2.00E-03 -2.70E-02
Otu Tepidimonas sp. 2.20E-03 2.10E-03 -1.60E-02
Otu Finegoldia sp. 1.10E-05 2.10E-03 -2.80E-02
Otu Corynebacterium sp. 5.50E-03 3.70E-03 -1.90E-02
Otu Thermoanaerobacterium sp. 2.60E-03 3.70E-03 -7.90E-03
Otu Micrococcus sp. 9.40E-04 3.70E-03 -7.00E-02
Otu Bradyrhizobium sp. 3.80E-07 5.10E-03 -3.30E-02
Otu Anaerococcus sp. 9.80E-03 8.50E-03 -1.20E-02
Otu Enhydrobacter sp. 6.50E-05 1.30E-02 -5.30E-02
Otu Kocuria palustris 2.20E-05 1.40E-02 -1.30E-02
Otu Anaerococcus sp. 1.40E-04 1.70E-02 -1.30E-02
Otu Pelomonas sp. 1.50E-07 1.90E-02 -2.30E-02
Otu Caulobacteraceae G. sp. 4.60E-03 2.70E-02 -1.30E-02
Otu Comamonadaceae G. sp. 1.60E-04 4.40E-02 -1.00E-01
Table A.2: Significant ADL associated taxa
Tax Level Taxa Wilcoxon (padj) MaAsLin (padj) Coef
Phylum Firmicutes 5.70E-04 2.30E-05 2.20E-01
Phylum Proteobacteria 4.60E-03 3.10E-03 -1.90E-01
Class Bacilli 1.00E-04 1.00E-06 2.40E-01
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Class Alphaproteobacteria 1.20E-02 1.50E-03 -8.30E-02
Class Betaproteobacteria 7.60E-06 3.10E-03 -1.70E-01
Class [Saprospirae] 1.20E-02 1.80E-02 -1.00E-02
Order Bacillales 8.20E-08 1.60E-11 2.70E-01
Order Rhizobiales 5.00E-03 1.50E-03 -8.00E-02
Order Burkholderiales 1.00E-05 3.10E-03 -1.70E-01
Order [Saprospirales] 1.20E-02 1.80E-02 -1.00E-02
Order Methylophilales 8.10E-03 1.90E-02 -1.20E-02
Order Lactobacillales 7.00E-04 2.70E-02 -5.80E-02
Family Staphylococcaceae 8.20E-08 3.50E-12 2.90E-01
Family Chitinophagaceae 1.20E-02 1.80E-02 -1.00E-02
Family Methylophilaceae 8.10E-03 1.90E-02 -1.20E-02
Family Comamonadaceae 6.50E-05 3.00E-02 -1.30E-01
Family Propionibacteriaceae 6.50E-05 3.00E-02 -1.50E-02
Genus Staphylococcus 8.20E-08 3.40E-12 2.90E-01
Genus Burkholderia 3.10E-02 1.30E-02 -4.50E-02
Genus Propionibacterium 9.20E-05 3.70E-02 -1.40E-02
Otu Staphylococcus aureus 4.50E-22 2.40E-16 3.00E-01
Otu Staphylococcus sp. 8.20E-08 3.90E-04 -6.50E-02
Otu Burkholderia sp. 6.40E-05 5.70E-04 -5.30E-02
Otu Corynebacterium sp. 7.00E-04 2.50E-02 1.10E-02
Otu Methylophilaceae G. sp. 1.70E-02 3.00E-02 -1.10E-02
Table A.3: Significant ADNL associated taxa
Tax Level Taxa Wilcoxon (padj) MaAsLin (padj) Coef
Phylum Firmicutes 5.60E-03 3.60E-02 1.00E-01
Phylum Proteobacteria 7.70E-05 4.90E-02 -1.20E-01
Order Neisseriales 1.40E-04 1.80E-02 1.40E-02
Order Methylophilales 3.20E-04 4.40E-02 -1.00E-02
Family Actinomycetaceae 9.10E-06 5.10E-04 2.40E-02
Family Peptostreptococcaceae 9.30E-07 5.10E-04 2.00E-02
Family Propionibacteriaceae 8.20E-03 5.10E-04 -2.10E-02
Family Rhizobiaceae 4.30E-03 1.50E-02 -1.30E-02
Family Neisseriaceae 1.40E-04 1.80E-02 1.40E-02
Family Veillonellaceae 9.00E-04 2.20E-02 1.80E-02
Family Prevotellaceae 4.90E-04 2.40E-02 2.70E-02
Family Fusobacteriaceae 4.90E-04 2.80E-02 9.50E-03
Family Corynebacteriaceae 2.50E-05 4.40E-02 6.80E-02
Family Carnobacteriaceae 4.30E-03 4.40E-02 1.10E-02
Family Methylophilaceae 3.20E-04 4.40E-02 -1.00E-02
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Genus Peptostreptococcus 4.20E-07 1.20E-07 1.90E-02
Genus Actinomyces 9.30E-07 5.10E-04 2.10E-02
Genus Propionibacterium 1.10E-02 6.30E-04 -2.00E-02
Genus Porphyromonas 1.90E-03 2.20E-02 1.50E-02
Genus Prevotella 4.90E-04 2.40E-02 2.70E-02
Genus Peptoniphilus 2.30E-03 2.70E-02 2.60E-02
Genus Fusobacterium 4.90E-04 2.80E-02 9.50E-03
Genus Corynebacterium 2.50E-05 4.40E-02 6.80E-02
Genus Streptococcus 2.30E-03 4.40E-02 3.10E-02
Otu Corynebacterium simulans 5.70E-18 2.10E-09 3.50E-02
Otu Peptostreptococcus anaerobius 1.50E-04 2.30E-05 1.50E-02
Otu Neisseriaceae G. sp. 6.70E-08 5.80E-04 8.50E-03
Otu Propionibacterium acnes 3.60E-02 1.10E-03 -2.00E-02
Otu Streptococcus sp. 2.30E-07 6.10E-03 1.20E-02
Otu Corynebacterium kroppenstedtii 2.20E-06 1.10E-02 1.80E-02
Otu Prevotella sp. 5.60E-04 1.10E-02 8.90E-03
Otu Prevotella sp. 6.80E-03 2.00E-02 1.10E-02
Otu Corynebacterium kroppenstedtii 1.10E-06 2.20E-02 2.20E-02
Otu Corynebacterium sp. 6.60E-05 2.40E-02 1.30E-02
Otu Anaerococcus sp. 5.10E-03 2.50E-02 1.10E-02
Otu Burkholderia sp. 1.40E-04 3.00E-02 -3.40E-02
Table A.4: Significant PSOL associated taxa
Tax Level Taxa Wilcoxon (padj) MaAsLin (padj) Coef
Order Neisseriales 5.00E-04 3.80E-03 1.90E-02
Family Actinomycetaceae 1.30E-03 2.40E-03 2.10E-02
Family Neisseriaceae 5.00E-04 3.80E-03 1.90E-02
Family Peptostreptococcaceae 2.40E-03 1.00E-02 1.50E-02
Family Fusobacteriaceae 2.40E-03 4.80E-02 8.40E-03
Genus Peptostreptococcus 1.30E-03 4.40E-04 1.30E-02
Genus Actinomyces 3.30E-04 9.70E-04 2.00E-02
Genus Porphyromonas 4.20E-02 4.30E-02 1.40E-02
Genus Fusobacterium 2.40E-03 4.80E-02 8.40E-03
Otu Corynebacterium simulans 6.40E-15 7.00E-10 3.70E-02
Otu Neisseriaceae G. sp. 3.50E-08 4.40E-04 1.90E-02
Otu Peptostreptococcus anaerobius 7.70E-03 1.40E-03 1.20E-02
Otu Anaerococcus sp. 1.00E-03 2.10E-03 1.50E-02
Otu Burkholderia sp. 2.10E-02 7.10E-03 -4.00E-02
Otu Streptococcus sp. 3.30E-06 1.10E-02 1.10E-02
Otu Corynebacterium kroppenstedtii 5.50E-05 1.30E-02 1.40E-02
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Otu Lactobacillus sp. 8.90E-09 4.80E-02 -1.10E-02
Otu Corynebacterium sp. 6.00E-04 4.80E-02 1.20E-02
Table A.5: Significant PSONL associated taxa
Level Taxa Wilx P(U) Mas P(U) Coef(U) Wilx P(M) Mas P(M) Coef(M)
Order Pasteurellales 2.13E-02 3.47E-02 -1.11E-02 1.22E-01 3.35E-02 -1.14E-02
Family Microbacteriaceae 2.73E-02 3.13E-02 -9.29E-03 3.61E-02 8.56E-02 -9.17E-03
Family Pasteurellaceae 2.13E-02 3.47E-02 -1.11E-02 1.22E-01 3.35E-02 -1.14E-02
Family Moraxellaceae 4.03E-06 3.47E-02 -6.93E-02 4.86E-05 5.70E-02 -5.66E-02
Family Prevotellaceae 2.23E-02 3.47E-02 -1.90E-02 6.27E-02 1.74E-02 -1.96E-02
Family Lachnospiraceae 8.71E-03 9.35E-03 -1.50E-02 5.92E-02 6.29E-03 -1.54E-02
Genus Prevotella 2.23E-02 3.47E-02 -1.90E-02 6.27E-02 1.74E-02 -1.96E-02
Genus Variovorax 4.78E-02 1.06E-02 -3.13E-02 1.33E-01 4.39E-03 -3.90E-02
Otu Anaerococcus sp. 9.83E-03 8.47E-03 -1.24E-02 9.12E-02 2.26E-03 -1.18E-02
Otu Caulobacteraceae G. sp. 4.65E-03 2.66E-02 -1.30E-02 5.03E-02 4.51E-02 -1.17E-02
Table A.6: Significant taxa for ADL-CTRL in the unmatched (U) but not significant in
matched cohort (M). Wilx and Mas correspond to Wilcoxon ranked sum and MaAsLin
respectively
Level Taxa Wilx P(U) Mas P(U) Coef(U) Wilx P(M) Mas P(M) Coef(M)
Phylum Firmicutes 5.59E-03 3.62E-02 1.01E-01 3.40E-02 5.97E-02 1.04E-01
Phylum Proteobacteria 7.69E-05 4.89E-02 -1.23E-01 4.92E-03 5.70E-02 -1.34E-01
Order Neisseriales 1.44E-04 1.83E-02 1.44E-02 6.53E-03 1.12E-01 1.02E-02
Family Prevotellaceae 4.95E-04 2.38E-02 2.65E-02 7.87E-03 6.35E-02 2.43E-02
Family Rhizobiaceae 4.29E-03 1.53E-02 -1.29E-02 5.57E-02 1.93E-02 -1.24E-02
Family Veillonellaceae 8.96E-04 2.19E-02 1.77E-02 9.08E-03 5.97E-02 1.67E-02
Family Neisseriaceae 1.44E-04 1.83E-02 1.44E-02 6.53E-03 1.12E-01 1.02E-02
Family Carnobacteriaceae 4.29E-03 4.43E-02 1.11E-02 4.46E-02 8.11E-02 1.09E-02
Family Fusobacteriaceae 4.95E-04 2.78E-02 9.46E-03 1.15E-02 8.45E-02 8.75E-03
Genus Prevotella 4.95E-04 2.38E-02 2.65E-02 7.87E-03 6.35E-02 2.43E-02
Genus Streptococcus 2.29E-03 4.44E-02 3.14E-02 1.02E-01 1.13E-01 3.04E-02
Genus Fusobacterium 4.95E-04 2.78E-02 9.46E-03 1.15E-02 8.45E-02 8.75E-03
Otu Corynebacterium kroppenstedtii 2.24E-06 1.06E-02 1.85E-02 2.26E-04 6.35E-02 1.78E-02
Otu Corynebacterium sp. 6.62E-05 2.42E-02 1.29E-02 1.62E-03 1.18E-01 1.10E-02
Otu Corynebacterium kroppenstedtii 1.06E-06 2.24E-02 2.22E-02 9.68E-04 6.35E-02 2.23E-02
Otu Prevotella sp. 6.80E-03 2.03E-02 1.06E-02 7.17E-02 5.97E-02 9.20E-03
Table A.7: Significant taxa for PSOL-CTRL in the unmatched (U) but not significant in





This appendix contains supplemental data for the integrative network chapter.
Module Description ID pvalue p.adjust
black extracellular matrix organization GO:0030198 9.67E-18 1.42E-14
black extracellular structure organization GO:0043062 9.67E-18 1.42E-14
black vasculature development GO:0001944 3.64E-14 3.57E-11
black cardiovascular system development GO:0072358 4.88E-14 3.60E-11
black blood vessel development GO:0001568 1.86E-13 1.09E-10
blue anterior/posterior pattern specification GO:0009952 2.48E-07 9.22E-04
blue regionalization GO:0003002 5.22E-07 9.70E-04
blue pattern specification process GO:0007389 6.25E-06 7.75E-03
blue cell part morphogenesis GO:0032990 1.48E-05 1.38E-02
blue cell projection morphogenesis GO:0048858 2.07E-05 1.54E-02
brown leukocyte activation GO:0045321 1.97E-66 6.29E-63
brown lymphocyte activation GO:0046649 5.18E-65 8.27E-62
brown leukocyte cell-cell adhesion GO:0007159 8.61E-58 9.17E-55
brown lymphocyte aggregation GO:0071593 1.51E-56 1.21E-53
brown T cell activation GO:0042110 1.17E-55 6.21E-53
cyan extracellular matrix organization GO:0030198 2.40E-12 2.99E-09
cyan extracellular structure organization GO:0043062 2.40E-12 2.99E-09
cyan blood vessel development GO:0001568 3.62E-09 3.00E-06
cyan angiogenesis GO:0001525 5.05E-09 3.14E-06
cyan vasculature development GO:0001944 7.49E-09 3.65E-06
darkred response to type I interferon GO:0034340 2.87E-31 1.87E-28
darkred innate immune response GO:0045087 3.14E-31 1.87E-28
darkred defense response to virus GO:0051607 1.22E-30 4.83E-28
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darkred type I interferon signaling pathway GO:0060337 1.28E-29 3.04E-27
darkred cellular response to type I interferon GO:0071357 1.28E-29 3.04E-27
green ncRNA metabolic process GO:0034660 5.57E-47 1.97E-43
green ribonucleoprotein complex biogenesis GO:0022613 2.69E-42 4.75E-39
green ribosome biogenesis GO:0042254 2.00E-41 2.36E-38
green ncRNA processing GO:0034470 4.33E-40 3.83E-37
green RNA processing GO:0006396 4.73E-34 3.35E-31
greenyellow monocarboxylic acid metabolic process GO:0032787 2.48E-19 4.81E-16
greenyellow fatty acid metabolic process GO:0006631 6.02E-18 5.84E-15
greenyellow lipid biosynthetic process GO:0008610 1.31E-14 8.47E-12
greenyellow small molecule biosynthetic process GO:0044283 5.67E-14 2.75E-11
greenyellow acylglycerol metabolic process GO:0006639 1.28E-12 4.97E-10
grey detection of chemical stimulus involved in se GO:0050911 2.71E-40 1.23E-36
grey sensory perception of smell GO:0007608 1.55E-37 3.49E-34
grey detection of chemical stimulus involved in se GO:0050907 1.11E-36 1.68E-33
grey detection of stimulus involved in sensory per GO:0050906 1.51E-31 1.71E-28
grey sensory perception of chemical stimulus GO:0007606 4.90E-31 4.43E-28
grey60 activation of immune response GO:0002253 5.06E-15 9.95E-12
grey60 positive regulation of immune response GO:0050778 2.33E-13 2.29E-10
grey60 innate immune response GO:0045087 9.40E-12 6.16E-09
grey60 innate immune response-activating signal tran GO:0002758 1.88E-10 8.49E-08
grey60 adaptive immune response GO:0002250 2.92E-10 8.49E-08
lightcyan nuclear-transcribed mRNA catabolic process, n GO:0000184 2.01E-27 3.31E-24
lightcyan SRP-dependent cotranslational protein targeti GO:0006614 6.43E-25 5.31E-22
lightcyan protein targeting to ER GO:0045047 1.68E-24 8.83E-22
lightcyan cotranslational protein targeting to membrane GO:0006613 2.67E-24 8.83E-22
lightcyan establishment of protein localization to endo GO:0072599 2.67E-24 8.83E-22
lightgreen molting cycle GO:0042303 1.86E-13 9.20E-11
lightgreen hair cycle GO:0042633 1.86E-13 9.20E-11
lightgreen epidermis development GO:0008544 6.96E-09 2.29E-06
lightgreen hair follicle development GO:0001942 2.01E-05 3.10E-03
lightgreen molting cycle process GO:0022404 2.01E-05 3.10E-03
lightyellow glycolipid metabolic process GO:0006664 1.39E-03 4.46E-01
lightyellow liposaccharide metabolic process GO:1903509 1.55E-03 4.46E-01
lightyellow membrane lipid metabolic process GO:0006643 1.59E-03 4.46E-01
lightyellow sphingolipid catabolic process GO:0030149 2.40E-03 5.05E-01
lightyellow membrane lipid catabolic process GO:0046466 3.49E-03 5.87E-01
magenta synapse assembly GO:0007416 2.57E-06 6.73E-03
magenta regulation of synapse assembly GO:0051963 1.85E-05 1.62E-02
magenta inorganic anion transmembrane transport GO:0098661 2.15E-05 1.62E-02
magenta inorganic ion transmembrane transport GO:0098660 2.48E-05 1.62E-02
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magenta monovalent inorganic cation transport GO:0015672 3.53E-05 1.75E-02
midnightblue keratinization GO:0031424 2.62E-08 5.55E-05
midnightblue skin development GO:0043588 7.59E-08 8.03E-05
midnightblue keratinocyte differentiation GO:0030216 4.46E-07 3.14E-04
midnightblue regulation of water loss via skin GO:0033561 5.22E-06 2.76E-03
midnightblue epidermis development GO:0008544 9.45E-06 3.41E-03
pink anatomical structure regression GO:0060033 1.12E-04 2.89E-01
pink regulation of synaptic plasticity GO:0048167 8.82E-04 5.01E-01
pink apoptotic process involved in morphogenesis GO:0060561 1.09E-03 5.01E-01
pink chemical synaptic transmission GO:0007268 1.39E-03 5.01E-01
pink anterograde trans-synaptic signaling GO:0098916 1.39E-03 5.01E-01
purple inflammatory response GO:0006954 5.58E-09 7.83E-06
purple response to biotic stimulus GO:0009607 9.34E-09 7.83E-06
purple response to external biotic stimulus GO:0043207 9.74E-09 7.83E-06
purple response to other organism GO:0051707 9.74E-09 7.83E-06
purple innate immune response GO:0045087 7.07E-08 4.55E-05
red mitotic cell cycle GO:0000278 3.56E-95 1.06E-91
red mitotic cell cycle process GO:1903047 7.25E-95 1.08E-91
red chromosome organization GO:0051276 3.69E-93 3.65E-90
red nuclear division GO:0000280 3.72E-73 2.76E-70
red organelle fission GO:0048285 5.21E-70 3.09E-67
royalblue triglyceride metabolic process GO:0006641 1.73E-06 7.88E-04
royalblue gluconeogenesis GO:0006094 2.08E-06 7.88E-04
royalblue hexose biosynthetic process GO:0019319 2.34E-06 7.88E-04
royalblue acylglycerol metabolic process GO:0006639 2.90E-06 7.88E-04
royalblue neutral lipid metabolic process GO:0006638 3.15E-06 7.88E-04
salmon protein methylation GO:0006479 3.42E-04 2.53E-01
salmon protein alkylation GO:0008213 3.42E-04 2.53E-01
salmon macromolecule methylation GO:0043414 1.07E-03 4.00E-01
salmon histone H3-K9 methylation GO:0051567 1.08E-03 4.00E-01
salmon histone lysine methylation GO:0034968 2.41E-03 5.84E-01
tan keratinization GO:0031424 7.36E-12 9.34E-09
tan keratinocyte differentiation GO:0030216 1.03E-11 9.34E-09
tan epidermal cell differentiation GO:0009913 1.43E-11 9.34E-09
tan skin development GO:0043588 1.77E-11 9.34E-09
tan peptide cross-linking GO:0018149 4.88E-11 2.05E-08
turquoise RNA splicing GO:0008380 2.36E-27 7.05E-24
turquoise RNA processing GO:0006396 9.51E-27 1.42E-23
turquoise mRNA processing GO:0006397 2.18E-25 2.17E-22
turquoise mRNA metabolic process GO:0016071 1.50E-21 1.12E-18
turquoise RNA splicing, via transesterification reactio GO:0000375 3.50E-21 1.50E-18
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yellow calcium-dependent cell-cell adhesion via plas GO:0016339 3.50E-09 1.18E-05
yellow homophilic cell adhesion via plasma membrane GO:0007156 2.32E-07 3.94E-04
yellow extracellular matrix organization GO:0030198 1.47E-06 1.25E-03
yellow extracellular structure organization GO:0043062 1.47E-06 1.25E-03
yellow glycosaminoglycan catabolic process GO:0006027 4.43E-06 2.84E-03
Table B.1: Top 5 GO BP terms for each ADL module
Module Description ID pvalue p.adjust
black extracellular matrix organization GO:0030198 4.26E-19 7.39E-16
black extracellular structure organization GO:0043062 4.26E-19 7.39E-16
black vasculature development GO:0001944 1.58E-14 1.83E-11
black cardiovascular system development GO:0072358 2.32E-14 2.02E-11
black blood vessel development GO:0001568 3.47E-14 2.41E-11
brown immune effector process GO:0002252 1.87E-68 6.83E-65
brown positive regulation of immune response GO:0050778 4.99E-68 9.12E-65
brown leukocyte activation GO:0045321 1.08E-65 1.31E-62
brown innate immune response GO:0045087 1.63E-65 1.49E-62
brown leukocyte cell-cell adhesion GO:0007159 1.59E-63 1.16E-60
cyan actin filament bundle assembly GO:0051017 1.03E-06 1.19E-03
cyan actin filament bundle organization GO:0061572 1.31E-06 1.19E-03
cyan reactive oxygen species metabolic process GO:0072593 1.60E-06 1.19E-03
cyan cell-substrate adhesion GO:0031589 2.09E-06 1.19E-03
cyan extracellular matrix organization GO:0030198 4.58E-06 1.75E-03
darkgreen muscle contraction GO:0006936 5.20E-21 7.53E-18
darkgreen muscle system process GO:0003012 1.76E-20 1.28E-17
darkgreen muscle cell differentiation GO:0042692 7.53E-12 3.64E-09
darkgreen muscle cell development GO:0055001 1.53E-11 5.56E-09
darkgreen smooth muscle contraction GO:0006939 3.26E-11 9.43E-09
greenyellow monocarboxylic acid metabolic process GO:0032787 5.76E-37 2.13E-33
greenyellow small molecule biosynthetic process GO:0044283 4.56E-26 8.41E-23
greenyellow organic acid catabolic process GO:0016054 1.03E-25 1.26E-22
greenyellow small molecule catabolic process GO:0044282 1.05E-24 9.69E-22
greenyellow fatty acid metabolic process GO:0006631 1.79E-24 1.32E-21
grey detection of chemical stimulus involved in se GO:0050911 2.07E-31 9.39E-28
grey sensory perception of smell GO:0007608 1.86E-29 4.22E-26
grey detection of chemical stimulus involved in se GO:0050907 1.96E-26 2.96E-23
grey sensory perception of chemical stimulus GO:0007606 4.24E-24 4.81E-21
grey detection of chemical stimulus GO:0009593 4.07E-21 3.69E-18
lightgreen molting cycle GO:0042303 4.75E-18 2.92E-15
lightgreen hair cycle GO:0042633 4.75E-18 2.92E-15
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lightgreen epidermis development GO:0008544 1.16E-12 4.73E-10
lightgreen hair follicle development GO:0001942 1.03E-09 2.10E-07
lightgreen molting cycle process GO:0022404 1.03E-09 2.10E-07
magenta tube formation GO:0035148 5.26E-08 1.20E-04
magenta stem cell differentiation GO:0048863 7.15E-08 1.20E-04
magenta epithelial tube formation GO:0072175 2.44E-07 2.14E-04
magenta tube development GO:0035295 2.56E-07 2.14E-04
magenta morphogenesis of embryonic epithelium GO:0016331 8.64E-07 5.79E-04
red mitotic cell cycle process GO:1903047 2.12E-89 5.49E-86
red mitotic cell cycle GO:0000278 4.64E-87 6.01E-84
red chromosome organization GO:0051276 5.79E-76 5.00E-73
red nuclear division GO:0000280 1.05E-66 6.77E-64
red organelle fission GO:0048285 2.14E-65 1.11E-62
royalblue response to peptide hormone GO:0043434 8.38E-06 1.97E-02
royalblue response to peptide GO:1901652 2.03E-05 2.38E-02
royalblue regulation of cellular carbohydrate metabolic GO:0010675 3.22E-05 2.51E-02
royalblue lipid catabolic process GO:0016042 4.49E-05 2.63E-02
royalblue negative regulation of protein phosphorylatio GO:0001933 6.96E-05 3.08E-02
tan skin development GO:0043588 6.81E-20 1.74E-16
tan keratinocyte differentiation GO:0030216 1.93E-19 2.47E-16
tan keratinization GO:0031424 1.17E-17 9.99E-15
tan epidermal cell differentiation GO:0009913 8.11E-17 5.18E-14
tan epidermis development GO:0008544 2.15E-16 1.10E-13
turquoise RNA processing GO:0006396 1.89E-35 7.56E-32
turquoise mRNA metabolic process GO:0016071 2.13E-29 4.26E-26
turquoise RNA splicing GO:0008380 6.31E-22 8.42E-19
turquoise mRNA processing GO:0006397 8.13E-20 8.13E-17
turquoise RNA splicing, via transesterification reactio GO:0000375 6.37E-16 3.64E-13
yellow extracellular matrix organization GO:0030198 1.58E-12 1.70E-09
yellow extracellular structure organization GO:0043062 1.58E-12 1.70E-09
yellow collagen fibril organization GO:0030199 1.31E-11 9.42E-09
yellow multicellular organismal macromolecule metabo GO:0044259 2.32E-11 1.25E-08
yellow multicellular organism metabolic process GO:0044236 1.08E-10 4.65E-08
Table B.2: Top 5 GO BP terms for each ADNL module
Module Description ID pvalue p.adjust
black vasculature development GO:0001944 2.02E-18 4.84E-15
black cardiovascular system development GO:0072358 2.91E-18 4.84E-15
black blood vessel development GO:0001568 9.65E-18 1.07E-14
black blood vessel morphogenesis GO:0048514 7.38E-15 6.13E-12
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black angiogenesis GO:0001525 4.79E-12 3.18E-09
darkgreen muscle contraction GO:0006936 9.31E-21 1.03E-17
darkgreen muscle system process GO:0003012 3.30E-19 1.83E-16
darkgreen smooth muscle contraction GO:0006939 2.53E-11 9.37E-09
darkgreen myofibril assembly GO:0030239 6.72E-10 1.86E-07
darkgreen striated muscle cell development GO:0055002 1.26E-09 2.80E-07
greenyellow monocarboxylic acid metabolic process GO:0032787 4.06E-30 1.57E-26
greenyellow small molecule biosynthetic process GO:0044283 1.66E-23 3.20E-20
greenyellow organic acid catabolic process GO:0016054 2.54E-20 2.51E-17
greenyellow fatty acid metabolic process GO:0006631 2.60E-20 2.51E-17
greenyellow cofactor metabolic process GO:0051186 5.47E-19 4.23E-16
grey detection of chemical stimulus involved in se GO:0050911 2.07E-28 9.41E-25
grey sensory perception of smell GO:0007608 3.69E-26 8.37E-23
grey detection of chemical stimulus involved in se GO:0050907 3.61E-25 5.46E-22
grey sensory perception of chemical stimulus GO:0007606 2.37E-23 2.69E-20
grey detection of chemical stimulus GO:0009593 8.68E-19 7.89E-16
lightcyan cilium assembly GO:0042384 5.80E-07 7.94E-04
lightcyan cilium organization GO:0044782 1.06E-06 7.94E-04
lightcyan cilium morphogenesis GO:0060271 1.42E-06 7.94E-04
lightcyan organelle assembly GO:0070925 5.61E-06 2.36E-03
lightcyan cellular component assembly involved in morph GO:0010927 1.90E-05 6.40E-03
lightgreen molting cycle GO:0042303 4.59E-13 4.13E-10
lightgreen hair cycle GO:0042633 4.59E-13 4.13E-10
lightgreen epidermis development GO:0008544 1.84E-08 1.11E-05
lightgreen hair follicle morphogenesis GO:0031069 9.13E-06 4.11E-03
lightgreen epidermis morphogenesis GO:0048730 1.51E-05 5.45E-03
magenta dopaminergic neuron differentiation GO:0071542 2.09E-07 7.39E-04
magenta anion transmembrane transport GO:0098656 7.77E-07 9.94E-04
magenta sodium ion transport GO:0006814 8.43E-07 9.94E-04
magenta monovalent inorganic cation homeostasis GO:0055067 3.18E-06 2.82E-03
magenta sodium ion transmembrane transport GO:0035725 8.97E-06 6.35E-03
salmon skin development GO:0043588 3.40E-20 1.13E-16
salmon epidermis development GO:0008544 7.58E-20 1.26E-16
salmon keratinocyte differentiation GO:0030216 1.21E-18 1.34E-15
salmon epidermal cell differentiation GO:0009913 2.81E-16 2.34E-13
salmon keratinization GO:0031424 5.78E-13 3.86E-10
turquoise RNA processing GO:0006396 7.39E-35 2.71E-31
turquoise mRNA metabolic process GO:0016071 2.28E-27 4.18E-24
turquoise RNA splicing GO:0008380 4.00E-23 4.89E-20
turquoise mRNA processing GO:0006397 1.14E-19 1.05E-16
turquoise RNA splicing, via transesterification reactio GO:0000375 4.35E-15 2.28E-12
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yellow extracellular matrix organization GO:0030198 4.13E-24 7.95E-21
yellow extracellular structure organization GO:0043062 4.13E-24 7.95E-21
yellow regulation of cell motility GO:2000145 4.32E-12 4.71E-09
yellow regulation of cell migration GO:0030334 4.89E-12 4.71E-09
yellow collagen fibril organization GO:0030199 7.91E-12 5.23E-09
Table B.3: Top 5 GO BP terms for each CAD module
Module Description ID pvalue p.adjust
black extracellular matrix organization GO:0030198 9.16E-33 1.38E-29
black extracellular structure organization GO:0043062 9.16E-33 1.38E-29
black vasculature development GO:0001944 2.70E-19 2.72E-16
black cardiovascular system development GO:0072358 3.85E-19 2.91E-16
black blood vessel development GO:0001568 1.67E-18 1.01E-15
blue skin development GO:0043588 8.92E-08 3.17E-04
blue epidermis development GO:0008544 1.03E-06 1.82E-03
blue inositol lipid-mediated signaling GO:0048017 4.54E-05 5.38E-02
blue phosphatidylinositol 3-kinase signaling GO:0014065 8.28E-05 5.61E-02
blue cellular lipid catabolic process GO:0044242 8.42E-05 5.61E-02
brown leukocyte activation GO:0045321 7.46E-70 2.06E-66
brown lymphocyte activation GO:0046649 7.13E-67 9.86E-64
brown leukocyte cell-cell adhesion GO:0007159 1.01E-58 9.31E-56
brown T cell activation GO:0042110 8.31E-57 4.60E-54
brown T cell aggregation GO:0070489 8.31E-57 4.60E-54
darkgreen muscle contraction GO:0006936 1.46E-24 1.49E-21
darkgreen muscle system process GO:0003012 6.50E-23 3.33E-20
darkgreen smooth muscle contraction GO:0006939 3.21E-12 1.10E-09
darkgreen actin filament-based process GO:0030029 1.09E-10 2.78E-08
darkgreen regulation of muscle contraction GO:0006937 2.30E-10 4.71E-08
darkturquoise B cell proliferation GO:0042100 1.40E-04 6.87E-03
darkturquoise humoral immune response GO:0006959 3.86E-04 9.45E-03
darkturquoise B cell activation GO:0042113 7.52E-04 1.09E-02
darkturquoise lymphocyte proliferation GO:0046651 1.15E-03 1.09E-02
darkturquoise mononuclear cell proliferation GO:0032943 1.18E-03 1.09E-02
green ncRNA metabolic process GO:0034660 5.97E-23 2.51E-19
green ribosome biogenesis GO:0042254 1.34E-17 2.05E-14
green ncRNA processing GO:0034470 1.46E-17 2.05E-14
green ribonucleoprotein complex biogenesis GO:0022613 3.22E-16 3.38E-13
green response to molecule of bacterial origin GO:0002237 6.17E-15 5.19E-12
greenyellow fatty acid metabolic process GO:0006631 4.74E-17 7.55E-14
greenyellow monocarboxylic acid metabolic process GO:0032787 1.54E-16 1.23E-13
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greenyellow lipid biosynthetic process GO:0008610 1.69E-12 8.97E-10
greenyellow acylglycerol metabolic process GO:0006639 4.20E-12 1.59E-09
greenyellow neutral lipid metabolic process GO:0006638 5.00E-12 1.59E-09
grey sensory perception of smell GO:0007608 2.23E-33 1.01E-29
grey detection of chemical stimulus involved in se GO:0050911 4.24E-32 9.60E-29
grey detection of chemical stimulus involved in se GO:0050907 3.04E-27 4.59E-24
grey sensory perception GO:0007600 4.79E-25 5.43E-22
grey sensory perception of chemical stimulus GO:0007606 6.91E-25 6.27E-22
lightgreen molting cycle GO:0042303 6.51E-16 1.28E-13
lightgreen hair cycle GO:0042633 6.51E-16 1.28E-13
lightgreen epidermis development GO:0008544 2.16E-09 2.85E-07
lightgreen aging GO:0007568 4.96E-07 4.90E-05
lightgreen hair follicle development GO:0001942 8.88E-06 4.75E-04
magenta growth GO:0040007 2.82E-06 7.04E-03
magenta regulation of growth GO:0040008 5.94E-06 7.04E-03
magenta negative regulation of locomotion GO:0040013 8.07E-06 7.04E-03
magenta negative regulation of cellular component mov GO:0051271 8.84E-06 7.04E-03
magenta signal release GO:0023061 1.28E-05 8.18E-03
purple defense response to virus GO:0051607 9.37E-43 1.93E-39
purple response to type I interferon GO:0034340 2.35E-41 2.42E-38
purple type I interferon signaling pathway GO:0060337 4.40E-40 2.26E-37
purple cellular response to type I interferon GO:0071357 4.40E-40 2.26E-37
purple response to virus GO:0009615 1.34E-38 5.50E-36
red mitotic cell cycle process GO:1903047 7.36E-115 1.56E-111
red mitotic cell cycle GO:0000278 1.00E-113 1.06E-110
red chromosome organization GO:0051276 1.17E-108 8.28E-106
red nuclear division GO:0000280 4.34E-93 2.29E-90
red organelle fission GO:0048285 6.40E-90 2.71E-87
salmon cilium assembly GO:0042384 1.40E-08 3.56E-05
salmon cilium organization GO:0044782 3.65E-08 3.85E-05
salmon cilium morphogenesis GO:0060271 5.73E-08 3.85E-05
salmon cell projection assembly GO:0030031 6.06E-08 3.85E-05
salmon cellular component assembly involved in morph GO:0010927 1.26E-07 6.38E-05
tan peptide cross-linking GO:0018149 5.94E-13 6.68E-10
tan keratinization GO:0031424 6.41E-12 3.60E-09
tan keratinocyte differentiation GO:0030216 2.26E-11 8.48E-09
tan epidermal cell differentiation GO:0009913 6.74E-10 1.90E-07
tan skin development GO:0043588 3.34E-08 7.52E-06
turquoise RNA processing GO:0006396 1.81E-36 5.62E-33
turquoise mRNA metabolic process GO:0016071 8.94E-31 1.38E-27
turquoise RNA splicing GO:0008380 4.41E-22 4.55E-19
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turquoise mRNA processing GO:0006397 1.38E-18 1.07E-15
turquoise RNA splicing, via transesterification reactio GO:0000375 1.68E-15 7.45E-13
yellow extracellular matrix organization GO:0030198 8.18E-13 1.29E-09
yellow extracellular structure organization GO:0043062 8.18E-13 1.29E-09
yellow regulation of endothelial cell migration GO:0010594 1.28E-08 1.35E-05
yellow vasculature development GO:0001944 3.59E-08 2.00E-05
yellow blood vessel development GO:0001568 4.05E-08 2.00E-05
Table B.4: Top 5 GO BP terms for each PSOL module
Module Description ID pvalue p.adjust
black lipid catabolic process GO:0016042 2.32E-06 4.10E-03
black monocarboxylic acid metabolic process GO:0032787 4.64E-06 4.10E-03
black response to peptide hormone GO:0043434 8.78E-06 4.23E-03
black fatty acid metabolic process GO:0006631 9.93E-06 4.23E-03
black lipid localization GO:0010876 1.20E-05 4.23E-03
brown leukocyte activation GO:0045321 5.47E-60 1.20E-56
brown lymphocyte activation GO:0046649 3.65E-58 4.00E-55
brown leukocyte cell-cell adhesion GO:0007159 1.19E-50 8.70E-48
brown T cell activation GO:0042110 2.70E-49 1.18E-46
brown T cell aggregation GO:0070489 2.70E-49 1.18E-46
cyan muscle contraction GO:0006936 2.14E-30 3.75E-27
cyan muscle system process GO:0003012 4.77E-29 4.18E-26
cyan regulation of muscle system process GO:0090257 2.71E-16 1.58E-13
cyan regulation of muscle contraction GO:0006937 1.30E-15 5.70E-13
cyan regulation of system process GO:0044057 1.04E-13 3.65E-11
greenyellow monocarboxylic acid metabolic process GO:0032787 1.05E-35 3.95E-32
greenyellow small molecule biosynthetic process GO:0044283 5.02E-30 9.44E-27
greenyellow organic acid catabolic process GO:0016054 6.87E-27 8.62E-24
greenyellow fatty acid metabolic process GO:0006631 1.72E-25 1.62E-22
greenyellow cofactor metabolic process GO:0051186 1.54E-24 1.03E-21
grey detection of chemical stimulus involved in se GO:0050911 1.08E-22 4.90E-19
grey sensory perception of smell GO:0007608 4.44E-21 1.01E-17
grey sensory perception of chemical stimulus GO:0007606 2.28E-20 3.45E-17
grey detection of chemical stimulus involved in se GO:0050907 3.05E-20 3.46E-17
grey detection of stimulus involved in sensory per GO:0050906 2.01E-16 1.82E-13
lightgreen molting cycle GO:0042303 6.65E-14 3.47E-11
lightgreen hair cycle GO:0042633 6.65E-14 3.47E-11
lightgreen epidermis development GO:0008544 7.96E-10 2.77E-07
lightgreen hair follicle development GO:0001942 3.93E-06 6.54E-04
lightgreen molting cycle process GO:0022404 3.93E-06 6.54E-04
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magenta negative regulation of cell differentiation GO:0045596 3.63E-08 1.31E-04
magenta negative regulation of developmental process GO:0051093 1.84E-07 3.33E-04
magenta tube formation GO:0035148 1.09E-06 1.32E-03
magenta negative regulation of cell migration GO:0030336 1.97E-06 1.78E-03
magenta negative regulation of cell motility GO:2000146 3.31E-06 2.40E-03
red mitotic cell cycle process GO:1903047 4.02E-85 5.09E-82
red mitotic cell cycle GO:0000278 6.30E-83 4.00E-80
red chromosome organization GO:0051276 5.60E-71 2.37E-68
red chromosome segregation GO:0007059 1.96E-66 6.23E-64
red nuclear division GO:0000280 6.97E-66 1.77E-63
salmon organelle assembly GO:0070925 1.70E-09 3.75E-06
salmon mitotic cell cycle GO:0000278 6.77E-09 5.37E-06
salmon sister chromatid cohesion GO:0007062 7.31E-09 5.37E-06
salmon nuclear chromosome segregation GO:0098813 1.46E-08 5.53E-06
salmon chromosome organization GO:0051276 1.58E-08 5.53E-06
turquoise RNA processing GO:0006396 2.15E-38 6.87E-35
turquoise mRNA metabolic process GO:0016071 1.24E-30 1.98E-27
turquoise RNA splicing GO:0008380 2.34E-25 2.49E-22
turquoise mRNA processing GO:0006397 2.63E-23 2.11E-20
turquoise RNA splicing, via transesterification reactio GO:0000375 4.98E-20 2.28E-17
yellow extracellular matrix organization GO:0030198 8.05E-34 1.58E-30
yellow extracellular structure organization GO:0043062 8.05E-34 1.58E-30
yellow vasculature development GO:0001944 9.05E-23 1.19E-19
yellow cardiovascular system development GO:0072358 1.75E-22 1.72E-19
yellow blood vessel development GO:0001568 2.49E-22 1.96E-19
Table B.5: Top 5 GO BP terms for each PSONL module
Module Description ID pvalue p.adjust
black lipid localization GO:0010876 1.88E-07 2.51E-04
black monocarboxylic acid metabolic process GO:0032787 2.94E-07 2.51E-04
black glycerolipid metabolic process GO:0046486 1.59E-06 8.31E-04
black response to peptide GO:1901652 2.37E-06 8.31E-04
black lipid catabolic process GO:0016042 2.43E-06 8.31E-04
darkgreen muscle contraction GO:0006936 6.60E-25 7.56E-22
darkgreen muscle system process GO:0003012 4.05E-23 2.32E-20
darkgreen smooth muscle contraction GO:0006939 2.99E-11 1.14E-08
darkgreen actin filament-based process GO:0030029 4.21E-11 1.21E-08
darkgreen regulation of muscle system process GO:0090257 6.06E-11 1.39E-08
greenyellow monocarboxylic acid metabolic process GO:0032787 2.60E-34 1.01E-30
greenyellow small molecule biosynthetic process GO:0044283 6.75E-30 1.31E-26
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greenyellow organic acid catabolic process GO:0016054 6.19E-29 8.01E-26
greenyellow small molecule catabolic process GO:0044282 3.17E-26 3.08E-23
greenyellow carboxylic acid catabolic process GO:0046395 1.53E-25 1.19E-22
grey detection of chemical stimulus involved in se GO:0050911 1.45E-25 6.61E-22
grey detection of chemical stimulus involved in se GO:0050907 1.32E-23 2.99E-20
grey sensory perception of smell GO:0007608 2.39E-23 3.62E-20
grey detection of stimulus involved in sensory per GO:0050906 8.49E-19 9.65E-16
grey sensory perception of chemical stimulus GO:0007606 1.21E-18 1.10E-15
lightgreen molting cycle GO:0042303 1.30E-15 8.98E-13
lightgreen hair cycle GO:0042633 1.30E-15 8.98E-13
lightgreen epidermis development GO:0008544 3.66E-12 1.69E-09
lightgreen skin development GO:0043588 1.27E-07 3.71E-05
lightgreen hair follicle development GO:0001942 1.89E-07 3.71E-05
magenta inorganic ion transmembrane transport GO:0098660 1.95E-07 6.37E-04
magenta anion transmembrane transport GO:0098656 3.66E-07 6.37E-04
magenta tube formation GO:0035148 6.93E-07 8.05E-04
magenta dopaminergic neuron differentiation GO:0071542 2.16E-06 1.88E-03
magenta inorganic anion transmembrane transport GO:0098661 3.06E-06 2.13E-03
salmon organelle assembly GO:0070925 4.88E-07 5.92E-04
salmon cilium assembly GO:0042384 5.08E-07 5.92E-04
salmon chromosome organization GO:0051276 1.08E-06 6.65E-04
salmon cilium organization GO:0044782 1.14E-06 6.65E-04
salmon cilium morphogenesis GO:0060271 1.67E-06 7.78E-04
tan skin development GO:0043588 3.21E-21 1.17E-17
tan keratinocyte differentiation GO:0030216 4.92E-20 8.95E-17
tan epidermis development GO:0008544 7.89E-19 9.58E-16
tan epidermal cell differentiation GO:0009913 4.55E-18 4.14E-15
tan keratinization GO:0031424 1.30E-15 9.45E-13
turquoise RNA processing GO:0006396 1.84E-28 6.60E-25
turquoise mRNA metabolic process GO:0016071 2.60E-21 4.66E-18
turquoise RNA splicing GO:0008380 5.30E-21 6.33E-18
turquoise mRNA processing GO:0006397 4.95E-18 4.44E-15
turquoise RNA splicing, via transesterification reactio GO:0000375 1.23E-14 6.28E-12
yellow extracellular matrix organization GO:0030198 3.87E-32 7.91E-29
yellow extracellular structure organization GO:0043062 3.87E-32 7.91E-29
yellow vasculature development GO:0001944 4.04E-22 5.50E-19
yellow blood vessel development GO:0001568 6.78E-22 6.73E-19
yellow cardiovascular system development GO:0072358 8.24E-22 6.73E-19
Table B.6: Top 5 GO BP terms for each CPSO module























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.1: Hierarchical clustering of ADL samples. Samples above the red line were
excluded from network construction.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure B.2: Hierarchical clustering of PSOL samples. Samples above the red line were
excluded from network construction.



















81 lipid localization 0.00025
72 muscle contraction 7.6e−22
1125 monocarboxylic acid metabolic process 1e−30
10818 sensory perception of smell * 6.6e−22
149 molting cycle 9e−13
551 inorganic ion transmembrane transport 0.00064
301 organelle assembly 0.00059
567 skin development 1.2e−17
1412 RNA processing 6.6e−25




















383 vasculature development 4.8e−15
74 muscle contraction 1e−17
910 monocarboxylic acid metabolic process 1.6e−26
10911 sensory perception of smell * 9.4e−25
146 cilium assembly 0.00079
191 molting cycle 4.1e−10
564 dopaminergic neuron differentiation 0.00074
494 skin development 1.1e−16
1771 RNA processing 2.7e−31
872 extracellular matrix organization 7.9e−21
Figure B.3: Module definitions of Control co-expression networks. (Left) Module size and
top GO biological process term for each module in the CAD network. (Right) Module size
and GO terms for the CPSO network.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ADNL (rows) vs. CAD (columns)
ADL (rows) vs. ADNL (columns) ADL (rows) vs. CAD (columns)
Figure B.4: Overlap of gene modules across AD networks. (Top left) - ADL modules
vs ADNL modules. (Top-right) - ADL vs CAD. (Bottom-left) ADNL vs CAD. The first
number in the heatmap tile is the number of genes which is present in both modules
from both networks. The second number is the (uncorrected) Fisher’s exact test p value.
Heatmap tile color corresponds to -log(pvalue). P values were capped at -log(1e-50).
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Figure B.5: Overlap of gene modules across PSO networks. (Top left) - PSOL modules
vs PSONL modules. (Top-right) - PSOL vs CPSO. (Bottom-left) PSONL vs CPSO. The
first number in the heatmap tile is the number of genes which is present in both modules
from both networks. The second number is the (uncorrected) Fisher’s exact test p value.
Heatmap tile color corresponds to -log(pvalue). P values were capped at -log(1e-50).















































































































































































































































































































































































































































































































































































































































































































































































































































ADL (rows) vs. PSOL (columns)
Figure B.6: Overlap of gene membership between ADL network modules and PSOL net-
work modules. Rows correspond to AD modules, and columns correspond to PSOL mod-
ules. The first number in the heatmap tile is the number of genes which is present in both
ADL and PSOL modules. The second number is the (uncorrected) Fisher’s exact test p
value. Heatmap tile color corresponds to -log(pvalue). P values were capped at -log(1e-50).
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Figure B.7: Zconnectivity statistics for module preservation analysis. Zconnectivity is
correlated with module size.































































































































































































































































































































































































































































































































Figure B.8: Associations between microbes and module eigengenes across all networks.
Heatmap tile corresponds to the correlation coefficient. Significant correlations (p < 0.1, r
> 0.30) are marked.
